ifosfamide has been researched along with Bone Neoplasms in 413 studies
Bone Neoplasms: Tumors or cancer located in bone tissue or specific BONES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lay abstract Traditional treatment for osteosarcoma (bone cancer) includes drugs that cause cell damage, such as ifosfamide and etoposide." | 9.41 | OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma. ( Bautista, F; Campbell-Hewson, Q; Gaspar, N; Huang, J; Okpara, CE, 2021) |
| "In most countries, reference chemotherapy for osteosarcoma is MAP regimen (M = high-dose methotrexate, AP = doxorubicin-cisplatinum)." | 9.27 | Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. ( Bompas, E; Bouvier, C; Brisse, HJ; Brugieres, L; Castex, MP; Cheurfa, N; Corradini, N; Delaye, J; Entz-Werlé, N; Gaspar, N; Gentet, JC; Italiano, A; Le Deley, MC; Lervat, C; Marec-Berard, P; Mascard, E; Occean, BV; Pacquement, H; Piperno-Neumann, S; Redini, F; Saumet, L; Schmitt, C; Tabone, MD; Verite-Goulard, C, 2018) |
| "This is the first instance of tumor lysis syndrome described in a patient with osteosarcoma undergoing ifosfamide monotherapy." | 9.22 | Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature. ( Chen, XT; Christ, AB; Hu, JS; Luminais, SN; Ma, B; Roman, D, 2022) |
| "Studies of baseline prognostic factors in patients with localized osteosarcoma treated without high dose methotrexate are limited." | 9.20 | Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients. ( Bakhshi, S; Batra, A; Khan, SA; Nataraj, V; Rastogi, S; Sharma, MC; Vishnubhatla, S, 2015) |
| "Cyclophosphamide may be able to replace ifosfamide in consolidation treatment of standard-risk Ewing sarcoma." | 9.19 | Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. ( Brennan, B; Craft, A; Dirksen, U; Hjorth, L; Judson, I; Juergens, H; Ladenstein, R; Le Deley, MC; Le Teuff, G; Lewis, I; Marec-Bérard, P; Michon, J; Oberlin, O; Paulussen, M; Ranft, A; van den Berg, H; Wheatley, K; Whelan, J, 2014) |
| "High-dose methotrexate (HD-MTX) is recognized as an efficient component of therapy against pediatric osteosarcoma in combination with other drugs such as cisplatin (CDP), carboplatin (CBDCA), doxorubicin (ADM), etoposide (VP-16) and ifosfamide (IFO)." | 9.19 | Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. ( Anurathapan, U; Choeyprasert, W; Chuansumrit, A; Hongeng, S; Nartthanarung, A; Pakakasama, S; Sirachainan, N; Songdej, D, 2014) |
| "This multicenter, phase II trial evaluated the efficacy and safety of everolimus, an mTOR inhibitor, in patients with metastatic or recurrent bone and soft-tissue sarcoma after the failure of anthracycline- and ifosfamide-containing regimens." | 9.17 | Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. ( Ahn, JH; Kim, TM; Kim, YJ; Lee, HJ; Lee, J; Lee, KH; Park, KH; Rha, SY; Yoo, C, 2013) |
| "We compared two chemotherapy regimens that included methotrexate (MTX), cisplatin (CDP), and doxorubicin (ADM) with or without ifosfamide (IFO) in patients with nonmetastatic osteosarcoma of the extremity." | 9.16 | Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. ( Alberghini, M; Bacci, G; Bertulli, R; Bisogno, G; Capanna, R; Cefalo, G; Comandone, A; Fagioli, F; Ferrari, S; Linari, A; Palmerini, E; Parafioriti, A; Picci, P; Ruggieri, P; Tamburini, A, 2012) |
| "Thirteen patients, median age 18 (range: 8-34), with metastatic or axial-skeletal osteosarcoma were treated with ifosfamide 2." | 9.12 | A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma. ( Lewis, I; McTiernan, A; Meyer, T; Michelagnoli, MP; Whelan, JS, 2006) |
| "In the prospective high-risk sarcoma (HIRISA) Phase II trial HIRISA1, pediatric patients with high-risk sarcomas received 3 cycles of intensive vincristine, ifosfamide, etoposide, cyclophosphamide, and doxorubicin (VACIE) before radiotherapy and/or surgery began at Week 9 with concurrent vincristine, cyclophosphamide, and doxorubicin (Week 9) and vincristine and ifosfamide (Week 12)." | 9.12 | Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience. ( Billups, CA; Cain, AM; Furman, WL; Hale, GA; Merchant, TE; Navid, F; Pappo, AS; Rao, BN; Santana, VM; Spunt, SL, 2006) |
| "The SFOP-OS94 randomised multi-centre trial was designed to determine whether preoperative chemotherapy regimen combining high-dose methotrexate courses and etoposide-ifosfamide could improve the proportion of good histologic response (5% viable cells) compared to a regimen based on high-dose methotrexate and doxorubicin, in children/adolescents with localised high-grade limb osteosarcoma." | 9.12 | SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. ( Brugières, L; Dupoüy, N; Entz-Werlé, N; Gentet, JC; Guinebretière, JM; Kalifa, C; Le Deley, MC; Marec-Bérard, P; Pacquement, H; Pichon, F; Schmitt, C; Tabone, MD; Vanel, D, 2007) |
| "This randomized prospective multicenter phase III trial was designed to compare progression-free survival of patients with advanced soft tissue sarcoma receiving either regimen of standard doxorubicin 75 mg/m2 every 21 days, ifosfamide 9 g/m2 over 3 days continuous infusion, or ifosfamide 3 g/m2 per day in 3 hours over 3 days." | 9.12 | Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. ( Blay, JY; Hogendoorn, PC; Kirkpatrick, A; Le Cesne, A; Leahy, MG; Lorigan, P; Papai, Z; Radford, JA; Rodenhuis, S; Van Glabbeke, MM; Verweij, J, 2007) |
| "The combination of cisplatin, ifosfamide and epirubicin is an active, reasonably well-tolerated regimen without grade 3 or 4 cardiac toxicity in patients with nonmetastatic extremity osteosarcoma and deserves further investigation in the context of prospective phase III trials." | 9.12 | A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas. ( Atalar, AC; Basaran, M; Bavbek, ES; Bilgic, B; Eralp, L; Onat, H; Ozger, H; Saglam, S; Sakar, B, 2007) |
| "The authors evaluated the efficacy and toxicity of cisplatin, ifosfamide, and doxorubicin with peripheral blood stem cell (PBSC) support in adult patients with osteosarcomas and variants with a poor prognosis." | 9.11 | A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. ( Benjamin, RS; Champlin, R; Donato, M; Lewis, VO; Lin, PP; Papadopolous, N; Patel, SR; Raymond, AK; Seong, CM; Yasko, AW, 2004) |
| "Ifosfamide and doxorubicin are the most effective agents in the treatment of sarcomas, although their contributions to survival are usually limited." | 9.11 | High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas. ( Akbulut, H; Buyukcelik, A; Demirkazik, A; Icli, F; Pamir, A; Utkan, G; Yalcin, B, 2004) |
| "To determine whether the addition of ifosfamide and/or muramyl tripeptide (MTP) encapsulated in liposomes to cisplatin, doxorubicin, and high-dose methotrexate (HDMTX) could improve the probability for event-free survival (EFS) in newly diagnosed patients with osteosarcoma (OS)." | 9.11 | Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. ( Bernstein, ML; Betcher, D; Conrad, E; Ferguson, W; Gebhardt, M; Goorin, AM; Grier, H; Harris, MB; Healey, J; Huvos, A; Kleinerman, ES; Krailo, M; Link, M; Meyers, PA; Montebello, J; Nadel, H; Nieder, M; Sato, J; Schwartz, CL; Siegal, G; Weiner, M; Wells, R; Wold, L; Womer, R, 2005) |
| "To explore the effect of high-dose ifosfamide in first-line treatment for patients < or = 40 years of age with nonmetastatic osteosarcoma of the extremity." | 9.11 | Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. ( Alvegard, TA; Bacci, G; Bernini, G; Bertoni, F; Böhling, T; Brosjö, O; Capanna, R; Comandone, A; Del Prever, AB; Ferrari, S; Longhi, A; Mercuri, M; Müller, C; Picci, P; Ruggieri, P; Saeter, G; Smeland, S; Tienghi, A; Wiebe, T, 2005) |
| "The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone." | 9.10 | Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2003) |
| "The objectives of this trial were to estimate the response rate, progression-free survival, and overall survival of patients who received therapy with etoposide and high-dose ifosfamide, and to define the toxicity of this combination when provided with standard chemotherapy in patients with newly diagnosed metastatic osteosarcoma." | 9.10 | Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. ( Bernstein, M; Devidas, M; Ferguson, W; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, MB; Link, M; Schwartz, CL; Siegal, GP, 2002) |
| "With the intention of starting an international protocol between Italy and Scandinavia on neoadjuvant treatment of extremity osteosarcoma using the four active drugs at maximum doses (doxorubicin 75 mg/m2 pre-operatively, and 90 mg/m2 post-operatively, cisplatin 120 mg/m2, methotrexate 12 g/m2, and ifosfamide 15 g/m2), a single center (the Rizzoli institute) performed a pilot study to closely monitor toxicity, safety, and tumor necrosis." | 9.10 | High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. ( Alvegard, TA; Bacci, G; Briccoli, A; Donati, D; Ferrari, S; Forni, C; Lari, S; Longhi, A; Manfrini, M; Mercuri, M; Picci, P; Saeter, G, 2002) |
| "The aim of this phase II study was to determine the efficacy of high-dose ifosfamide with moderate dose etoposide in childhood osteosarcoma." | 9.08 | Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. ( Avet-Loiseau, H; Berger, C; Bernard, JL; Brunat-Mentigny, M; De Lumley, L; Demaille, MC; Gentet, JC; Kalifa, C; Pacquement, H; Pein, F; Pillon, P; Sariban, E; Schmitt, C, 1997) |
| "To evaluate the efficacy and feasibility of high-dose ifosfamide (HDI) at a total dose of 14 g/m2 per cycle with mesna in combination with granulocyte colony-stimulating factor (G-CSF) in adult patients with sarcomas." | 9.08 | High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. ( Benjamin, RS; Burgess, MA; Hays, C; Papadopolous, N; Patel, SR; Plager, C; Vadhan-Raj, S, 1997) |
| "This Phase II trial of paclitaxel/ifosfamide included patients with bi-dimensionally measurable metastatic breast cancer in second or third relapse, following anthracycline-containing regimens; ECOG PS < 2, and adequate hepatic, cardiac, renal, and hematological functions." | 9.08 | Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer. ( Amorim, WC; Ferreira-Filho, AF; Guimaraes, RC; Morici, AC; Murad, AM; Schwartsmann, G, 1997) |
| " The aim of the present study was to assess long-term renal function in children and adolescents who received at-risk chemotherapy, including cisplatin, ifosfamide, and methotrexate, to treat an osteosarcoma." | 9.08 | Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. ( Brunat-Mentigny, M; Cochat, P; Dubourg, L; Hadj-Aïssa, A; Koch Nogueira, PC; Schell, M, 1998) |
| "Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are characterized by a marked dose-response relationship." | 9.08 | Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). ( Bacchi, M; Bressoud, A; Cerny, T; Hermann, R; Leyvraz, S; Lissoni, A; Sessa, C, 1998) |
| "Doxorubicin alone or with dacarbazine (DTIC; AD) is considered the best available therapy for metastatic adult sarcomas." | 9.07 | An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. ( Antman, K; Balcerzak, SP; Barlogie, B; Cooper, RM; Crowley, J; Elias, A; Natale, RB; Rivkin, SE; Trump, DL; Weiss, GR, 1993) |
| "Nine patients with osteosarcoma were treated by chemotherapy combined with caffeine and surgery." | 9.07 | Effect of chemotherapy combined with caffeine for osteosarcoma. ( Baba, H; Tomita, K; Tsuchiya, H; Ueda, Y; Yasutake, H; Yokogawa, A, 1992) |
| "In this phase II trial, 105 eligible patients with no prior chemotherapy and advanced sarcoma received doxorubicin, ifosfamide, and dacarbazine (DTIC) with mesna uroprotection (MAID)." | 9.06 | Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. ( Aisner, J; Antman, KH; Collins, J; Elias, A; Ryan, L; Sulkes, A, 1989) |
| "Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma." | 8.91 | Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2015) |
| "The efficacy of ifosfamide-based chemotherapy in the treatment of osteosarcoma has been investigated; however, results are inconsistent." | 8.91 | Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis. ( Cai, GP; Ding, GM; Fan, XL; Zhu, LL, 2015) |
| "To assess testicular function after standard dose ifosfamide, we evaluated 6 young adult osteosarcoma survivors (median age at diagnosis, 16." | 8.90 | Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: a case series and review of the literature. ( Diller, L; Duffey-Lind, E; Ebb, D; Grier, H; Kenney, LB; Sklar, CA, 2014) |
| "Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma." | 8.88 | Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2012) |
| "Ifosfamide is a chemotherapeutic prodrug used in the treatment of several tumor entities, including bone and soft-tissue sarcoma." | 8.86 | Palifosfamide, a bifunctional alkylator for the treatment of sarcomas. ( Jung, S; Kasper, B, 2010) |
| "Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma." | 8.86 | Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2010) |
| "The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas." | 8.81 | Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. ( Ballo, MT; Benjamin, RS; Burgess, MA; Cormier, JN; Feig, BW; Herzog, CE; Hunt, KK; Patel, SR; Pisters, PW; Raney, RB; Zagars, GK, 2001) |
| "Ifosfamide is an alkylating agent with clinical activity in the treatment of sarcomas, and data support a dose-response relationship in this disease." | 8.79 | High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. ( Demetri, GD, 1996) |
| "We have used ifosfamide to treat patients with sarcomas in four completed single-agent protocols and one pilot study since 1985." | 8.78 | Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. ( Benjamin, RS; Legha, SS; Nicaise, C; Patel, SR, 1993) |
| "Following the 20th week of ifosfamide treatment, the patient's follow-up with the diagnosis of osteosarcoma developed neurological findings." | 8.02 | Ifosfamide induced encephalopathy in a child with osteosarcoma. ( Atay, AA; Demir, ÜF; Malbora, B; Sarbay, H; Yılmaz, G, 2021) |
| "For Ewing sarcoma, interval-compressed vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide administered every 2 weeks rather than every 3 weeks has been shown to improve event-free survival in pediatric patients." | 7.96 | Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide. ( Bassale, S; Davis, LE; Lim, JY; Lu, E; Ryan, CW, 2020) |
| "Current treatment of high-grade osteosarcoma consists of preoperative chemotherapy, typically using some combination of doxorubicin, cisplatin, ifosfamide, and/or high-dose methotrexate followed by surgical resection." | 7.91 | Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 Mutation. ( Savani, M; Skubitz, KM, 2019) |
| "All treatment naive consecutive patients of osteosarcoma were prospectively treated on a novel institutional regimen (named OGS-12) comprising of eight sequential doublets of the following drugs: doxorubicin, cisplatin and ifosfamide in four courses each, given in the neoadjuvant and adjuvant settings." | 7.85 | Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'. ( Bajpai, J; Banavali, SD; Chandrakanth, MV; Chandrasekharan, A; Ghosh, J; Gupta, S; Khan, A; Khurana, S; Rekhi, B; Simha, V; Talreja, V; Vora, T, 2017) |
| "Children and adolescents with nonmetastatic osteosarcoma were treated with MAP (methotrexate, doxorubicin, cisplatin) or MAPI (MAP/ifosfamide)." | 7.83 | Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. ( Bernstein, ML; Devidas, M; Gebhardt, MC; Goorin, AM; Grier, HE; Healey, JH; Krailo, MD; Lipshultz, SE; Meyers, PA; Sato, JK; Schwartz, CL; Steinherz, LJ; Teot, LA; Wexler, LH, 2016) |
| "The combination of topotecan and cyclophosphamide is active in relapsed Ewing sarcoma family of tumors (ESFT)." | 7.83 | Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. ( Bond, MC; Felgenhauer, JL; Femino, JD; Gorlick, R; Krailo, MD; Laack, NN; Marina, N; Mascarenhas, L; Meyer, J; Ranganathan, S; Villaluna, D; Womer, RB, 2016) |
| "Pirarubicin (THP), a novel anthracycline derivative of doxorubicin (ADM), is effective in treating patients with advanced, relapsed or recurrent high-grade osteosarcoma." | 7.81 | Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter? ( Lin, F; Shen, Z; Tang, L; Yao, Y; Yu, W, 2015) |
| "The aim of this retrospective study was to evaluate the feasibility and efficacy of response to continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for patients with recurrent or refractory osteosarcoma." | 7.81 | Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study. ( He, AN; Huang, YJ; Min, DL; Shen, Z; Sun, YJ; Yao, Y, 2015) |
| "In this study, ifosfamide-loaded poly (lactic-co-glycolic acid) (PLGA)-dextran polymeric nanoparticles (PD/IFS) was developed and studied its anticancer efficacy against multiple osteosarcoma cancer cells." | 7.81 | Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma. ( Chen, B; Lin, XJ; Wang, LF; Yang, JZ; Zhang, YJ, 2015) |
| "Ifosfamide combined with other antineoplastic agents has been effective in the treatment of osteosarcoma, although adverse effects are reported in the increasing use of ifosfamide." | 7.80 | Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury. ( Enokida, H; Hayami, H; Komiya, S; Nagano, S; Nakagawa, M; Nishimura, H; Yokouchi, M, 2014) |
| "We sought to (1) evaluate the disease-specific survival at 2 and 5 years of patients with dedifferentiated chondrosarcoma; (2) assess the prognostic variables (both patient- and treatment-related), including the use of chemotherapy with ifosfamide, that relate to survivorship; and (3) assess specific toxicities associated with ifosfamide use." | 7.80 | Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma? ( Deavers, M; Harun, N; Kawaguchi, S; Lewis, VO; Lin, PP; Sun, T, 2014) |
| "Ifosfamide and methotrexate are widely used for the treatment of pediatric osteosarcoma." | 7.80 | Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy. ( Bruneau, B; Chappé, C; Gandemer, V; Robert, G; Taque, S, 2014) |
| "This systemic analysis was conducted to evaluate the efficacy and safety of an ifosfamide- containing regimen in treating patients with osteosarcoma." | 7.80 | Ifosfamide-containing regimens for treating patients with osteosarcomas. ( Dong, YG; Jiang, XM; Li, YY; Ma, YB; Xu, G, 2014) |
| "A retrospective study was performed to assess toxicity and response rate of ifosfamide salvage treatment for dogs diagnosed with metastatic osteosarcoma (OSA)." | 7.80 | Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma. ( Batschinski, K; Dervisis, NG; Kitchell, BE, 2014) |
| "To determine demographic data, prognostic factors and outcome of childhood osteosarcoma treated with a carboplatin-based chemotherapeutic protocol at Chiang Mai University." | 7.79 | Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand. ( Charoenkwan, P; Choeyprasert, W; Natesirinilkul, R; Sittipreechacharn, S, 2013) |
| "The clinical data of 75 patients who received pirarubicin-based (n = 52) or gemcitabine-docetaxel (n = 23) chemotherapy as a second-line treatment for relapsed and refractory osteosarcoma between January 2005 and September 2011were reviewed retrospectively." | 7.79 | Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience. ( He, A; Huang, Y; Qi, W; Shen, Z; Sun, Y; Yang, Y; Yao, Y; Zhao, H, 2013) |
| "The objective of this study was to investigate the efficacy and toxic side effects of two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide on treating Chinese osteosarcoma patients." | 7.77 | Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. ( Dong, Y; Lin, F; Shen, Z; Sun, Y; Tang, L; Wang, Q; Yao, Y; Yu, W; Zheng, S, 2011) |
| "We retrospectively examined the incidence, severity, and risk factors of ifosfamide encephalopathy in 61 Japanese patients with bone and soft tissue sarcomas at our institution." | 7.76 | Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors. ( Kikuchi, S; Konno, S; Tajino, T; Takeda, A; Yamada, H, 2010) |
| "This study assessed the therapeutic effect of and adverse reactions to pirarubicin (THP) chemotherapy in osteosarcoma patients with lung metastasis, and analyzed the relationship between THP therapeutic effect and expression of p-glycoprotein and topoisomerase-II." | 7.76 | Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis. ( Chen, P; Lin, F; Sun, Y; Wang, Z; Yao, Y; Zhao, H, 2010) |
| "In an attempt to find leads to such markers, we have obtained microarray gene expression profiles from a panel of 10 different human osteosarcoma xenografts and related the results to their sensitivity to ifosfamide, doxorubicin, and cisplatin." | 7.75 | Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide. ( Bruheim, S; Fodstad, O; Ju, J; Xi, Y, 2009) |
| " Flow cytometric analyses by means of annexin-V and propidium iodide double staining and immunofluorescence staining of active caspase-3 revealed that cells subjected to a lethal dose of chloroacetaldehyde displayed features characteristic of necrosis and that caspase-3 was not activated in response to chloroacetaldehyde." | 7.74 | Necrotic pathway in human osteosarcoma Saos-2 cell death induced by chloroacetaldehyde. ( Fujimoto, Y; Sakurai, K; Takahashi, K; Tanaka, H, 2007) |
| " We report a 9-year-old boy with osteosarcoma who experienced 2 episodes of pancreatitis 1 day and 48 days after infusion of ifosfamide (IFOS), respectively." | 7.74 | Acute pancreatitis associated with ifosfamide. ( Hung, GY; Hung, MC; Lin, PC; Tien, YC; Tiu, CM, 2007) |
| "Sixteen pediatric osteosarcoma patients, previously treated with conventional chemotherapy (including ifosfamide (IFX), 9 g/m(2)) were retreated with high-dose ifosfamide (HD-IFX, 14 g/m(2) per course), following relapse or development of a new bone tumor." | 7.73 | High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. ( Berberoğlu, S; Berrak, SG; Ilhan, IE; Jaffe, N; Pearson, M, 2005) |
| "Cyclophosphamide (CTX) and ifosfamide (IFX) are alkylating agents used to treat osteosarcoma (OS)." | 7.73 | Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. ( Duan, X; Jia, SF; Kleinerman, ES; Koshkina, N, 2006) |
| "A 16-year-old girl with a distal femur osteosarcoma became pain-free with the first treatment of methotrexate 12." | 7.72 | Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid. ( Cohen, IJ, 2003) |
| "To determine the activity of carboplatin/ifosfamide in patients with previously untreated osteosarcoma and to estimate patient outcomes after a multiagent chemotherapy protocol that eliminated cisplatin." | 7.71 | Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. ( Fletcher, BD; Harper, J; Jenkins, JJ; Mahmoud, HH; Marina, NM; Meyer, WH; Neel, M; Pappo, AS; Parham, DM; Poquette, CA; Pratt, CB; Rao, BN, 2001) |
| "Ifosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor." | 7.70 | [Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)]. ( Agata, H; Fujimoto, T; Hamaguchi, N; Hirota, T; Iwata, A; Katano, N; Kitagawa, S; Kobayashi, S; Konno, K; Sato, T; Sawada, K; Takeuchi, M, 1998) |
| "This prospective study was designed to test the activity of an ifosfamide-etoposide (VP-16) regimen on poor-risk, nonmetastatic, osteogenic sarcoma." | 7.70 | Postsurgical etoposide-ifosfamide regimen in poor-risk nonmetastatic osteogenic sarcoma. ( Ben Arush, MW; Drumea, K; Haim, N; Kuten, A; Meller, I; Moses, M; Stein, ME, 1998) |
| "Ifosfamide is a leading drug in soft tissue sarcoma therapy." | 7.70 | Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. ( Bergnolo, P; Boglione, A; Bumma, C; Colussi, AM; Comandone, A; Dal Canton, O; Frustaci, S; Leone, L; Monteleone, M; Oliva, C, 1998) |
| "Ifosfamide and cisplatin are active agents that are currently used in the treatment of osteosarcoma." | 7.70 | Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma. ( Arndt, C; Hawkins, D; Liedtke, R; Miser, J; Morgenstern, B; Wilson, D, 1999) |
| "We attempted to ascertain renal, hematologic, and neurologic tolerance to ifosfamide (IFX) in pediatric patients previously treated with large single and cumulative doses of cis-Diamminedichloroplatinum-II (CDP) for osteosarcoma (OS)." | 7.69 | Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations. ( Canpolat, C; Jaffe, N; Pearson, P; Robertson, R, 1996) |
| " A 16-year-old girl with metastatic osteosarcoma experienced recurrent bouts of symptomatic pancreatitis 24 hours after treatment with ifosfamide administered as a single agent." | 7.69 | Acute pancreatitis after ifosfamide therapy. ( Adamson, PC; Balis, FM; Blaney, SM; Izraeli, S, 1994) |
| "From January 1990 to December 1995 we treated 35 patients (pts) with bone and soft tissue sarcoma with ifosfamide (IFM)." | 7.69 | [The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T; Yonemoto, T, 1997) |
| "A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects." | 7.68 | [Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993) |
| "A total of 46 consecutive patients were entered into this study to assess the efficacy and toxicity of an epirubicin/ifosfamide combination in treating locally advanced and/or metastatic adult sarcomas (38 soft-tissue sarcomas and 7 bone sarcomas in 45 evaluable patients)." | 7.68 | Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. ( Albanese, E; Barisone, A; Canavese, G; Cantoni, E; Palumbo, R; Reggiardo, G; Rosso, R; Santi, L; Toma, S, 1993) |
| "To improve the accuracy of magnetic resonance imaging (MRI) in evaluating the response of osteosarcomas to preoperative chemotherapy, the authors developed a technique of mapping tumor necrosis and viability by quantitating slope values of gadolinium-DTPA (Gd-DTPA) uptake on dynamic fast low-angle shot (FLASH) images." | 7.68 | Assessment of osteosarcoma response to preoperative chemotherapy using dynamic FLASH gadolinium-DTPA-enhanced magnetic resonance mapping. ( Fairclough, DL; Fletcher, BD; Hanna, SL; Le, AH; Meyer, WH; Parham, DM, 1992) |
| "A 13-year-old boy with unresectable pulmonary metastatic osteosarcoma, which was refractory to high dose methotrexate, adriamycin, cisplatin and combination of bleomycin, cyclophosphamide and actinomycin D, was treated by aggressive chemotherapy including the combination of ifosfamide (1 g/m2 x day 1-4), Carboplatin (100 mg/m2 x day 1-4) and Vindesine (4 mg/m2 x day 1)." | 7.68 | [Successful treatment of metastatic and refractory osteosarcoma by ifosfamide, carboplatin and vindesine: case report]. ( Fujita, H; Ishimoto, K; Kiyokawa, N; Kyo, K; Mizuno, T; Takada, K; Yabuta, K, 1991) |
| "We have evaluated the activity of ifosfamide in 75 patients with recurrent sarcomas and pediatric solid tumors." | 7.67 | A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. ( Arasi, V; Magrath, I; Miser, J; Raynor, A; Rosenberg, S; Sandlund, J, 1986) |
| "" The regimen included an intensification of ifosfamide dosing from 1,800 mg/m(2) /day × 5 days per cycle to 2,800 mg/m(2) /day × 5 days per cycle." | 6.80 | Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. ( Chou, AJ; Goodbody, CM; Magnan, H; Pratilas, CA; Riedel, E; Wexler, LH, 2015) |
| "Patients <30 years old with Ewing sarcoma were eligible." | 6.80 | Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1. ( Abujamra, AL; Almeida, MT; Benites, E; Boldrini, E; Brunetto, AL; Castillo, LA; Costa, C; Gadelha, A; Gregianin, LJ; Kirst, D; Macedo, CD; Morais, V; Nakasato, A; Pereira, WV; Petrilli, AS; Pizza, M; Rodriguez-Galindo, C; Watanabe, FM, 2015) |
| " The authors evaluated the impact of factors such as age and prior nephrotoxic agents on MTX pharmacokinetics in children and young adults with osteosarcoma and examined whether MTX pharmacokinetic parameters were associated with outcome." | 6.71 | High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. ( Crews, KR; Daw, NC; Link, MP; Liu, T; Meyer, WH; Panetta, JC; Rodriguez-Galindo, C; Tan, M, 2004) |
| "Ifosfamide has been used in neoadjuvant chemotherapy since the mid-1980s." | 6.52 | Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials. ( Lai, Z; Lin, Y; Mo, Y; Su, W; Wu, F; Wu, J; Yang, Z, 2015) |
| "Dose-intensive chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide is more effective, less toxic, and shorter in duration for all stages of newly diagnosed Ewing sarcoma than vincristine, ifosfamide, doxorubicin, and etoposide induction and should now be the standard of care for Ewing sarcoma." | 5.51 | Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. ( Brennan, B; Fenwick, N; Gaspar, N; Gelderblom, H; Kirton, L; Laurence, V; Marec-Bérard, P; Martín-Broto, J; Moroz, V; Owens, C; Sastre, A; Strauss, S; Wheatley, K; Whelan, J, 2022) |
| "Lay abstract Traditional treatment for osteosarcoma (bone cancer) includes drugs that cause cell damage, such as ifosfamide and etoposide." | 5.41 | OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma. ( Bautista, F; Campbell-Hewson, Q; Gaspar, N; Huang, J; Okpara, CE, 2021) |
| "Osteosarcoma is the first primary malignant bone tumor, characterized by a complex genetic and resistance to conventional treatments." | 5.37 | Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. ( Alberti, L; Besse, A; Blay, JY; Duc, A; Dutour, A; Gougelet, A; Perez, J; Pissaloux, D, 2011) |
| "Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity." | 5.37 | High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. ( Baek, KK; Chang, MH; Han, B; Lee, J; Lee, SH; Lim, T; Park, JO, 2011) |
| "The effect of immunotherapy with interleukin-18 (IL-18) in combination with preoperative chemotherapy on the postoperative progression of pulmonary metastasis was examined using a spontaneous pulmonary metastasis model of mouse osteosarcoma." | 5.35 | Immunotherapy with interleukin-18 in combination with preoperative chemotherapy with ifosfamide effectively inhibits postoperative progression of pulmonary metastases in a mouse osteosarcoma model. ( Futani, H; Hata, M; Kogoe, N; Nakasho, K; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamanegi, K, 2009) |
| "Despite the fact that Ewing sarcoma family of tumors (ET) is chemosensitive, long-term survival is extremely rare for patients with primary refractory or recurrent disease." | 5.32 | VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors. ( Allam, A; Bazarbashi, S; El Foudeh, M; El Hassan, I; El Weshi, A; Ezzat, A; Memon, M; Pai, C; Rahal, M; Raja, M, 2004) |
| "In most countries, reference chemotherapy for osteosarcoma is MAP regimen (M = high-dose methotrexate, AP = doxorubicin-cisplatinum)." | 5.27 | Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. ( Bompas, E; Bouvier, C; Brisse, HJ; Brugieres, L; Castex, MP; Cheurfa, N; Corradini, N; Delaye, J; Entz-Werlé, N; Gaspar, N; Gentet, JC; Italiano, A; Le Deley, MC; Lervat, C; Marec-Berard, P; Mascard, E; Occean, BV; Pacquement, H; Piperno-Neumann, S; Redini, F; Saumet, L; Schmitt, C; Tabone, MD; Verite-Goulard, C, 2018) |
| "We examined the clinical significance of neoadjuvant chemotherapy (NACT) in limb salvage treatment of osteosarcoma and its effect on the Glutaminase 1 gene (GLS1) expression." | 5.27 | Significance of neoadjuvant chemotherapy (NACT) in limb salvage treatment of osteosarcoma and its effect on GLS1 expression. ( Li, H; Li, X; Sun, XH; Yan, XF; Zhang, SP, 2018) |
| "The European Organization for Research and Treatment of Cancer (EORTC) 62012 study was a Phase III trial of doxorubicin versus doxorubicin-ifosfamide chemotherapy in 455 patients with advanced soft tissue sarcoma (STS)." | 5.24 | Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. ( Collin, F; Daugaard, S; Fisher, C; Gronchi, A; Grünwald, V; Hogendoorn, PCW; Judson, I; Lia, M; Litière, S; Mechtersheimer, G; Messiou, C; Sciot, R; van der Graaf, W; Wardelmann, E; Young, RJ, 2017) |
| "This is the first instance of tumor lysis syndrome described in a patient with osteosarcoma undergoing ifosfamide monotherapy." | 5.22 | Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature. ( Chen, XT; Christ, AB; Hu, JS; Luminais, SN; Ma, B; Roman, D, 2022) |
| "Patients with resectable osteosarcoma aged ≤40 years were treated with the MAP regimen, comprising pre-operatively of two 5-week cycles of cisplatin 120 mg/m(2), doxorubicin 75 mg/m(2), methotrexate 12 g/m(2) × 2 (MAP) and post-operatively two further cycles of MAP and two cycles of just MA." | 5.20 | EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. ( Anninga, J; Bernstein, M; Bielack, SS; Böhling, T; Butterfass-Bahloul, T; Calaminus, G; Capra, M; Deffenbaugh, C; Dhooge, C; Eriksson, M; Flanagan, AM; Gelderblom, H; Goorin, A; Gorlick, R; Gosheger, G; Grimer, RJ; Hall, KS; Helmke, K; Hogendoorn, PC; Hook, JM; Jovic, G; Jundt, G; Kager, L; Krailo, M; Kuehne, T; Lau, CC; Letson, GD; Marina, N; Meyer, J; Meyers, PA; Morris, C; Mottl, H; Nadel, H; Nagarajan, R; Randall, RL; Schomberg, P; Schwarz, R; Smeland, S; Sydes, MR; Teot, LA; Whelan, JS, 2015) |
| "Based on the randomised Euro-EWING99-R1 trial, vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide (VAI) in the treatment of standard-risk Ewing sarcoma." | 5.20 | Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial. ( Brennan, B; Brichard, B; Craft, A; Dirksen, U; Gaspar, N; Gelderblom, H; Hjorth, L; Judson, I; Juergens, H; Kruseova, J; Kühne, T; Ladenstein, RL; Le Deley, MC; Le Teuff, G; Marec-Berard, P; Paulussen, M; van den Berg, H; Wheatley, K; Whelan, J, 2015) |
| "Studies of baseline prognostic factors in patients with localized osteosarcoma treated without high dose methotrexate are limited." | 5.20 | Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients. ( Bakhshi, S; Batra, A; Khan, SA; Nataraj, V; Rastogi, S; Sharma, MC; Vishnubhatla, S, 2015) |
| "Cyclophosphamide may be able to replace ifosfamide in consolidation treatment of standard-risk Ewing sarcoma." | 5.19 | Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. ( Brennan, B; Craft, A; Dirksen, U; Hjorth, L; Judson, I; Juergens, H; Ladenstein, R; Le Deley, MC; Le Teuff, G; Lewis, I; Marec-Bérard, P; Michon, J; Oberlin, O; Paulussen, M; Ranft, A; van den Berg, H; Wheatley, K; Whelan, J, 2014) |
| "High-dose methotrexate (HD-MTX) is recognized as an efficient component of therapy against pediatric osteosarcoma in combination with other drugs such as cisplatin (CDP), carboplatin (CBDCA), doxorubicin (ADM), etoposide (VP-16) and ifosfamide (IFO)." | 5.19 | Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. ( Anurathapan, U; Choeyprasert, W; Chuansumrit, A; Hongeng, S; Nartthanarung, A; Pakakasama, S; Sirachainan, N; Songdej, D, 2014) |
| "To improve the treatment results of patients with locally advanced osteosarcoma with large volume using neoadjuvant chemotherapy (NACT) (ifosfamide at a dose of 18 g/ml) and planning of organ-conserving surgery by evaluating the state of tumor pseudocapsule." | 5.17 | Treatment of large osteosarcoma in children: new approach. ( Golovko, TS; Gulak, LO; Kobys, VL; Konovalenko, VF; Matyushok, OF; Repinа, NV; Tarasova, TO; Zaharycheva, EV, 2013) |
| "This multicenter, phase II trial evaluated the efficacy and safety of everolimus, an mTOR inhibitor, in patients with metastatic or recurrent bone and soft-tissue sarcoma after the failure of anthracycline- and ifosfamide-containing regimens." | 5.17 | Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. ( Ahn, JH; Kim, TM; Kim, YJ; Lee, HJ; Lee, J; Lee, KH; Park, KH; Rha, SY; Yoo, C, 2013) |
| "We compared two chemotherapy regimens that included methotrexate (MTX), cisplatin (CDP), and doxorubicin (ADM) with or without ifosfamide (IFO) in patients with nonmetastatic osteosarcoma of the extremity." | 5.16 | Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. ( Alberghini, M; Bacci, G; Bertulli, R; Bisogno, G; Capanna, R; Cefalo, G; Comandone, A; Fagioli, F; Ferrari, S; Linari, A; Palmerini, E; Parafioriti, A; Picci, P; Ruggieri, P; Tamburini, A, 2012) |
| "Chemotherapy with alternating vincristine-doxorubicin-cyclophosphamide and ifosfamide-etoposide cycles and primary tumor treatment with surgery and/or radiation therapy constitute the usual approach to localized Ewing sarcoma in North America." | 5.16 | Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. ( Dickman, PS; Dormans, JP; Grier, HE; Healey, JH; Krailo, MD; Marcus, K; Pawel, BR; Sailer, S; Weiss, AR; West, DC; Womer, RB, 2012) |
| "Patients aged ≤40 years with nonmetastatic Ewing sarcoma (ES) received vincristine (V), doxorubicin (A), cyclofosfamide (C), actinomycin (Ac), ifosfamide (I) and etoposide (E) (VACAc-IE regimen) as induction chemotherapy." | 5.15 | Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. ( Alberghini, M; Alvegard, TA; Bacci, G; Barbieri, E; Brach Del Prever, A; Capanna, R; Carli, M; Fagioli, F; Ferrari, S; Gandola, L; Luksch, R; Mapelli, S; Mercuri, M; Picci, P; Prete, A; Smeland, S; Sundby Hall, K; Tamburini, A; Tienghi, A; Wiebe, T, 2011) |
| "To compare three-drug chemotherapy with cisplatin, doxorubicin, and methotrexate with four-drug chemotherapy with cisplatin, doxorubicin, methotrexate, and ifosfamide for the treatment of osteosarcoma." | 5.13 | Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. ( Bernstein, ML; Betcher, D; Ferguson, WS; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, M; Healey, JH; Kleinerman, E; Krailo, MD; Link, MP; Meyers, PA; Nadel, H; Nieder, M; Schwartz, CL; Siegal, GP; Weiner, MA; Wells, RJ; Womer, RB, 2008) |
| "Thirteen patients, median age 18 (range: 8-34), with metastatic or axial-skeletal osteosarcoma were treated with ifosfamide 2." | 5.12 | A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma. ( Lewis, I; McTiernan, A; Meyer, T; Michelagnoli, MP; Whelan, JS, 2006) |
| "The outcome of patients with metastatic osteosarcoma treated in two consecutive trials from 1986 to 1997 was analyzed to evaluate the efficacy of carboplatin-based multiagent chemotherapy and to identify prognostic factors." | 5.12 | Metastatic osteosarcoma. ( Billups, CA; Cain, AM; Daw, NC; Jenkins, JJ; McCarville, MB; Meyer, WH; Neel, MD; Rao, BN; Rodriguez-Galindo, C, 2006) |
| "In the prospective high-risk sarcoma (HIRISA) Phase II trial HIRISA1, pediatric patients with high-risk sarcomas received 3 cycles of intensive vincristine, ifosfamide, etoposide, cyclophosphamide, and doxorubicin (VACIE) before radiotherapy and/or surgery began at Week 9 with concurrent vincristine, cyclophosphamide, and doxorubicin (Week 9) and vincristine and ifosfamide (Week 12)." | 5.12 | Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience. ( Billups, CA; Cain, AM; Furman, WL; Hale, GA; Merchant, TE; Navid, F; Pappo, AS; Rao, BN; Santana, VM; Spunt, SL, 2006) |
| "Patients < or = 30 years with Ewing sarcoma, primitive neuroectodermal tumor or primitive sarcoma of bone were randomly assigned to receive chemotherapy with doxorubicin, vincristine, cyclophosphamide, and dactinomycin, (VACA) or with these four drugs alternating with ifosfamide and etoposide (VACA-IE)." | 5.12 | Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group. ( Bernstein, M; Chen, Z; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, M; Laurie, F; Miser, JS; Tarbell, NJ; Yock, TI, 2006) |
| "The SFOP-OS94 randomised multi-centre trial was designed to determine whether preoperative chemotherapy regimen combining high-dose methotrexate courses and etoposide-ifosfamide could improve the proportion of good histologic response (5% viable cells) compared to a regimen based on high-dose methotrexate and doxorubicin, in children/adolescents with localised high-grade limb osteosarcoma." | 5.12 | SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. ( Brugières, L; Dupoüy, N; Entz-Werlé, N; Gentet, JC; Guinebretière, JM; Kalifa, C; Le Deley, MC; Marec-Bérard, P; Pacquement, H; Pichon, F; Schmitt, C; Tabone, MD; Vanel, D, 2007) |
| "This randomized prospective multicenter phase III trial was designed to compare progression-free survival of patients with advanced soft tissue sarcoma receiving either regimen of standard doxorubicin 75 mg/m2 every 21 days, ifosfamide 9 g/m2 over 3 days continuous infusion, or ifosfamide 3 g/m2 per day in 3 hours over 3 days." | 5.12 | Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. ( Blay, JY; Hogendoorn, PC; Kirkpatrick, A; Le Cesne, A; Leahy, MG; Lorigan, P; Papai, Z; Radford, JA; Rodenhuis, S; Van Glabbeke, MM; Verweij, J, 2007) |
| "The combination of cisplatin, ifosfamide and epirubicin is an active, reasonably well-tolerated regimen without grade 3 or 4 cardiac toxicity in patients with nonmetastatic extremity osteosarcoma and deserves further investigation in the context of prospective phase III trials." | 5.12 | A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas. ( Atalar, AC; Basaran, M; Bavbek, ES; Bilgic, B; Eralp, L; Onat, H; Ozger, H; Saglam, S; Sakar, B, 2007) |
| "The objective of this study was to estimate the time to treatment failure and survival rate of the three-drug combination of doxorubicin, cisplatin, and ifosfamide as primary and postoperative, adjunctive treatment for teenagers and adults with osteosarcoma (OS)." | 5.11 | Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139. ( Antman, K; Biermann, JS; Budd, GT; Lanier, KS; Lucas, DR; Meyers, FJ; Muler, J; Rankin, C; Ryan, JR; Zalupski, MM, 2004) |
| "The authors evaluated the efficacy and toxicity of cisplatin, ifosfamide, and doxorubicin with peripheral blood stem cell (PBSC) support in adult patients with osteosarcomas and variants with a poor prognosis." | 5.11 | A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. ( Benjamin, RS; Champlin, R; Donato, M; Lewis, VO; Lin, PP; Papadopolous, N; Patel, SR; Raymond, AK; Seong, CM; Yasko, AW, 2004) |
| "Adding ifosfamide and etoposide to standard therapy does not improve outcomes of patients with Ewing's sarcoma or PNET of bone with metastases at diagnosis." | 5.11 | Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2004) |
| "Ifosfamide and doxorubicin are the most effective agents in the treatment of sarcomas, although their contributions to survival are usually limited." | 5.11 | High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas. ( Akbulut, H; Buyukcelik, A; Demirkazik, A; Icli, F; Pamir, A; Utkan, G; Yalcin, B, 2004) |
| "To determine whether the addition of ifosfamide and/or muramyl tripeptide (MTP) encapsulated in liposomes to cisplatin, doxorubicin, and high-dose methotrexate (HDMTX) could improve the probability for event-free survival (EFS) in newly diagnosed patients with osteosarcoma (OS)." | 5.11 | Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. ( Bernstein, ML; Betcher, D; Conrad, E; Ferguson, W; Gebhardt, M; Goorin, AM; Grier, H; Harris, MB; Healey, J; Huvos, A; Kleinerman, ES; Krailo, M; Link, M; Meyers, PA; Montebello, J; Nadel, H; Nieder, M; Sato, J; Schwartz, CL; Siegal, G; Weiner, M; Wells, R; Wold, L; Womer, R, 2005) |
| "To explore the effect of high-dose ifosfamide in first-line treatment for patients < or = 40 years of age with nonmetastatic osteosarcoma of the extremity." | 5.11 | Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. ( Alvegard, TA; Bacci, G; Bernini, G; Bertoni, F; Böhling, T; Brosjö, O; Capanna, R; Comandone, A; Del Prever, AB; Ferrari, S; Longhi, A; Mercuri, M; Müller, C; Picci, P; Ruggieri, P; Saeter, G; Smeland, S; Tienghi, A; Wiebe, T, 2005) |
| "The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone." | 5.10 | Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2003) |
| "The objectives of this trial were to estimate the response rate, progression-free survival, and overall survival of patients who received therapy with etoposide and high-dose ifosfamide, and to define the toxicity of this combination when provided with standard chemotherapy in patients with newly diagnosed metastatic osteosarcoma." | 5.10 | Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. ( Bernstein, M; Devidas, M; Ferguson, W; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, MB; Link, M; Schwartz, CL; Siegal, GP, 2002) |
| "With the intention of starting an international protocol between Italy and Scandinavia on neoadjuvant treatment of extremity osteosarcoma using the four active drugs at maximum doses (doxorubicin 75 mg/m2 pre-operatively, and 90 mg/m2 post-operatively, cisplatin 120 mg/m2, methotrexate 12 g/m2, and ifosfamide 15 g/m2), a single center (the Rizzoli institute) performed a pilot study to closely monitor toxicity, safety, and tumor necrosis." | 5.10 | High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. ( Alvegard, TA; Bacci, G; Briccoli, A; Donati, D; Ferrari, S; Forni, C; Lari, S; Longhi, A; Manfrini, M; Mercuri, M; Picci, P; Saeter, G, 2002) |
| "Twenty-four patients with soft tissue or bone sarcoma who were treated with high dose ifosfamide-based chemotherapy were enrolled in this study." | 5.09 | Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma. ( Akbulut, H; Demirkazik, A; Dinçol, D; Içli, F; Onur, H; Pamir, A; Samur, M; Sencan, O; Senler, FC; Yalçin, B, 2000) |
| "Patients with nonmetastatic osteosarcoma of the extremity were preoperatively treated with high-dose methotrexate, cisplatin, and doxorubicin (ADM)." | 5.09 | Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. ( Bacci, G; Bertoni, F; Campanacci, M; Casadei, R; Fabbri, N; Ferrari, S; Forni, C; Longhi, A; Picci, P; Ruggieri, P; Versari, M, 2000) |
| "The aim of this phase II study was to determine the efficacy of high-dose ifosfamide with moderate dose etoposide in childhood osteosarcoma." | 5.08 | Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. ( Avet-Loiseau, H; Berger, C; Bernard, JL; Brunat-Mentigny, M; De Lumley, L; Demaille, MC; Gentet, JC; Kalifa, C; Pacquement, H; Pein, F; Pillon, P; Sariban, E; Schmitt, C, 1997) |
| "To evaluate the efficacy and feasibility of high-dose ifosfamide (HDI) at a total dose of 14 g/m2 per cycle with mesna in combination with granulocyte colony-stimulating factor (G-CSF) in adult patients with sarcomas." | 5.08 | High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. ( Benjamin, RS; Burgess, MA; Hays, C; Papadopolous, N; Patel, SR; Plager, C; Vadhan-Raj, S, 1997) |
| "This Phase II trial of paclitaxel/ifosfamide included patients with bi-dimensionally measurable metastatic breast cancer in second or third relapse, following anthracycline-containing regimens; ECOG PS < 2, and adequate hepatic, cardiac, renal, and hematological functions." | 5.08 | Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer. ( Amorim, WC; Ferreira-Filho, AF; Guimaraes, RC; Morici, AC; Murad, AM; Schwartsmann, G, 1997) |
| " The aim of the present study was to assess long-term renal function in children and adolescents who received at-risk chemotherapy, including cisplatin, ifosfamide, and methotrexate, to treat an osteosarcoma." | 5.08 | Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. ( Brunat-Mentigny, M; Cochat, P; Dubourg, L; Hadj-Aïssa, A; Koch Nogueira, PC; Schell, M, 1998) |
| "Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are characterized by a marked dose-response relationship." | 5.08 | Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). ( Bacchi, M; Bressoud, A; Cerny, T; Hermann, R; Leyvraz, S; Lissoni, A; Sessa, C, 1998) |
| "In an effort to intensify osteosarcoma therapy, systemic ifosfamide was added pre- and postoperatively to an already aggressive three-drug regimen." | 5.08 | Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. ( Bielack, SS; Bieling, P; Delling, G; Epler, D; Fuchs, N; Graf, N; Heise, U; Jürgens, H; Körholz, D; Kotz, R; Salzer-Kuntschik, M; Weinel, P; Werner, M; Winkler, K, 1998) |
| "To estimate the duration of survival (S) of patients with metastatic osteosarcoma (MOS) at diagnosis treated with a multiagent, ifosfamide-containing chemotherapeutic and surgical regimen and to evaluate the toxicity of this regimen." | 5.08 | Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. ( Ayala, A; Ferguson, WS; Gieser, P; Goorin, AM; Harris, MB; Holbrook, T; Link, MP; Shochat, SJ, 1998) |
| "Doxorubicin alone or with dacarbazine (DTIC; AD) is considered the best available therapy for metastatic adult sarcomas." | 5.07 | An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. ( Antman, K; Balcerzak, SP; Barlogie, B; Cooper, RM; Crowley, J; Elias, A; Natale, RB; Rivkin, SE; Trump, DL; Weiss, GR, 1993) |
| "Nine patients with osteosarcoma were treated by chemotherapy combined with caffeine and surgery." | 5.07 | Effect of chemotherapy combined with caffeine for osteosarcoma. ( Baba, H; Tomita, K; Tsuchiya, H; Ueda, Y; Yasutake, H; Yokogawa, A, 1992) |
| "In this phase II trial, 105 eligible patients with no prior chemotherapy and advanced sarcoma received doxorubicin, ifosfamide, and dacarbazine (DTIC) with mesna uroprotection (MAID)." | 5.06 | Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. ( Aisner, J; Antman, KH; Collins, J; Elias, A; Ryan, L; Sulkes, A, 1989) |
| "Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma." | 4.91 | Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2015) |
| "The efficacy of ifosfamide-based chemotherapy in the treatment of osteosarcoma has been investigated; however, results are inconsistent." | 4.91 | Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis. ( Cai, GP; Ding, GM; Fan, XL; Zhu, LL, 2015) |
| "We observed a correlation of higher planned methotrexate total dosage and DI with better treatment outcomes in osteosarcoma patients." | 4.90 | Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years. ( Li, B; Li, H; Li, Y; Sun, L; Ye, Z; Zhang, J, 2014) |
| "To assess testicular function after standard dose ifosfamide, we evaluated 6 young adult osteosarcoma survivors (median age at diagnosis, 16." | 4.90 | Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: a case series and review of the literature. ( Diller, L; Duffey-Lind, E; Ebb, D; Grier, H; Kenney, LB; Sklar, CA, 2014) |
| " The BSTTSG has currently been conducting a Phase III trial, JCOG 0905, to investigate the superiority of the addition of ifosfamide to the standard chemotherapy with methotrexate, cisplatin and doxorubicin for operable, high-grade osteosarcoma." | 4.88 | The activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group. ( Iwamoto, Y; Tanaka, K, 2012) |
| "Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma." | 4.88 | Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2012) |
| "Ifosfamide is a chemotherapeutic prodrug used in the treatment of several tumor entities, including bone and soft-tissue sarcoma." | 4.86 | Palifosfamide, a bifunctional alkylator for the treatment of sarcomas. ( Jung, S; Kasper, B, 2010) |
| "Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma." | 4.86 | Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2010) |
| "At present, patients with nonmetastatic osteosarcoma of the extremity aged less than 40 years have an expected 5-year survival rate of 70% with a chemotherapy regimen based on methotrexate, cisplatin, doxorubicin and ifosfamide." | 4.84 | Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. ( Ferrari, S; Palmerini, E, 2007) |
| "Phase II studies conducted in Europe and the USA on pediatric solid tumors have shown that ifosfamide, as a single agent, is an active drug against a variety of neoplasms - rhabdomyosarcoma (RMS), some non-RMS soft tissue sarcomas, Wilms' tumor, bone sarcomas and neuroblastoma." | 4.82 | Ifosfamide in pediatric solid tumors. ( Bisogno, G; Carli, M; Passone, E; Perilongo, G, 2003) |
| "The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas." | 4.81 | Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. ( Ballo, MT; Benjamin, RS; Burgess, MA; Cormier, JN; Feig, BW; Herzog, CE; Hunt, KK; Patel, SR; Pisters, PW; Raney, RB; Zagars, GK, 2001) |
| "Ifosfamide is an alkylating agent with clinical activity in the treatment of sarcomas, and data support a dose-response relationship in this disease." | 4.79 | High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. ( Demetri, GD, 1996) |
| "Using high-dose methotrexate, doxorubicin, and cisplatinum (or BCD) for adjuvant chemotherapy in osteosarcoma of the extremities, we achieved 8-year metastasis-free survival rates of 60-70%." | 4.78 | Treatment of osteosarcoma: experience of the Cooperative Osteosarcoma Study Group (COSS). ( Bielack, SS; Delling, G; Jürgens, H; Kotz, R; Salzer-Kuntschik, M; Winkler, K, 1993) |
| "We have used ifosfamide to treat patients with sarcomas in four completed single-agent protocols and one pilot study since 1985." | 4.78 | Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. ( Benjamin, RS; Legha, SS; Nicaise, C; Patel, SR, 1993) |
| " The most active single agents against osteosarcoma are doxorubicin (overall response rate, 21%), methotrexate (30% to 40%), cisplatin (25%), and ifosfamide (28%)." | 4.78 | Chemotherapy of advanced sarcomas of bone and soft tissue. ( Antman, KH, 1992) |
| "Interval compression (IC), a regimen of alternating vincristine/doxorubicin/cyclophosphamide and ifosfamide/etoposide every 2 weeks, improves survival for localized Ewing sarcoma (ES), with uncertain effect on metastatic disease." | 4.31 | Outcomes of Pediatric Patients With Metastatic Ewing Sarcoma Treated With Interval Compression. ( Ghandour, K; Halalsheh, H; Ibrahimi, AKH; Ismael, T; Sarhan, N; Shehadeh, A; Sultan, I; Zandaki, D, 2023) |
| "We recruited 14 patients with osteosarcoma having acquirable lesions to establish PDX models and examine the sensitivity of nine drugs, including methotrexate (MTX), ifosfamide (IFO), epirubicin, and etoposide." | 4.31 | Predicting chemosensitivity based on mini patient-derived xenografts in osteosarcoma patients: A retrospective study. ( Chen, G; Ji, C; Li, J; Li, M; Long, Z; Lu, Y; Wang, Q; Wang, Z; Xiang, L; Yu, H, 2023) |
| "Following the 20th week of ifosfamide treatment, the patient's follow-up with the diagnosis of osteosarcoma developed neurological findings." | 4.02 | Ifosfamide induced encephalopathy in a child with osteosarcoma. ( Atay, AA; Demir, ÜF; Malbora, B; Sarbay, H; Yılmaz, G, 2021) |
| "The usefulness of adjuvant chemotherapy for high-grade osteosarcoma was established by two randomized, controlled trials conducted in the 1980s, which used six drugs, doxorubicin, cisplatin, high-dose methotrexate, bleomycin, cyclophosphamide and actinomycin D." | 4.02 | Adjuvant and neoadjuvant chemotherapy for osteosarcoma: JCOG Bone and Soft Tissue Tumor Study Group. ( Hiraga, H; Ozaki, T, 2021) |
| "For Ewing sarcoma, interval-compressed vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide administered every 2 weeks rather than every 3 weeks has been shown to improve event-free survival in pediatric patients." | 3.96 | Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide. ( Bassale, S; Davis, LE; Lim, JY; Lu, E; Ryan, CW, 2020) |
| "Current treatment of high-grade osteosarcoma consists of preoperative chemotherapy, typically using some combination of doxorubicin, cisplatin, ifosfamide, and/or high-dose methotrexate followed by surgical resection." | 3.91 | Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 Mutation. ( Savani, M; Skubitz, KM, 2019) |
| "All treatment naive consecutive patients of osteosarcoma were prospectively treated on a novel institutional regimen (named OGS-12) comprising of eight sequential doublets of the following drugs: doxorubicin, cisplatin and ifosfamide in four courses each, given in the neoadjuvant and adjuvant settings." | 3.85 | Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'. ( Bajpai, J; Banavali, SD; Chandrakanth, MV; Chandrasekharan, A; Ghosh, J; Gupta, S; Khan, A; Khurana, S; Rekhi, B; Simha, V; Talreja, V; Vora, T, 2017) |
| "Children and adolescents with nonmetastatic osteosarcoma were treated with MAP (methotrexate, doxorubicin, cisplatin) or MAPI (MAP/ifosfamide)." | 3.83 | Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. ( Bernstein, ML; Devidas, M; Gebhardt, MC; Goorin, AM; Grier, HE; Healey, JH; Krailo, MD; Lipshultz, SE; Meyers, PA; Sato, JK; Schwartz, CL; Steinherz, LJ; Teot, LA; Wexler, LH, 2016) |
| "The combination of topotecan and cyclophosphamide is active in relapsed Ewing sarcoma family of tumors (ESFT)." | 3.83 | Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. ( Bond, MC; Felgenhauer, JL; Femino, JD; Gorlick, R; Krailo, MD; Laack, NN; Marina, N; Mascarenhas, L; Meyer, J; Ranganathan, S; Villaluna, D; Womer, RB, 2016) |
| "Pirarubicin (THP), a novel anthracycline derivative of doxorubicin (ADM), is effective in treating patients with advanced, relapsed or recurrent high-grade osteosarcoma." | 3.81 | Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter? ( Lin, F; Shen, Z; Tang, L; Yao, Y; Yu, W, 2015) |
| "In recent years, chemotherapy with caffeine has manifested potently high efficacy against osteosarcoma, although adverse effects have been observed." | 3.81 | Development of tumor-specific caffeine-potentiated chemotherapy using a novel drug delivery system with Span 80 nano-vesicles. ( Iwasaki, T; Kidani, T; Masumoto, J; Miura, H; Miyazaki, T; Nakamura, A; Nakata, H; Sakayama, K, 2015) |
| "The aim of this retrospective study was to evaluate the feasibility and efficacy of response to continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for patients with recurrent or refractory osteosarcoma." | 3.81 | Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study. ( He, AN; Huang, YJ; Min, DL; Shen, Z; Sun, YJ; Yao, Y, 2015) |
| "In this study, ifosfamide-loaded poly (lactic-co-glycolic acid) (PLGA)-dextran polymeric nanoparticles (PD/IFS) was developed and studied its anticancer efficacy against multiple osteosarcoma cancer cells." | 3.81 | Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma. ( Chen, B; Lin, XJ; Wang, LF; Yang, JZ; Zhang, YJ, 2015) |
| "Ifosfamide combined with other antineoplastic agents has been effective in the treatment of osteosarcoma, although adverse effects are reported in the increasing use of ifosfamide." | 3.80 | Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury. ( Enokida, H; Hayami, H; Komiya, S; Nagano, S; Nakagawa, M; Nishimura, H; Yokouchi, M, 2014) |
| "We sought to (1) evaluate the disease-specific survival at 2 and 5 years of patients with dedifferentiated chondrosarcoma; (2) assess the prognostic variables (both patient- and treatment-related), including the use of chemotherapy with ifosfamide, that relate to survivorship; and (3) assess specific toxicities associated with ifosfamide use." | 3.80 | Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma? ( Deavers, M; Harun, N; Kawaguchi, S; Lewis, VO; Lin, PP; Sun, T, 2014) |
| "Ifosfamide and methotrexate are widely used for the treatment of pediatric osteosarcoma." | 3.80 | Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy. ( Bruneau, B; Chappé, C; Gandemer, V; Robert, G; Taque, S, 2014) |
| "We reviewed the records of 50 patients with osteosarcoma who underwent marginal resection following effective preoperative chemotherapy; 18 were treated with the MMIA (high-dose methotrexate (HD-MTX), adriamycin (ADR), ifosfamide (IFO)) and cisplatin (DDP), and 32 patients were treated with the DIA (DDP, ADR and IFO)." | 3.80 | Marginal resection for osteosarcoma with effective neoadjuvant chemotherapy: long-term outcomes. ( Xu, M; Xu, S; Yu, X, 2014) |
| "This systemic analysis was conducted to evaluate the efficacy and safety of an ifosfamide- containing regimen in treating patients with osteosarcoma." | 3.80 | Ifosfamide-containing regimens for treating patients with osteosarcomas. ( Dong, YG; Jiang, XM; Li, YY; Ma, YB; Xu, G, 2014) |
| "A retrospective study was performed to assess toxicity and response rate of ifosfamide salvage treatment for dogs diagnosed with metastatic osteosarcoma (OSA)." | 3.80 | Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma. ( Batschinski, K; Dervisis, NG; Kitchell, BE, 2014) |
| "A 73-year-old man was diagnosed with osteosarcoma and treated with four cycles of preoperative chemotherapy with ifosfamide and doxorubicin followed by wide resection." | 3.79 | Metastasis of osteosarcoma to stomach made clinically evident by hematemesis: a case report. ( Arai, E; Futamura, N; Hirata, A; Ishiguro, N; Kozawa, E; Miyahara, R; Nishida, Y; Tsukushi, S; Tsurudome, I; Urakawa, H, 2013) |
| "To determine demographic data, prognostic factors and outcome of childhood osteosarcoma treated with a carboplatin-based chemotherapeutic protocol at Chiang Mai University." | 3.79 | Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand. ( Charoenkwan, P; Choeyprasert, W; Natesirinilkul, R; Sittipreechacharn, S, 2013) |
| "The clinical data of 75 patients who received pirarubicin-based (n = 52) or gemcitabine-docetaxel (n = 23) chemotherapy as a second-line treatment for relapsed and refractory osteosarcoma between January 2005 and September 2011were reviewed retrospectively." | 3.79 | Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience. ( He, A; Huang, Y; Qi, W; Shen, Z; Sun, Y; Yang, Y; Yao, Y; Zhao, H, 2013) |
| "The objective of this study was to investigate the efficacy and toxic side effects of two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide on treating Chinese osteosarcoma patients." | 3.77 | Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. ( Dong, Y; Lin, F; Shen, Z; Sun, Y; Tang, L; Wang, Q; Yao, Y; Yu, W; Zheng, S, 2011) |
| "We retrospectively examined the incidence, severity, and risk factors of ifosfamide encephalopathy in 61 Japanese patients with bone and soft tissue sarcomas at our institution." | 3.76 | Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors. ( Kikuchi, S; Konno, S; Tajino, T; Takeda, A; Yamada, H, 2010) |
| "This study assessed the therapeutic effect of and adverse reactions to pirarubicin (THP) chemotherapy in osteosarcoma patients with lung metastasis, and analyzed the relationship between THP therapeutic effect and expression of p-glycoprotein and topoisomerase-II." | 3.76 | Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis. ( Chen, P; Lin, F; Sun, Y; Wang, Z; Yao, Y; Zhao, H, 2010) |
| "In an attempt to find leads to such markers, we have obtained microarray gene expression profiles from a panel of 10 different human osteosarcoma xenografts and related the results to their sensitivity to ifosfamide, doxorubicin, and cisplatin." | 3.75 | Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide. ( Bruheim, S; Fodstad, O; Ju, J; Xi, Y, 2009) |
| " Flow cytometric analyses by means of annexin-V and propidium iodide double staining and immunofluorescence staining of active caspase-3 revealed that cells subjected to a lethal dose of chloroacetaldehyde displayed features characteristic of necrosis and that caspase-3 was not activated in response to chloroacetaldehyde." | 3.74 | Necrotic pathway in human osteosarcoma Saos-2 cell death induced by chloroacetaldehyde. ( Fujimoto, Y; Sakurai, K; Takahashi, K; Tanaka, H, 2007) |
| " We report a 9-year-old boy with osteosarcoma who experienced 2 episodes of pancreatitis 1 day and 48 days after infusion of ifosfamide (IFOS), respectively." | 3.74 | Acute pancreatitis associated with ifosfamide. ( Hung, GY; Hung, MC; Lin, PC; Tien, YC; Tiu, CM, 2007) |
| "Sixteen pediatric osteosarcoma patients, previously treated with conventional chemotherapy (including ifosfamide (IFX), 9 g/m(2)) were retreated with high-dose ifosfamide (HD-IFX, 14 g/m(2) per course), following relapse or development of a new bone tumor." | 3.73 | High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. ( Berberoğlu, S; Berrak, SG; Ilhan, IE; Jaffe, N; Pearson, M, 2005) |
| "Cyclophosphamide (CTX) and ifosfamide (IFX) are alkylating agents used to treat osteosarcoma (OS)." | 3.73 | Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. ( Duan, X; Jia, SF; Kleinerman, ES; Koshkina, N, 2006) |
| "A 16-year-old girl with a distal femur osteosarcoma became pain-free with the first treatment of methotrexate 12." | 3.72 | Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid. ( Cohen, IJ, 2003) |
| " During the initial therapy, an ifosfamide-induced encephalopathy occurred as status epilepticus." | 3.72 | Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide? ( Bellos, F; Egerer, G; Harter, C; Ho, AD; Kasper, B; Krasniqi, F; Meissner, J, 2004) |
| " Three drugs have recently been approved: Gleevec (imatinib mesylate) at a starting dose of 400 or 600 mg daily for the treatment of malignant unresectable and/or metastatic gastrointestinal stromal tumors; Mesnex (mesna) tablets as a prophylactic agent to reduce the incidence of ifosfamide-induced hemorrhagic cystitis, and Zometa (zoledronic acid) for the treatment of patients with multiple myeloma and for patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy." | 3.71 | U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. ( Cohen, MH; Dagher, R; Griebel, DJ; Ibrahim, A; Martin, A; Pazdur, R; Scher, NS; Sokol, GH; Williams, GA, 2002) |
| "To determine the activity of carboplatin/ifosfamide in patients with previously untreated osteosarcoma and to estimate patient outcomes after a multiagent chemotherapy protocol that eliminated cisplatin." | 3.71 | Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. ( Fletcher, BD; Harper, J; Jenkins, JJ; Mahmoud, HH; Marina, NM; Meyer, WH; Neel, M; Pappo, AS; Parham, DM; Poquette, CA; Pratt, CB; Rao, BN, 2001) |
| "Between January 1995 and December 1999, 11 patients with synchronous multifocal osteosarcoma (SMO) received neoadjuvant treatment with high-dose methotrexate, cisplatinum, Adriamycin, and ifosfamide." | 3.71 | Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases. ( Bacci, G; Bernini, G; Biagini, R; Briccoli, A; Capanna, R; Donati, D; Fabbri, N; Ferrari, S; Longhi, A; Versari, M, 2001) |
| "Ifosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor." | 3.70 | [Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)]. ( Agata, H; Fujimoto, T; Hamaguchi, N; Hirota, T; Iwata, A; Katano, N; Kitagawa, S; Kobayashi, S; Konno, K; Sato, T; Sawada, K; Takeuchi, M, 1998) |
| "This prospective study was designed to test the activity of an ifosfamide-etoposide (VP-16) regimen on poor-risk, nonmetastatic, osteogenic sarcoma." | 3.70 | Postsurgical etoposide-ifosfamide regimen in poor-risk nonmetastatic osteogenic sarcoma. ( Ben Arush, MW; Drumea, K; Haim, N; Kuten, A; Meller, I; Moses, M; Stein, ME, 1998) |
| "A neoadjuvant chemotherapy protocol (1/93-1/95) for extremity osteosarcoma preoperatively using high-dose methotrexate (HDMTX) as single agent per cycle and three different combinations of other drugs (CDP/IFO,CDP/ADM,IFO/ADM) is reported." | 3.70 | Neoadjuvant chemotherapy for extremity osteosarcoma--preliminary results of the Rizzoli's 4th study. ( Bacci, G; Bernini, G; Brach del Prever, A; Capanna, R; Cesari, M; Comandone, A; Ferrari, S; Longhi, A; Mercuri, M; Picci, P; Tienghi, A, 1998) |
| "Ifosfamide is a leading drug in soft tissue sarcoma therapy." | 3.70 | Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. ( Bergnolo, P; Boglione, A; Bumma, C; Colussi, AM; Comandone, A; Dal Canton, O; Frustaci, S; Leone, L; Monteleone, M; Oliva, C, 1998) |
| "Ifosfamide and cisplatin are active agents that are currently used in the treatment of osteosarcoma." | 3.70 | Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma. ( Arndt, C; Hawkins, D; Liedtke, R; Miser, J; Morgenstern, B; Wilson, D, 1999) |
| "We attempted to ascertain renal, hematologic, and neurologic tolerance to ifosfamide (IFX) in pediatric patients previously treated with large single and cumulative doses of cis-Diamminedichloroplatinum-II (CDP) for osteosarcoma (OS)." | 3.69 | Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations. ( Canpolat, C; Jaffe, N; Pearson, P; Robertson, R, 1996) |
| "A 20-year old man was treated for an osteosarcoma with a chemotherapy regimen that included ifosfamide, methotrexate, and doxorubicin." | 3.69 | Ifosfamide-induced Fanconi syndrome. ( Garcia, AA, 1995) |
| " A 16-year-old girl with metastatic osteosarcoma experienced recurrent bouts of symptomatic pancreatitis 24 hours after treatment with ifosfamide administered as a single agent." | 3.69 | Acute pancreatitis after ifosfamide therapy. ( Adamson, PC; Balis, FM; Blaney, SM; Izraeli, S, 1994) |
| "Three chemotherapy regimens comprised of doxorubicin, high dose methotrexate, cisplatin, and ifosfamide were retrospectively analyzed in 67 pediatric osteosarcoma patients." | 3.69 | Neoadjuvant chemotherapy for pediatric osteosarcoma patients. ( Araki, N; Myoui, A; Shinto, Y; Uchida, A; Ueda, T; Yoshikawa, H, 1997) |
| "High-dose ifosfamide (HD-IFX) has shown significant antitumor activity in advanced sarcoma and breast carcinoma." | 3.69 | Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis. ( Albanell, J; Baselga, J; Bellmunt, J; Casado, S; Eres, N; Ribas, A, 1997) |
| "Eighteen patients with high grade malignant fibrous histiocytoma (MFH) of bone and 112 patients with high grade osteosarcoma (OS) of the extremity were treated with neoadjuvant chemotherapy comprised of methotrexate, cisplatinum, doxorubicin and ifosfamide." | 3.69 | Neoadjuvant chemotherapy for osseous malignant fibrous histiocytoma of the extremity: results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen. ( Bacci, G; Bertoni, F; Campanacci, M; Cesari, M; Ferrari, S; Forni, C; Gasbarrini, A; Mercuri, M; Sottili, S; Tienghi, A, 1997) |
| "From January 1990 to December 1995 we treated 35 patients (pts) with bone and soft tissue sarcoma with ifosfamide (IFM)." | 3.69 | [The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T; Yonemoto, T, 1997) |
| "A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects." | 3.68 | [Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993) |
| "A total of 46 consecutive patients were entered into this study to assess the efficacy and toxicity of an epirubicin/ifosfamide combination in treating locally advanced and/or metastatic adult sarcomas (38 soft-tissue sarcomas and 7 bone sarcomas in 45 evaluable patients)." | 3.68 | Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. ( Albanese, E; Barisone, A; Canavese, G; Cantoni, E; Palumbo, R; Reggiardo, G; Rosso, R; Santi, L; Toma, S, 1993) |
| "To improve the accuracy of magnetic resonance imaging (MRI) in evaluating the response of osteosarcomas to preoperative chemotherapy, the authors developed a technique of mapping tumor necrosis and viability by quantitating slope values of gadolinium-DTPA (Gd-DTPA) uptake on dynamic fast low-angle shot (FLASH) images." | 3.68 | Assessment of osteosarcoma response to preoperative chemotherapy using dynamic FLASH gadolinium-DTPA-enhanced magnetic resonance mapping. ( Fairclough, DL; Fletcher, BD; Hanna, SL; Le, AH; Meyer, WH; Parham, DM, 1992) |
| "A 13-year-old boy with unresectable pulmonary metastatic osteosarcoma, which was refractory to high dose methotrexate, adriamycin, cisplatin and combination of bleomycin, cyclophosphamide and actinomycin D, was treated by aggressive chemotherapy including the combination of ifosfamide (1 g/m2 x day 1-4), Carboplatin (100 mg/m2 x day 1-4) and Vindesine (4 mg/m2 x day 1)." | 3.68 | [Successful treatment of metastatic and refractory osteosarcoma by ifosfamide, carboplatin and vindesine: case report]. ( Fujita, H; Ishimoto, K; Kiyokawa, N; Kyo, K; Mizuno, T; Takada, K; Yabuta, K, 1991) |
| "We have evaluated the activity of ifosfamide in 75 patients with recurrent sarcomas and pediatric solid tumors." | 3.67 | A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. ( Arasi, V; Magrath, I; Miser, J; Raynor, A; Rosenberg, S; Sandlund, J, 1986) |
| "Patients with cutaneous/subcutaneous Ewing sarcoma may have better prognosis than those with Ewing sarcoma at other anatomical sites." | 3.01 | Clinical characteristics of primary cutaneous and subcutaneous Ewing sarcoma. ( Aiba, H; Arakawa, A; Imai, T; Iwata, S; Kawai, A; Kimura, H; Kobayashi, E; Kojima, Y; Ogawa, C; Shimoi, T; Sudo, K; Yazaki, S; Yonemori, K; Yoshida, A, 2023) |
| "Based on preclinical data for the antitumour effect of zoledronate in osteosarcoma, we assessed whether zoledronate combined with chemotherapy and surgery improved event-free survival in children and adults with osteosarcoma." | 2.82 | Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. ( Blay, JY; Bompas, E; Bonnet, N; Brisse, H; Brugières, L; Chevance, A; Corradini, N; Entz-Werlé, N; Gentet, JC; Gomez-Brouchet, A; Gouin, F; Guinebretière, JM; Italiano, A; Le Deley, MC; Lervat, C; Marec-Bérard, P; Mascard, E; Pacquement, H; Penel, N; Petit, P; Piperno-Neumann, S; Rédini, F; Tabone, MD, 2016) |
| "" The regimen included an intensification of ifosfamide dosing from 1,800 mg/m(2) /day × 5 days per cycle to 2,800 mg/m(2) /day × 5 days per cycle." | 2.80 | Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. ( Chou, AJ; Goodbody, CM; Magnan, H; Pratilas, CA; Riedel, E; Wexler, LH, 2015) |
| "Patients <30 years old with Ewing sarcoma were eligible." | 2.80 | Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1. ( Abujamra, AL; Almeida, MT; Benites, E; Boldrini, E; Brunetto, AL; Castillo, LA; Costa, C; Gadelha, A; Gregianin, LJ; Kirst, D; Macedo, CD; Morais, V; Nakasato, A; Pereira, WV; Petrilli, AS; Pizza, M; Rodriguez-Galindo, C; Watanabe, FM, 2015) |
| "The standard treatment of osteosarcoma includes cisplatin and high-dose methotrexate (HDMTX); both agents exert significant toxicity, and HDMTX requires complex pharmacokinetic monitoring and leucovorin rescue." | 2.76 | Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. ( Billups, CA; Daw, NC; Jenkins, JJ; Luchtman-Jones, L; Neel, MD; Quintana, J; Rao, BN; Santana, VM; Villarroel, M; Wu, J, 2011) |
| "The European Intergroup Cooperative Ewing's Sarcoma Study investigated whether cyclophosphamide has a similar efficacy as ifosfamide in standard-risk (SR) patients and whether the addition of etoposide improves survival in high-risk (HR) patients." | 2.73 | Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. ( Cassoni, A; Craft, AW; Douglas, C; Dunst, J; Grimer, R; Hackshaw, A; Hunold, A; Jürgens, H; Köhler, G; Ladenstein, R; Lewis, I; McTiernan, A; Paulussen, M; Poremba, C; Schuck, A; Spooner, D; van den Berg, H; Whelan, J; Winkelmann, W; Zoubek, A, 2008) |
| "Median age at diagnosis of Ewing sarcoma was 12 years, and median length of follow-up, 8 years." | 2.73 | Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. ( Askin, FB; Bhatia, S; Burden, L; Chen, Z; Dickman, PS; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Perlman, EJ; Rausen, AR; Robison, LL; Vietti, TJ, 2007) |
| " The authors evaluated the impact of factors such as age and prior nephrotoxic agents on MTX pharmacokinetics in children and young adults with osteosarcoma and examined whether MTX pharmacokinetic parameters were associated with outcome." | 2.71 | High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. ( Crews, KR; Daw, NC; Link, MP; Liu, T; Meyer, WH; Panetta, JC; Rodriguez-Galindo, C; Tan, M, 2004) |
| "Grade 3 thrombocytopenia was observed in five cases (36%)." | 2.71 | Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report. ( Kitamura, T; Kume, H; Matsumoto, S; Nishimatsu, H; Okamoto, N; Suzuki, M; Takahashi, S; Tomita, K, 2005) |
| " was applied in combination with high-dose methotrexate (HDMTX) and adriamycin (ADM) within a three-drug regimen." | 2.70 | A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. ( Bacchini, P; Bacci, G; Bertoni, F; De Giorgi, U; Ferrari, S; Fiorentini, G; Forni, C; Longhi, A; Mercuri, M; Picci, P; Rimondini, S; Tienghi, A, 2001) |
| "Six hundred ninety Ewing tumor patients were treated between 1992 and 1999 with local therapy and vincristine." | 2.70 | Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. ( Ahrens, S; Aulitzky, WE; Dunst, J; Fölsch, UR; Göbel, U; Harms, D; Hense, HW; Henze, G; Jürgens, H; Kremens, B; Lehnert, M; Niemeyer, C; Paulussen, M; Reiter, A; Taeger, D; Voûte, PA; Wagner, A; Zoubek, A, 2001) |
| "Two hundred one patients had no metastases." | 2.69 | Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. ( Cotterill, S; Craft, A; Grimer, R; Imeson, J; Lewis, I; Malcolm, A; Souhami, R; Spooner, D, 1998) |
| "The Cooperative Ewing Sarcoma Study (CESS 86), conducted by the German Society of Pediatric Oncology and Hematology (GPOH), was planned on the basis of the results of the preceding CESS 81 study." | 2.69 | Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study. ( Ahrens, S; Braun-Munzinger, G; Dunst, J; Göbel, U; Harms, D; Heinecke, A; Hoffmann, C; Jabar, S; Jürgens, H; Paulussen, M; Rübe, C; Treuner, J; Winkelmann, W; Winkler, K, 1999) |
| "The first Scandinavian protocol for Ewing's sarcoma, SSG IV, resulted in a local control rate of 74% and 5-year metastasis-free survival (MFS) of 43%." | 2.69 | Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol. ( Akerman, M; Alvegård, TA; Björk, O; Blomqvist, CP; Elomaa, I; Saeter, G; Stenwig, E; Wiebe, T, 2000) |
| "Malignant fibrous histiocytoma (MFH) is a rare bone tumor usually treated like osteosarcoma." | 2.68 | Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors. ( Bacci, G; Ferrari, S; Mercuri, M; Picci, P, 1997) |
| "Extraosseous Ewing sarcoma is a rare, poorly differentiated round-cell tumour that is part of the Ewing sarcoma family of tumours." | 2.61 | Primary Ewing sarcoma of the larynx with distant metastasis: a case report and review of the literature. ( Khalifeh, I; Maroun, CA; Moukarbel, RV; Tfayli, A, 2019) |
| "Ifosfamide has been used in neoadjuvant chemotherapy since the mid-1980s." | 2.52 | Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials. ( Lai, Z; Lin, Y; Mo, Y; Su, W; Wu, F; Wu, J; Yang, Z, 2015) |
| "Osteosarcoma is a rare tumor and any effort should be made to improve the level of International collaboration." | 2.52 | An update on chemotherapy for osteosarcoma. ( Ferrari, S; Serra, M, 2015) |
| "Chemotherapy for treatment of osteosarcoma was demonstrated to be effective in eradicating primary tumor and pulmonary metastases in the mid-twentieth century." | 2.50 | Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma. ( Jaffe, N, 2014) |
| "While most invasive primary breast cancers are epithelial derived adenocarcinomas, rare neoplasms such as the phyllodes tumor may arise from mesenchymal tissue." | 2.49 | Unusual aggressive breast cancer: metastatic malignant phyllodes tumor. ( Singer, A; Tresley, J; Velazquez-Vega, J; Yepes, M, 2013) |
| "Here, we present an approach to the treatment of Ewing sarcoma in a patient with PFIC1." | 1.91 | Successful Treatment of Patient With Ewing Sarcoma in the Setting of Inherited Cholestatic Liver Disease. ( Bailey, KM; Daley, J; Friehling, E; Halligan, K; Howrie, D; Salgado, CM; Superdock, A, 2023) |
| "Osteosarcoma is one of the most common childhood bone malignancies." | 1.91 | Outcomes and survival rates of childhood osteosarcoma in Iran, A report from MAHAK Pediatric Cancer Treatment and Research Center, from 2007 to 2020. ( Mehrvar, A; Mehrvar, N; Sadeghi, Y; Tashvighi, M, 2023) |
| "However, because sarcoma is very rare, there is little evidence regarding the management of elderly patients with sarcoma." | 1.72 | Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. ( Ozaki, T; Tanaka, K, 2022) |
| "Most aspects of osteosarcoma have been addressed in detail, but there is no comprehensive analysis of deceased patients and causes of death." | 1.72 | Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS). ( Bielack, SS; Blattmann, C; Borkhardt, A; Csóka, M; Hassenpflug, W; Hecker-Nolting, S; Kabíčková, E; Kager, L; Kessler, T; Kevric, M; Kratz, C; Kühne, T; Lehrnbecher, T; Mayer-Steinacker, R; Mettmann, V; Metzler, M; Reichardt, P; Rossig, C; Sorg, B; von Luettichau, I; Windhager, R, 2022) |
| "Osteosarcoma is the most common primary bone malignancy in both children and adults." | 1.62 | A Retrospective Comparative Analysis of Outcomes and Prognostic Factors in Adult and Pediatric Patients with Osteosarcoma. ( Bui, NQ; Charville, GW; Ganjoo, KN; Hu, BD; Pribnow, A; Saadeh, NL; Spunt, SL; Testa, S, 2021) |
| "Adult Ewing sarcoma (ES) is a rare disease, the optimal treatment model is unknown." | 1.51 | Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience. ( He, A; Hu, H; Huang, Y; Shen, Z; Sun, Y; Yao, Y; Zhang, J; Zhou, Y, 2019) |
| "The management of osteosarcoma is challenging especially in lower-income and middle-income countries, and there is an unmet need to evolve efficient and sustainable chemotherapy regimens." | 1.51 | Osteosarcoma journey over two decades in India: Small steps, big changes. ( Bajpai, J; Banavali, S; Chandrasekharan, A; Ghosh, J; Gupta, S; Hingmare, S; Mandal, T; Rangarajan, B; Rekhi, B; Shah, K; Shetty, N; Simha, V; Vora, T, 2019) |
| "Ifosfamide (IFA) is a potent alkylating antitumoral agent, but its use is limited by neurological side effects." | 1.48 | Possible role of CYP2B6 genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases. ( Bellien, J; Duflot, T; Filhon, B; Joannidès, R; Lamoureux, F; Marie-Cardine, A; Massy-Guillemant, N; Pereira, T; Verstuyft, C, 2018) |
| "Considering the physical condition of patient, the patient underwent surgical resection of the right lung lesion after receiving endostar combined with chemotherapy and maintained endostar alone for 47 cycles." | 1.46 | Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report. ( Dong, Y; Jiang, S; Wang, G, 2017) |
| "Patients with bones or brain metastases were treated with palliative radiotherapy only or combined with Doxorubicin." | 1.43 | Treatment of Patients with Distant Metastases from Phyllodes Tumor of the Breast. ( Blecharz, P; Jakubowicz, J; Kulpa, J; Mituś, JW; Reinfuss, M; Walasek, T, 2016) |
| "The incidence of Ewing sarcoma is lower in non-Caucasian populations, compared with Caucasian populations, for unknown reasons." | 1.43 | Treatment outcomes of Japanese patients with Ewing sarcoma: differences between skeletal and extraskeletal Ewing sarcoma. ( Aoki, Y; Araki, N; Hamada, K; Imura, Y; Joyama, S; Kakunaga, S; Naka, N; Obata, H; Takenaka, S; Ueda, T; Yoshikawa, H, 2016) |
| "Data on patients with localized Ewing sarcoma family of tumors (ESFT) who have received a uniform chemotherapy protocol are minimal." | 1.42 | Developing a prognostic model for localized Ewing sarcoma family of tumors: A single institutional experience of 224 cases treated with uniform chemotherapy protocol. ( Agarwala, S; Bakhshi, S; Biswas, B; Deo, SV; Khan, SA; Mohanti, BK; Rastogi, S; Sharma, MC; Shukla, NK; Vishnubhatla, S, 2015) |
| "A 9-year-old girl with Ewing sarcoma had one ovary excised and cryopreserved prior to chemo- and radiotherapy." | 1.39 | Case report: stimulation of puberty in a girl with chemo- and radiation therapy induced ovarian failure by transplantation of a small part of her frozen/thawed ovarian tissue. ( Andersen, CY; Birkebæk, NH; Clausen, N; Ernst, E; Kjærsgaard, M, 2013) |
| "Mice implanted with Ewing's sarcoma tumours received the following treatments: saline, ifosfamide, ifosfamide + NAC concurrently, pre-treatment with NAC + ifosfamide, or NAC alone." | 1.38 | The Effects of N-acetylcysteine on ifosfamide efficacy in a mouse xenograft model. ( Figueredo, R; Hanly, L; Koren, G; Koropatnick, J; Rieder, MJ, 2012) |
| "Alveolar soft part sarcomas are rarely seen and highly malignant tumors, and the prognosis of stage IV ASPS is poor." | 1.38 | [Treatment and prognosis of stage IV alveolar soft part sarcoma]. ( Yang, Y; Zhao, J, 2012) |
| "Information is scarce on systemic treatment of pelvic osteosarcoma because most chemotherapy protocols for osteosarcoma include patients with extremity tumors and aged up to 30-40 years." | 1.38 | Osteosarcoma of the pelvis: a monoinstitutional experience in patients younger than 41 years. ( Alberghini, M; Fabbri, N; Ferrari, C; Ferrari, S; Palmerini, E; Picci, P; Staals, E, 2012) |
| "Osteosarcoma is the first primary malignant bone tumor, characterized by a complex genetic and resistance to conventional treatments." | 1.37 | Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. ( Alberti, L; Besse, A; Blay, JY; Duc, A; Dutour, A; Gougelet, A; Perez, J; Pissaloux, D, 2011) |
| "We evaluated whether Korean Ewing sarcoma family of tumors patients have poorer outcomes than Euro-American patients." | 1.37 | Treatment outcome of Korean patients with localized Ewing sarcoma family of tumors: a single institution experience. ( Cho, J; Cho, WH; Jeon, DG; Kim, DH; Kim, MS; Koh, JS; Kong, CB; Lee, JA; Lee, SY; Lim, JS; Song, WS; Yoo, JY, 2011) |
| "Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity." | 1.37 | High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. ( Baek, KK; Chang, MH; Han, B; Lee, J; Lee, SH; Lim, T; Park, JO, 2011) |
| "Ifosfamide is a widely used chemotherapeutic agent for the treatment of a broad spectrum of solid tumors." | 1.36 | Ifosfamide-induced encephalopathy and movement disorder. ( Ames, B; Chaffee, S; Kim, J; Lewis, LD; Morse, R, 2010) |
| "The emergence of a primitive neuroectodermal tumor (PNET) within a germ-cell tumor (GCT) is rare." | 1.36 | Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor. ( Andreoiu, M; Beck, SDW; Brames, MJ; Cheng, L; Ehrlich, Y; Einhorn, LH; Foster, RS; Ulbright, TM, 2010) |
| "Neuroblastoma is the most common extracranial solid malignancy in children but rarely described in adults, being 10% of all cases diagnosed after the first decade of life." | 1.36 | Neuroblastoma in an adult: case report. ( Ferreti Bonan, PR; Martelli-Júnior, H; Miranda Soares, PB; Pereira DE Souza, W; Quirino Filho, S, 2010) |
| "We present a case of pleomorphic malignant fibrous histiocytoma arising from the left forearm in a 45-year-old man who had undergone resection and radiotherapy for a tumor 3 years previously." | 1.35 | Pleomorphic malignant fibrous histiocytoma: response of bone, lung, and brain metastases to chemotherapy. ( Hoshi, M; Ieguchi, M; Takami, M, 2008) |
| "The outcome of Ewing's sarcoma depends on the anatomical site of the tumor." | 1.35 | Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone. ( Arpaci, F; Ataergin, S; Beyzadeoglu, M; Komurcu, S; Oysul, K; Ozet, A; Ozturk, M; Solchaga, L; Surenkok, S; Turan, M, 2009) |
| "After a search for Ewing tumors in the database of a single institution over a period of 20 years, 16 out of 192 cases were found to have extra-osseous primary tumors." | 1.35 | Extra-osseous Ewing sarcoma. ( Heinen, RC; Merks, JH; van den Berg, H; van der Pal, HJ, 2009) |
| "The effect of immunotherapy with interleukin-18 (IL-18) in combination with preoperative chemotherapy on the postoperative progression of pulmonary metastasis was examined using a spontaneous pulmonary metastasis model of mouse osteosarcoma." | 1.35 | Immunotherapy with interleukin-18 in combination with preoperative chemotherapy with ifosfamide effectively inhibits postoperative progression of pulmonary metastases in a mouse osteosarcoma model. ( Futani, H; Hata, M; Kogoe, N; Nakasho, K; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamanegi, K, 2009) |
| "Advances in the treatment of Ewing sarcoma family of tumors (ESFT) are the result of improvements in systemic and local therapies." | 1.35 | Prognostic factors for local and distant control in Ewing sarcoma family of tumors. ( Billups, CA; Krasin, MJ; Liu, T; Navid, F; Rao, BN; Rodríguez-Galindo, C, 2008) |
| "Forty patients with localized Ewing sarcoma (ES) were treated with primary site RT at one institution." | 1.34 | Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma. ( Mai, WY; Nguyen, TX; Paulino, AC; Teh, BS; Wen, BC, 2007) |
| "From 1979 to 2002, 27 patients with Ewing's sarcoma (20) or PNET (7) were treated." | 1.34 | Ewing's sarcoma and primitive neuroectodermal tumour in adults: single-centre experience in The Netherlands. ( Boven, E; Meijer, OW; Smorenburg, CH; van Groeningen, CJ; Visser, M, 2007) |
| " Adverse reactions (AR) were evaluated; quality assurance of data collection reviewed." | 1.33 | Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. ( Craft, A; Juergens, C; Juergens, H; Lewis, I; Michon, J; Oberlin, O; Paulussen, M; Weston, C; Whelan, J; Zoubek, A, 2006) |
| "The number of metastases at diagnosis and the completeness of surgical resection of all clinically detected tumor sites are of independent prognostic value in patients with proven primary metastatic osteosarcoma." | 1.32 | Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. ( Bielack, SS; Branscheid, D; Flege, S; Gadner, H; Jundt, G; Jürgens, H; Kabisch, H; Kager, L; Kastner, U; Kempf-Bielack, B; Kotz, R; Pötschger, U; Reichardt, P; Salzer-Kuntschik, M; Winkelmann, W; Zoubek, A, 2003) |
| "Thirty-seven patients had distant metastases at presentation." | 1.32 | Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. ( Hatano, H; Hotta, T; Kawashima, H; Morita, T; Ogose, A; Ueda, T; Yazawa, Y, 2003) |
| "An ileoilealic intussusception was found, caused by a small bowel tumour, which almost completely obstructed the intestinal lumen." | 1.32 | Ileoileal intussusception caused by a Ewing sarcoma tumour. An unusual case report. ( Boehm, R; Joppich, I; Landes, J; Schmid, I; Till, H, 2003) |
| "Spinal cord compression has also been rarely reported in all age groups." | 1.32 | Spinal cord compression and lung metastasis of Wilms' tumor in a pregnant adolescent. ( Akansel, G; Arisoy, AE; Calişkan, M; Corapcioglu, F; Dillioğlugil, O; Sarper, N, 2004) |
| "Osteosarcoma is the most common primary malignant tumor of bone (annual incidence: 2 - 3/Mio)." | 1.32 | [Goal and results of the COSS study]. ( Bielack, S; Flege, S, 2004) |
| "Despite the fact that Ewing sarcoma family of tumors (ET) is chemosensitive, long-term survival is extremely rare for patients with primary refractory or recurrent disease." | 1.32 | VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors. ( Allam, A; Bazarbashi, S; El Foudeh, M; El Hassan, I; El Weshi, A; Ezzat, A; Memon, M; Pai, C; Rahal, M; Raja, M, 2004) |
| "Older age and axial location of Ewing's sarcoma have been reported as unfavorable prognostic factors." | 1.32 | Ewing's sarcoma of the axial system in patients older than 15 years: dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment. ( Argon, A; Basaran, M; Bavbek, SE; Camlica, H; Darendeliler, E; Dizdar, Y; Onat, H; Ozger, H; Sakar, B; Yaman, F, 2004) |
| "Although the overall results of treatment of Ewing's tumors have improved, patients with high-risk factors, including metastatic disease at diagnosis, bulky primary tumors, axial sites, and age >15 years, continue to have poor prognoses." | 1.31 | High-dose chemotherapy and autologous peripheral blood stem-cell transfusion after conventional chemotherapy for patients with high-risk Ewing's tumors. ( Iwamoto, Y; Matsuda, S; Matsunobu, T; Sakamoto, A; Tanaka, K, 2002) |
| "Ewing sarcoma is the second most common bone tumor in childhood." | 1.31 | Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide. ( Delattre, O; Poupon, MF; Sancéau, J; Sastre-Garau, X; Wietzerbin, J, 2002) |
| "Data on 359 patients with nonmetastatic Ewing's sarcoma of bone treated at a single institution between January 1979 and April 1995 were retrospectively considered." | 1.31 | Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. ( Bacchini, P; Bacci, G; Bertoni, F; Donati, D; Ferrari, S; Forni, C; Longhi, A; Manfrini, M; Picci, P; Rimondini, S, 2000) |
| "Patients had Ewing's sarcoma/primitive neuroectodermal tumour (PNET), rhabdomyosarcoma, non-rhabdo soft tissue sarcomas or other advanced soft tissue tumours." | 1.31 | Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. ( Daller, RT; Fenton, JG; Miser, JS; Womer, RB, 2000) |
| "Our 35-year-old patient had atypical carcinoid tumor metastatic to cervical, supraclavicular, mediastinal, and mesenteric lymph nodes and to the liver and bone." | 1.31 | High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor. ( Anthony, LB; Drouant, G; Espanan, GD; Maloney, TJ; McCarthy, KE; Meyers, MO; Woltering, EA, 2000) |
| "A young woman presented with a pineoblastoma treated initially with whole neuraxis radiotherapy." | 1.31 | Long-term survival following extra-neural metastasis from a pineoblastoma. ( Fraser, G; Nicoll, J; Rampling, R; Smith, C; Stephen, M, 2000) |
| "Cooperative Ewing's Sarcoma Study (CESS) 86 aimed at improving event-free survival (EFS) in patients with high-risk localized Ewing tumor of bone." | 1.31 | Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. ( Ahrens, S; Amann, G; Dockhorn-Dworniczak, B; Dunst, J; Exner, GU; Gadner, H; Göbel, U; Harms, D; Janka-Schaub, G; Jürgens, H; Kornhuber, B; Kotz, R; Müller-Weihrich, S; Paulussen, M; Treuner, J; Voûte, PA; Welte, K; Winkelmann, W; Zoubek, A, 2001) |
| "We describe a 16-year-old girl with a Ewing sarcoma who was given post-operative treatment with HDI (15 mg/m(2) infused over 5 days)." | 1.31 | Painful peripheral neuropathy after treatment with high-dose ifosfamide. ( Frisk, P; Stålberg, E; Strömberg, B, 2001) |
| "Osteosarcoma is a primary malignancy of bone." | 1.31 | Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection. ( Berend, KR; Dibernardo, L; Harrelson, JM; Moore, JO; Pietrobon, R; Scully, SP, 2001) |
| "Since 1985, 54 with localized Ewing's sarcoma of bone were treated at the Onco-Orthopedics Clinic of the Sofia University Hospital (Sofia, Bulgaria)." | 1.31 | [Treatment of Ewing's sarcoma with 2 different protocols]. ( Mihova, A; Mumdjiev, I; Sokolov, T; Stoianova, A, 2001) |
| "Records of 34 patients with ES/PNET who received the IVAD chemotherapy regimens were reviewed." | 1.30 | The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours. ( Fisher, C; Harmer, CL; Judson, IR; Thomas, JM; Verrill, MW; Wiltshaw, E, 1997) |
| "The interval between diagnosis of Ewing's sarcoma and the diagnosis of the SM was 17-78 months for the four AMLs, 96 months for the MDS and 82-136 months for the three sarcomas." | 1.30 | Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies. ( Ahrens, S; Dunst, J; Harms, D; Jürgens, H; Paulussen, M; Rübe, C; Winkelmann, W; Zoubek, A, 1998) |
| "Chondrosarcomas are alleged to be resistant to chemotherapy." | 1.30 | Chemotherapy and P-glycoprotein expression in chondrosarcoma. ( Albino, AP; Devaney, K; Glantz, L; Healey, JH; Mak, S; Schwartz, GK; Terek, RM, 1998) |
| "The patient died due to brain metastases 20 months after the start of intra-arterial chemotherapy." | 1.30 | [A case of metastatic liver tumors from prostatic cancer responding to intra-arterial infusion chemotherapy with CDDP and ifosfamide using implantable port]. ( Hasegawa, N; Kazama, A; Kondo, N; Tomita, M, 1999) |
| "The OHS osteosarcoma tumors caused sclerotic lesions with high and uniform isotope uptake, and the MHMX unclassified sarcoma showed a mixed pattern with both sclerotic and lytic areas, whereas the LOX melanoma caused lytic bone lesions with low uptake of the radionuclide." | 1.29 | Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats. ( Bruland, O; Fodstad, O; Kjønniksen, I; Winderen, M, 1994) |
| " Moreover, a dose-response relationship was detectable: 1/6 patients without lung irradiation vs." | 1.29 | Lung irradiation for Ewing's sarcoma with pulmonary metastases at diagnosis: results of the CESS-studies. ( Dunst, J; Jürgens, H; Paulussen, M, 1993) |
| " For this first step a daily dosage of 300 mg/m2 of body surface resulted in only moderate leukopenia, whereas a daily dosage of 450 mg/m2 caused severe leukopenia." | 1.29 | Development of a canine chemotherapeutic model with ifosfamide. ( Chao, EY; Donehower, RC; Frassica, FJ; Ikeda, K; Inoue, N; Tomita, K, 1996) |
| "Twelve patients with localized Ewing's sarcoma were treated between 1980-1990 at the Istanbul School of Medicine, Department of Pediatric Oncology-Hematology, Oncology Research and Treatment Center and Our Children Leukemia Foundation." | 1.28 | Ewing's sarcoma: experience with 12 cases. ( Gedikoğlu, G; Zülfikar, B, 1992) |
| "Two cases of Ewing's sarcoma originating from the adult rib were reported." | 1.28 | [Two cases of Ewing's sarcoma originating from the adult rib]. ( Akiba, Y; Fujita, Y; Ikushima, Y; Ishida, S; Ohosaki, Y; Onodera, S; Sakai, E; Saotome, K; Shimizu, T; Tagaki, S, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (2.66) | 18.7374 |
| 1990's | 106 (25.67) | 18.2507 |
| 2000's | 137 (33.17) | 29.6817 |
| 2010's | 128 (30.99) | 24.3611 |
| 2020's | 31 (7.51) | 2.80 |
| Authors | Studies |
|---|---|
| Testa, S | 1 |
| Hu, BD | 1 |
| Saadeh, NL | 1 |
| Pribnow, A | 1 |
| Spunt, SL | 3 |
| Charville, GW | 1 |
| Bui, NQ | 1 |
| Ganjoo, KN | 1 |
| Tanaka, K | 4 |
| Ozaki, T | 4 |
| Zandaki, D | 1 |
| Ismael, T | 1 |
| Halalsheh, H | 2 |
| Ibrahimi, AKH | 1 |
| Sarhan, N | 1 |
| Ghandour, K | 1 |
| Shehadeh, A | 2 |
| Sultan, I | 2 |
| Stacchiotti, S | 2 |
| Van der Graaf, WTA | 1 |
| Sanfilippo, RG | 1 |
| Marreaud, SI | 1 |
| Van Houdt, WJ | 1 |
| Judson, IR | 2 |
| Gronchi, A | 3 |
| Gelderblom, H | 7 |
| Litiere, S | 3 |
| Kasper, B | 4 |
| Luminais, SN | 1 |
| Chen, XT | 1 |
| Roman, D | 1 |
| Ma, B | 1 |
| Christ, AB | 1 |
| Hu, JS | 1 |
| Lucari, B | 1 |
| Tallis, E | 1 |
| Sutton, VR | 1 |
| Porea, T | 1 |
| Bielack, SS | 8 |
| Blattmann, C | 1 |
| Borkhardt, A | 1 |
| Csóka, M | 1 |
| Hassenpflug, W | 1 |
| Kabíčková, E | 1 |
| Kager, L | 3 |
| Kessler, T | 1 |
| Kratz, C | 1 |
| Kühne, T | 3 |
| Kevric, M | 2 |
| Lehrnbecher, T | 1 |
| Mayer-Steinacker, R | 2 |
| Mettmann, V | 1 |
| Metzler, M | 1 |
| Reichardt, P | 2 |
| Rossig, C | 1 |
| Sorg, B | 1 |
| von Luettichau, I | 1 |
| Windhager, R | 1 |
| Hecker-Nolting, S | 1 |
| Corvest, V | 1 |
| Marec-Bérard, P | 10 |
| Lervat, C | 3 |
| Pacquement, H | 6 |
| Toulmonde, M | 1 |
| Gentet, JC | 8 |
| Laurence, V | 6 |
| Cleirec, M | 1 |
| Mansuy, L | 1 |
| Bompas, E | 4 |
| Castex, MP | 2 |
| Taque, S | 2 |
| Filhon, B | 2 |
| Tabone, MD | 5 |
| Verité, C | 1 |
| Entz-Werle, N | 4 |
| Saumet, L | 2 |
| Guimard, G | 1 |
| Pondrom, M | 1 |
| Chevreau, C | 2 |
| Flandrin, J | 1 |
| Duranteau, L | 1 |
| Rousset-Jablonski, C | 1 |
| Brugières, L | 6 |
| Jimenez, M | 1 |
| Le Deley, MC | 8 |
| Gaspar, N | 7 |
| Fresneau, B | 1 |
| Brennan, B | 5 |
| Kirton, L | 2 |
| Martín-Broto, J | 4 |
| Sastre, A | 3 |
| Owens, C | 3 |
| Fenwick, N | 3 |
| Strauss, S | 3 |
| Moroz, V | 3 |
| Whelan, J | 7 |
| Wheatley, K | 5 |
| Daley, J | 1 |
| Halligan, K | 1 |
| Howrie, D | 1 |
| Salgado, CM | 1 |
| Superdock, A | 1 |
| Friehling, E | 1 |
| Bailey, KM | 1 |
| Long, Z | 1 |
| Lu, Y | 1 |
| Li, M | 1 |
| Ji, C | 1 |
| Chen, G | 1 |
| Li, J | 2 |
| Xiang, L | 1 |
| Yu, H | 1 |
| Wang, Q | 2 |
| Wang, Z | 4 |
| Aiba, H | 1 |
| Kojima, Y | 1 |
| Shimoi, T | 1 |
| Sudo, K | 1 |
| Yazaki, S | 1 |
| Imai, T | 1 |
| Yoshida, A | 1 |
| Iwata, S | 2 |
| Kobayashi, E | 1 |
| Kawai, A | 2 |
| Arakawa, A | 1 |
| Ogawa, C | 1 |
| Kimura, H | 1 |
| Yonemori, K | 1 |
| Mehrvar, A | 1 |
| Mehrvar, N | 1 |
| Sadeghi, Y | 1 |
| Tashvighi, M | 1 |
| Foroughi, A | 1 |
| Arefpour, AM | 1 |
| Nikoofar, A | 1 |
| Sanei, M | 1 |
| Mahdavi, SH | 1 |
| Javadinia, SA | 1 |
| Cash, T | 1 |
| Krailo, MD | 8 |
| Buxton, AB | 1 |
| Pawel, BR | 2 |
| Healey, JH | 7 |
| Binitie, O | 1 |
| Marcus, KJ | 2 |
| Grier, HE | 13 |
| Grohar, PJ | 1 |
| Reed, DR | 1 |
| Weiss, AR | 2 |
| Gorlick, R | 4 |
| Janeway, KA | 3 |
| DuBois, SG | 3 |
| Womer, RB | 7 |
| Salah, S | 1 |
| Abuhijla, F | 1 |
| Ismail, T | 1 |
| Yaser, S | 1 |
| Abdelal, S | 1 |
| Almousa, A | 1 |
| Jaber, O | 1 |
| Abu-Hijlih, R | 1 |
| Maroun, CA | 1 |
| Khalifeh, I | 1 |
| Tfayli, A | 1 |
| Moukarbel, RV | 1 |
| Zhang, J | 2 |
| Huang, Y | 2 |
| Sun, Y | 5 |
| He, A | 2 |
| Zhou, Y | 1 |
| Hu, H | 1 |
| Yao, Y | 8 |
| Shen, Z | 6 |
| Anderton, J | 1 |
| Kaiser, S | 1 |
| Fernández-Pinto, M | 1 |
| Evans, A | 1 |
| Lu, E | 1 |
| Ryan, CW | 1 |
| Bassale, S | 1 |
| Lim, JY | 1 |
| Davis, LE | 1 |
| Zhang, B | 1 |
| Zhang, Y | 2 |
| Li, R | 1 |
| Lu, X | 1 |
| D'Ambrosio, L | 1 |
| Touati, N | 1 |
| Blay, JY | 6 |
| Grignani, G | 2 |
| Flippot, R | 1 |
| Czarnecka, AM | 1 |
| Piperno-Neumann, S | 4 |
| Sanfilippo, R | 1 |
| Katz, D | 1 |
| Duffaud, F | 2 |
| Vincenzi, B | 1 |
| Stark, DP | 1 |
| Mazzeo, F | 1 |
| Tuchscherer, A | 1 |
| Sherriff, J | 1 |
| Estival, A | 1 |
| Sents, W | 1 |
| Ray-Coquard, I | 2 |
| Tolomeo, F | 1 |
| Le Cesne, A | 4 |
| Rutkowski, P | 1 |
| Totadri, S | 1 |
| Bansal, D | 1 |
| Rao, KLN | 1 |
| Jain, R | 1 |
| Saxena, AK | 1 |
| Kapoor, R | 1 |
| Samujh, R | 1 |
| Trehan, A | 1 |
| Han, J | 1 |
| Yu, Y | 1 |
| Wu, S | 1 |
| Zhang, W | 1 |
| Zhao, M | 1 |
| Hu, Y | 1 |
| Wang, W | 3 |
| Liu, X | 1 |
| Yu, W | 4 |
| Cheng, J | 1 |
| Yu, L | 1 |
| Bao, Q | 1 |
| Zhang, G | 1 |
| Yu, X | 2 |
| Song, R | 1 |
| Verma, P | 1 |
| Jain, S | 1 |
| Kapoor, G | 1 |
| Tripathi, R | 1 |
| Sharma, P | 1 |
| Doval, DC | 1 |
| Sarbay, H | 1 |
| Demir, ÜF | 1 |
| Yılmaz, G | 1 |
| Atay, AA | 1 |
| Malbora, B | 1 |
| Howe, AS | 1 |
| Pearce, J | 1 |
| Lian, F | 1 |
| Ribbons, L | 1 |
| Chumbalkar, V | 1 |
| Nazeer, T | 1 |
| Kogan, BA | 1 |
| Bajpai, J | 3 |
| Panda, GS | 1 |
| Chandrasekharan, A | 3 |
| Bhargava, P | 1 |
| Srinivas, S | 1 |
| Laskar, S | 1 |
| Dandekar, S | 1 |
| Mokal, S | 1 |
| Rekhi, B | 3 |
| Khanna, N | 1 |
| Menon, N | 1 |
| Patil, V | 1 |
| Noronha, V | 1 |
| Joshi, A | 1 |
| Prabhash, K | 1 |
| Banavali, SD | 2 |
| Gupta, S | 3 |
| Koscielniak, E | 1 |
| Sparber-Sauer, M | 1 |
| Scheer, M | 1 |
| Vokuhl, C | 1 |
| Kazanowska, B | 1 |
| Ladenstein, R | 3 |
| Niggli, F | 1 |
| Ljungman, G | 1 |
| Paulussen, M | 13 |
| Seitz, G | 1 |
| Fuchs, J | 1 |
| Hallmen, E | 1 |
| Klingebiel, T | 1 |
| Paul, A | 1 |
| Duncan, A | 1 |
| Bacchetta, J | 1 |
| Dubourg, L | 2 |
| Tanné, C | 1 |
| Hiraga, H | 1 |
| Campbell-Hewson, Q | 1 |
| Huang, J | 1 |
| Okpara, CE | 1 |
| Bautista, F | 1 |
| Kim, SH | 2 |
| Shin, KH | 3 |
| Moon, SH | 1 |
| Kong, Y | 1 |
| Suh, JS | 2 |
| Yang, WI | 2 |
| Young, RJ | 1 |
| Lia, M | 1 |
| Hogendoorn, PCW | 1 |
| Fisher, C | 2 |
| Mechtersheimer, G | 1 |
| Daugaard, S | 1 |
| Sciot, R | 1 |
| Collin, F | 1 |
| Messiou, C | 1 |
| Grünwald, V | 1 |
| van der Graaf, W | 1 |
| Wardelmann, E | 1 |
| Judson, I | 3 |
| Teepen, JC | 1 |
| van Leeuwen, FE | 1 |
| Tissing, WJ | 1 |
| van Dulmen-den Broeder, E | 1 |
| van den Heuvel-Eibrink, MM | 1 |
| van der Pal, HJ | 2 |
| Loonen, JJ | 1 |
| Bresters, D | 1 |
| Versluys, B | 1 |
| Neggers, SJCMM | 1 |
| Jaspers, MWM | 1 |
| Hauptmann, M | 1 |
| van der Heiden-van der Loo, M | 1 |
| Visser, O | 1 |
| Kremer, LCM | 1 |
| Ronckers, CM | 1 |
| Deng, ZP | 1 |
| Liu, BY | 1 |
| Jin, T | 1 |
| Li, B | 2 |
| Ding, Y | 1 |
| Niu, XH | 1 |
| Talreja, V | 1 |
| Simha, V | 2 |
| Chandrakanth, MV | 1 |
| Khurana, S | 1 |
| Khan, A | 1 |
| Vora, T | 2 |
| Ghosh, J | 2 |
| Ahmed, SK | 1 |
| Randall, RL | 2 |
| Harmsen, WS | 1 |
| Krailo, M | 6 |
| Geller, DS | 1 |
| Sorger, JI | 1 |
| Granowetter, L | 3 |
| Gorlick, RG | 1 |
| Laack, NNI | 1 |
| Meazza, C | 1 |
| Cefalo, G | 3 |
| Massimino, M | 2 |
| Daolio, P | 2 |
| Pastorino, U | 1 |
| Scanagatta, P | 1 |
| Morosi, C | 1 |
| Podda, M | 2 |
| Ferrari, A | 2 |
| Terenziani, M | 1 |
| Spreafico, F | 1 |
| Casanova, M | 1 |
| Parafioriti, A | 2 |
| Collini, P | 1 |
| Gandola, L | 3 |
| Bastoni, S | 1 |
| Biassoni, V | 1 |
| Schiavello, E | 1 |
| Chiaravalli, S | 1 |
| Puma, N | 1 |
| Bergamaschi, L | 1 |
| Luksch, R | 4 |
| Occean, BV | 2 |
| Bouvier, C | 1 |
| Brisse, HJ | 1 |
| Cheurfa, N | 1 |
| Corradini, N | 3 |
| Delaye, J | 2 |
| Italiano, A | 3 |
| Mascard, E | 2 |
| Redini, F | 3 |
| Schmitt, C | 4 |
| Verite-Goulard, C | 1 |
| Duflot, T | 1 |
| Marie-Cardine, A | 1 |
| Verstuyft, C | 1 |
| Pereira, T | 1 |
| Massy-Guillemant, N | 1 |
| Joannidès, R | 1 |
| Bellien, J | 1 |
| Lamoureux, F | 2 |
| Jiang, S | 1 |
| Wang, G | 1 |
| Dong, Y | 2 |
| Savani, M | 1 |
| Skubitz, KM | 1 |
| Jamshidi, K | 1 |
| Ramezan Shirazi, M | 1 |
| Bagherifard, A | 1 |
| Mirzaei, A | 1 |
| Zhang, SP | 1 |
| Li, X | 1 |
| Li, H | 2 |
| Sun, XH | 1 |
| Yan, XF | 1 |
| Paasch, C | 1 |
| De Santo, G | 1 |
| Boettge, KR | 1 |
| Strik, MW | 1 |
| Wakamatsu, T | 1 |
| Kakunaga, S | 2 |
| Takenaka, S | 2 |
| Outani, H | 1 |
| Hamada, K | 3 |
| Imura, Y | 2 |
| Hori, Y | 1 |
| Naka, N | 3 |
| Kudawara, I | 2 |
| Yoshikawa, H | 5 |
| Ueda, T | 7 |
| Mandal, T | 1 |
| Shah, K | 1 |
| Hingmare, S | 1 |
| Rangarajan, B | 1 |
| Shetty, N | 1 |
| Banavali, S | 1 |
| Cupissol, D | 1 |
| Perrin, C | 1 |
| Penel, N | 3 |
| Rios, M | 1 |
| Anract, P | 2 |
| de Pinieux, G | 2 |
| Collard, O | 1 |
| Bertucci, F | 1 |
| Aoki, Y | 2 |
| Araki, N | 3 |
| Nakanishi, H | 1 |
| Matsumine, A | 2 |
| Ieguchi, M | 2 |
| Mori, S | 1 |
| Myoui, A | 3 |
| Kuratsu, S | 1 |
| Hashimoto, N | 2 |
| Urakawa, H | 1 |
| Tsukushi, S | 1 |
| Tsurudome, I | 1 |
| Hirata, A | 1 |
| Arai, E | 1 |
| Kozawa, E | 1 |
| Futamura, N | 1 |
| Miyahara, R | 1 |
| Ishiguro, N | 1 |
| Nishida, Y | 1 |
| Palmerini, E | 9 |
| Maki, RG | 2 |
| Staals, EL | 1 |
| Alberghini, M | 4 |
| Antonescu, CR | 1 |
| Ferrari, C | 3 |
| Ruggieri, P | 10 |
| Mavrogenis, A | 1 |
| Bertoni, F | 14 |
| Cesari, M | 10 |
| Paioli, A | 2 |
| Marchesi, E | 2 |
| Picci, P | 23 |
| Ferrari, S | 42 |
| Bi, W | 1 |
| Han, G | 2 |
| Jia, J | 1 |
| Xu, M | 3 |
| Choeyprasert, W | 2 |
| Natesirinilkul, R | 1 |
| Charoenkwan, P | 1 |
| Sittipreechacharn, S | 1 |
| Singer, A | 1 |
| Tresley, J | 1 |
| Velazquez-Vega, J | 1 |
| Yepes, M | 1 |
| Al-Hader, AA | 1 |
| Jain, A | 1 |
| Al-Nasrallah, N | 1 |
| Einhorn, LH | 2 |
| Kobys, VL | 1 |
| Konovalenko, VF | 1 |
| Repinа, NV | 1 |
| Golovko, TS | 1 |
| Gulak, LO | 1 |
| Tarasova, TO | 1 |
| Zaharycheva, EV | 1 |
| Matyushok, OF | 1 |
| Lionel, AP | 1 |
| Chinnaswamy, G | 1 |
| John, RR | 1 |
| Mathai, S | 1 |
| Yoo, C | 1 |
| Lee, J | 2 |
| Rha, SY | 2 |
| Park, KH | 1 |
| Kim, TM | 1 |
| Kim, YJ | 1 |
| Lee, HJ | 1 |
| Lee, KH | 1 |
| Ahn, JH | 2 |
| Fagioli, F | 6 |
| Tamburini, A | 4 |
| Abate, ME | 3 |
| Balladelli, A | 5 |
| Pratelli, L | 2 |
| Nishimura, H | 1 |
| Enokida, H | 1 |
| Nagano, S | 1 |
| Yokouchi, M | 1 |
| Hayami, H | 1 |
| Komiya, S | 1 |
| Nakagawa, M | 1 |
| Kawaguchi, S | 1 |
| Sun, T | 1 |
| Lin, PP | 2 |
| Deavers, M | 1 |
| Harun, N | 1 |
| Lewis, VO | 2 |
| Boye, K | 1 |
| Del Prever, AB | 3 |
| Eriksson, M | 3 |
| Saeter, G | 4 |
| Tienghi, A | 8 |
| Lindholm, P | 2 |
| Skjeldal, S | 1 |
| Hall, KS | 4 |
| Robert, G | 1 |
| Chappé, C | 1 |
| Bruneau, B | 1 |
| Gandemer, V | 1 |
| Cao, J | 1 |
| Huang, XE | 1 |
| Liu, J | 2 |
| Wu, XY | 1 |
| Lu, YY | 1 |
| Sun, L | 1 |
| Li, Y | 1 |
| Ye, Z | 1 |
| Kenney, LB | 1 |
| Duffey-Lind, E | 1 |
| Ebb, D | 1 |
| Sklar, CA | 1 |
| Grier, H | 2 |
| Diller, L | 1 |
| Kushnir, I | 1 |
| Kolander, Y | 1 |
| Bickels, J | 2 |
| Gortzak, Y | 1 |
| Flusser, G | 1 |
| Issakov, J | 2 |
| Merimsky, O | 3 |
| Jaffe, N | 4 |
| Lewis, I | 6 |
| Ranft, A | 2 |
| Le Teuff, G | 2 |
| Michon, J | 2 |
| van den Berg, H | 4 |
| Hjorth, L | 3 |
| Juergens, H | 3 |
| Craft, A | 4 |
| Oberlin, O | 4 |
| Dirksen, U | 3 |
| Raciborska, A | 1 |
| Bilska, K | 1 |
| Drabko, K | 1 |
| Chaber, R | 1 |
| Sobol, G | 1 |
| Pogorzała, M | 1 |
| Wyrobek, E | 1 |
| Połczyńska, K | 1 |
| Rogowska, E | 1 |
| Rodriguez-Galindo, C | 6 |
| Wożniak, W | 1 |
| Seok, SO | 1 |
| Cho, YJ | 1 |
| Noh, JK | 1 |
| Hung, GY | 2 |
| Yen, HJ | 1 |
| Yen, CC | 1 |
| Chen, WM | 1 |
| Chen, PC | 1 |
| Wu, HT | 1 |
| Chiou, HJ | 1 |
| Chang, WH | 1 |
| Hsu, HE | 1 |
| Xu, S | 1 |
| Xiao, X | 1 |
| Whelan, JS | 4 |
| Marina, N | 6 |
| Smeland, S | 6 |
| Jovic, G | 1 |
| Hook, JM | 1 |
| Anninga, J | 1 |
| Butterfass-Bahloul, T | 1 |
| Böhling, T | 2 |
| Calaminus, G | 1 |
| Capra, M | 1 |
| Deffenbaugh, C | 1 |
| Dhooge, C | 1 |
| Flanagan, AM | 1 |
| Goorin, A | 2 |
| Gosheger, G | 2 |
| Grimer, RJ | 1 |
| Helmke, K | 1 |
| Hogendoorn, PC | 2 |
| Jundt, G | 2 |
| Kuehne, T | 1 |
| Lau, CC | 1 |
| Letson, GD | 1 |
| Meyer, J | 3 |
| Meyers, PA | 11 |
| Morris, C | 1 |
| Mottl, H | 1 |
| Nadel, H | 3 |
| Nagarajan, R | 1 |
| Schomberg, P | 1 |
| Schwarz, R | 1 |
| Teot, LA | 2 |
| Sydes, MR | 1 |
| Bernstein, M | 4 |
| Tang, L | 2 |
| Lin, F | 4 |
| Vredenburg, G | 1 |
| den Braver-Sewradj, S | 1 |
| van Vugt-Lussenburg, BM | 1 |
| Vermeulen, NP | 1 |
| Commandeur, JN | 1 |
| Vos, JC | 1 |
| Li, YY | 1 |
| Jiang, XM | 1 |
| Dong, YG | 1 |
| Xu, G | 1 |
| Ma, YB | 1 |
| Pakakasama, S | 1 |
| Sirachainan, N | 1 |
| Songdej, D | 1 |
| Chuansumrit, A | 1 |
| Anurathapan, U | 1 |
| Hongeng, S | 1 |
| Nartthanarung, A | 1 |
| Biswas, B | 1 |
| Rastogi, S | 2 |
| Khan, SA | 2 |
| Shukla, NK | 1 |
| Deo, SV | 1 |
| Agarwala, S | 1 |
| Mohanti, BK | 1 |
| Sharma, MC | 2 |
| Vishnubhatla, S | 2 |
| Bakhshi, S | 2 |
| Su, W | 1 |
| Lai, Z | 1 |
| Wu, F | 1 |
| Lin, Y | 1 |
| Mo, Y | 1 |
| Yang, Z | 1 |
| Wu, J | 2 |
| Hattinger, CM | 2 |
| Michelacci, F | 1 |
| Sella, F | 1 |
| Magagnoli, G | 1 |
| Benini, S | 2 |
| Gambarotti, M | 1 |
| Serra, M | 5 |
| Magnan, H | 1 |
| Goodbody, CM | 1 |
| Riedel, E | 1 |
| Pratilas, CA | 1 |
| Wexler, LH | 4 |
| Chou, AJ | 1 |
| Nakata, H | 1 |
| Miyazaki, T | 1 |
| Iwasaki, T | 1 |
| Nakamura, A | 1 |
| Kidani, T | 1 |
| Sakayama, K | 1 |
| Masumoto, J | 1 |
| Miura, H | 1 |
| Huang, YJ | 1 |
| He, AN | 1 |
| Sun, YJ | 1 |
| Min, DL | 1 |
| Brunetto, AL | 2 |
| Castillo, LA | 1 |
| Petrilli, AS | 2 |
| Macedo, CD | 1 |
| Boldrini, E | 1 |
| Costa, C | 1 |
| Almeida, MT | 2 |
| Kirst, D | 1 |
| Pereira, WV | 1 |
| Watanabe, FM | 1 |
| Pizza, M | 1 |
| Benites, E | 1 |
| Morais, V | 1 |
| Gadelha, A | 1 |
| Nakasato, A | 1 |
| Abujamra, AL | 1 |
| Gregianin, LJ | 1 |
| Vulsteke, C | 1 |
| Lurquin, E | 1 |
| Debiec-Rychter, M | 1 |
| Gheysens, O | 1 |
| Nuyts, S | 1 |
| Schoenaers, J | 1 |
| Politis, C | 1 |
| Mebis, J | 1 |
| Hauben, E | 1 |
| Clement, PM | 1 |
| Saste, A | 1 |
| Cabrera Fernandez, DF | 1 |
| Gulati, R | 1 |
| Gamalski, S | 1 |
| Karski, EE | 1 |
| McIlvaine, E | 1 |
| Segal, MR | 1 |
| Felgenhauer, J | 2 |
| Ladenstein, RL | 1 |
| Kruseova, J | 1 |
| Brichard, B | 1 |
| Shkalim-Zemer, V | 1 |
| Ash, S | 2 |
| Toledano, H | 1 |
| Kollender, Y | 2 |
| Yaniv, I | 2 |
| Cohen, IJ | 3 |
| Nataraj, V | 1 |
| Batra, A | 1 |
| Schwartz, CL | 4 |
| Devidas, M | 3 |
| Steinherz, LJ | 1 |
| Goorin, AM | 5 |
| Gebhardt, MC | 6 |
| Sato, JK | 1 |
| Bernstein, ML | 4 |
| Lipshultz, SE | 1 |
| Mulder, RL | 3 |
| Paulides, M | 4 |
| Langer, T | 4 |
| Kremer, LC | 3 |
| van Dalen, EC | 3 |
| Mituś, JW | 1 |
| Blecharz, P | 1 |
| Walasek, T | 1 |
| Reinfuss, M | 1 |
| Jakubowicz, J | 1 |
| Kulpa, J | 1 |
| Chen, B | 1 |
| Yang, JZ | 1 |
| Wang, LF | 1 |
| Zhang, YJ | 1 |
| Lin, XJ | 1 |
| Mascarenhas, L | 1 |
| Felgenhauer, JL | 1 |
| Bond, MC | 1 |
| Villaluna, D | 1 |
| Femino, JD | 1 |
| Laack, NN | 1 |
| Ranganathan, S | 1 |
| Fan, XL | 1 |
| Cai, GP | 1 |
| Zhu, LL | 1 |
| Ding, GM | 1 |
| Ben-Ami, T | 1 |
| Waldman, E | 1 |
| Marc, W | 1 |
| Weintraub, M | 1 |
| Revel-Vilk, S | 1 |
| Fried, I | 1 |
| Yonemoto, T | 2 |
| Takahashi, M | 1 |
| Maru, M | 1 |
| Tomioka, A | 1 |
| Saito, M | 1 |
| Araki, Y | 1 |
| Tazaki, M | 1 |
| Tsuchiya, M | 1 |
| Kamoda, H | 1 |
| Ishii, T | 4 |
| Yılmaz, S | 1 |
| Özçakar, ZB | 1 |
| Taktak, A | 1 |
| Kiremitçi, S | 1 |
| Ensari, A | 1 |
| Dinçaslan, H | 1 |
| Yalçınkaya, F | 1 |
| Obata, H | 2 |
| Joyama, S | 1 |
| Nodomi, S | 1 |
| Umeda, K | 1 |
| Okamoto, T | 1 |
| Saida, S | 1 |
| Hiramatsu, H | 1 |
| Watanabe, K | 1 |
| Adachi, S | 1 |
| Heike, T | 1 |
| Petit, P | 1 |
| Brisse, H | 1 |
| Gomez-Brouchet, A | 1 |
| Guinebretière, JM | 2 |
| Gouin, F | 2 |
| Chevance, A | 1 |
| Bonnet, N | 1 |
| Miolo, G | 1 |
| Viel, A | 1 |
| Canzonieri, V | 2 |
| Baresic, T | 1 |
| Buonadonna, A | 1 |
| Santeufemia, DA | 1 |
| Lara, DP | 1 |
| Corona, G | 1 |
| Biason, P | 1 |
| Iacoboni, E | 1 |
| Gagno, S | 1 |
| Fanelli, M | 1 |
| Tavanti, E | 1 |
| Vella, S | 1 |
| Roli, A | 1 |
| Roncato, R | 1 |
| Giodini, L | 1 |
| Scotlandi, K | 2 |
| Toffoli, G | 1 |
| Zhang, T | 1 |
| Zhang, S | 1 |
| Yang, F | 1 |
| Wang, L | 1 |
| Zhu, S | 1 |
| Qiu, B | 1 |
| Li, S | 1 |
| Deng, Z | 1 |
| Helman, LJ | 1 |
| Reaman, GH | 1 |
| Craft, AW | 2 |
| Hackshaw, A | 1 |
| Douglas, C | 1 |
| Dunst, J | 9 |
| Schuck, A | 3 |
| Winkelmann, W | 6 |
| Köhler, G | 1 |
| Poremba, C | 1 |
| Zoubek, A | 7 |
| Hunold, A | 1 |
| Cassoni, A | 1 |
| Spooner, D | 3 |
| Grimer, R | 3 |
| McTiernan, A | 3 |
| Jürgens, H | 18 |
| Ottaviani, S | 1 |
| Forest, A | 1 |
| Descamps, V | 1 |
| Meyer, O | 1 |
| Dieudé, P | 1 |
| Hoshi, M | 1 |
| Takami, M | 1 |
| Ataergin, S | 1 |
| Ozet, A | 1 |
| Solchaga, L | 1 |
| Turan, M | 1 |
| Beyzadeoglu, M | 1 |
| Oysul, K | 1 |
| Arpaci, F | 1 |
| Komurcu, S | 1 |
| Surenkok, S | 1 |
| Ozturk, M | 1 |
| Tomita, Y | 1 |
| Inoue, A | 1 |
| Fujimoto, T | 2 |
| Hatazawa, J | 1 |
| Osanai, T | 1 |
| Tsuchiya, T | 1 |
| Sugawara, M | 1 |
| Pintoffl, J | 1 |
| Meisinger, I | 1 |
| Mayer, F | 1 |
| Horger, M | 1 |
| von Weyhern, C | 1 |
| Kanz, L | 2 |
| Hartmann, JT | 1 |
| Womer, R | 2 |
| Wang, C | 1 |
| Leavey, P | 1 |
| Gebhardt, M | 2 |
| Healey, J | 2 |
| Shamberger, RC | 1 |
| Miser, J | 3 |
| Arndt, CA | 3 |
| Sailer, S | 2 |
| Marcus, K | 2 |
| Perlman, E | 1 |
| Dickman, P | 1 |
| Ding, L | 1 |
| Wang, HX | 1 |
| Xue, M | 1 |
| Zhu, L | 1 |
| Yan, HM | 1 |
| Duan, LN | 1 |
| Wang, ZD | 1 |
| Staals, E | 2 |
| Longhi, A | 17 |
| Bacci, G | 34 |
| Berretta, M | 1 |
| Zanet, E | 1 |
| Taibi, R | 1 |
| Martellotta, F | 1 |
| Pavone, P | 1 |
| Bearz, A | 1 |
| Gobitti, C | 1 |
| Ciancia, EM | 1 |
| Tirelli, U | 1 |
| Heinen, RC | 1 |
| Merks, JH | 1 |
| Briccoli, A | 8 |
| Rocca, M | 2 |
| Salone, M | 1 |
| Di Fiore, M | 1 |
| Zoccali, C | 1 |
| Prencipe, U | 1 |
| Ferraresi, V | 1 |
| Salducca, N | 1 |
| Lashkari, A | 1 |
| Chow, WA | 1 |
| Valdes, F | 1 |
| Leong, L | 1 |
| Phan, V | 1 |
| Twardowski, P | 1 |
| Kapoor, N | 1 |
| Molina, A | 1 |
| Al-Kadhimi, Z | 1 |
| Frankel, P | 1 |
| Somlo, G | 1 |
| Peeters, J | 1 |
| Meitert, J | 1 |
| Beck, JD | 1 |
| Bölling, T | 1 |
| Ernst, I | 1 |
| Willich, N | 3 |
| Yamada, N | 1 |
| Hata, M | 1 |
| Ohyama, H | 1 |
| Yamanegi, K | 1 |
| Kogoe, N | 1 |
| Nakasho, K | 1 |
| Futani, H | 2 |
| Okamura, H | 1 |
| Terada, N | 2 |
| Bruheim, S | 1 |
| Xi, Y | 1 |
| Ju, J | 1 |
| Fodstad, O | 2 |
| Ames, B | 1 |
| Lewis, LD | 1 |
| Chaffee, S | 1 |
| Kim, J | 1 |
| Morse, R | 1 |
| Jung, S | 1 |
| Cai, JY | 1 |
| Tang, JY | 1 |
| Pan, C | 1 |
| Xue, HL | 1 |
| Zhou, M | 1 |
| Dong, L | 1 |
| Ye, QD | 1 |
| Jiang, H | 1 |
| Shen, SH | 1 |
| Chen, J | 1 |
| Tajino, T | 1 |
| Kikuchi, S | 1 |
| Yamada, H | 1 |
| Takeda, A | 1 |
| Konno, S | 1 |
| Gatcombe, HG | 1 |
| Olson, TA | 1 |
| Esiashvili, N | 1 |
| Ehrlich, Y | 1 |
| Beck, SDW | 1 |
| Ulbright, TM | 1 |
| Cheng, L | 1 |
| Brames, MJ | 1 |
| Andreoiu, M | 1 |
| Foster, RS | 1 |
| Xing, PY | 1 |
| Shi, YK | 1 |
| Feng, FY | 1 |
| Qin, Y | 1 |
| Liu, P | 1 |
| Zhao, H | 2 |
| Chen, P | 1 |
| Machak, GN | 1 |
| Polotskiĭ, BE | 1 |
| Meluzova, OM | 1 |
| Chernov, IS | 1 |
| Aliev, MD | 1 |
| Buchbinder, D | 1 |
| Steinberg, G | 1 |
| Linetsky, M | 1 |
| Casillas, J | 1 |
| Lindet, C | 1 |
| Vanhuyse, M | 1 |
| Thebaud, E | 1 |
| Robin, YM | 1 |
| Indelicato, DJ | 1 |
| Keole, SR | 1 |
| Lagmay, JP | 1 |
| Morris, CG | 1 |
| Gibbs, CP | 1 |
| Scarborough, MT | 2 |
| Islam, S | 1 |
| Marcus, RB | 1 |
| Odri, GA | 1 |
| Dumoucel, S | 1 |
| Picarda, G | 1 |
| Battaglia, S | 1 |
| Rousseau, J | 1 |
| Tirode, F | 1 |
| Laud, K | 1 |
| Delattre, O | 2 |
| Heymann, D | 1 |
| Gougelet, A | 1 |
| Pissaloux, D | 1 |
| Besse, A | 1 |
| Perez, J | 1 |
| Duc, A | 1 |
| Dutour, A | 1 |
| Alberti, L | 1 |
| Sundby Hall, K | 1 |
| Wiebe, T | 3 |
| Alvegard, TA | 4 |
| Brach Del Prever, A | 5 |
| Mercuri, M | 20 |
| Capanna, R | 5 |
| Mapelli, S | 1 |
| Prete, A | 2 |
| Carli, M | 2 |
| Barbieri, E | 9 |
| Miranda Soares, PB | 1 |
| Quirino Filho, S | 1 |
| Pereira DE Souza, W | 1 |
| Ferreti Bonan, PR | 1 |
| Martelli-Júnior, H | 1 |
| Wang, Y | 1 |
| Bi, WZ | 1 |
| Wang, DJ | 1 |
| Lu, SB | 1 |
| Zhang, L | 1 |
| Zhao, B | 1 |
| Lee, JA | 1 |
| Kim, DH | 1 |
| Cho, J | 1 |
| Lim, JS | 1 |
| Koh, JS | 1 |
| Yoo, JY | 1 |
| Kim, MS | 1 |
| Kong, CB | 1 |
| Song, WS | 1 |
| Cho, WH | 1 |
| Lee, SY | 1 |
| Jeon, DG | 1 |
| Cui, Q | 1 |
| Jiang, W | 1 |
| Guo, J | 1 |
| Liu, C | 1 |
| Li, D | 1 |
| Wang, X | 1 |
| Zeng, Y | 1 |
| Bruland, OS | 1 |
| Brosjö, O | 2 |
| Bjerkehagen, B | 1 |
| Osterlundh, G | 1 |
| Jakobson, A | 1 |
| Monge, OR | 1 |
| Björk, O | 2 |
| Alvegaard, TA | 1 |
| Daw, NC | 3 |
| Neel, MD | 3 |
| Rao, BN | 7 |
| Billups, CA | 5 |
| Jenkins, JJ | 4 |
| Quintana, J | 1 |
| Luchtman-Jones, L | 1 |
| Villarroel, M | 1 |
| Santana, VM | 2 |
| Hong, S | 1 |
| Shin, SJ | 1 |
| Jung, M | 1 |
| Jeong, J | 1 |
| Lee, YJ | 1 |
| Roh, JK | 1 |
| Braquet, P | 1 |
| Chapelle, A | 1 |
| Jorgensen, C | 1 |
| Pers, YM | 1 |
| Lee, SH | 1 |
| Chang, MH | 1 |
| Baek, KK | 1 |
| Han, B | 1 |
| Lim, T | 1 |
| Park, JO | 1 |
| Mirza, T | 1 |
| Ameerally, P | 1 |
| Zheng, S | 2 |
| Fernandez-Pineda, I | 1 |
| Bahrami, A | 1 |
| Green, JF | 1 |
| McGregor, LM | 1 |
| Davidoff, AM | 2 |
| Sandoval, JA | 1 |
| Zils, K | 1 |
| Ebner, F | 1 |
| Ott, M | 1 |
| Müller, J | 1 |
| Baumhoer, D | 1 |
| Greulich, M | 1 |
| Rehnitz, D | 1 |
| Rempen, A | 1 |
| Schaetzle, S | 1 |
| Wilhelm, M | 1 |
| Bielack, S | 5 |
| Fukunaga, S | 1 |
| Tsukamoto, Y | 1 |
| Ono, J | 1 |
| Okamoto, N | 2 |
| Otsuka, Y | 1 |
| Tanizawa, T | 1 |
| Tomatsuri, M | 1 |
| Yoshiya, S | 1 |
| Qi, W | 1 |
| Yang, Y | 3 |
| Comandone, A | 5 |
| Bertulli, R | 1 |
| Bisogno, G | 3 |
| Linari, A | 1 |
| Iwamoto, Y | 2 |
| Punanov, IuA | 1 |
| Gafton, GI | 1 |
| Gudz', IuV | 1 |
| Nabokov, VV | 1 |
| Ivanova, TV | 1 |
| Safonova, SA | 1 |
| Levchenko, EV | 1 |
| Kupatadze, DD | 1 |
| Novik, VI | 1 |
| Lazareva, IuR | 1 |
| Krzhivitskiĭ, PI | 1 |
| Petrov, VG | 1 |
| Yamada, SM | 1 |
| Ishii, Y | 1 |
| Yamada, S | 1 |
| Kuribayashi, S | 1 |
| Kumita, S | 1 |
| Matsuno, A | 1 |
| Min, D | 1 |
| Tan, L | 1 |
| Dede, DS | 1 |
| Aksoy, S | 1 |
| Cengiz, M | 1 |
| Gullu, I | 1 |
| Altundag, K | 1 |
| Kuperman, AA | 1 |
| Kornreich, L | 1 |
| Feinmesser, M | 1 |
| Batschinski, K | 1 |
| Dervisis, NG | 1 |
| Kitchell, BE | 1 |
| Hanly, L | 1 |
| Figueredo, R | 1 |
| Rieder, MJ | 1 |
| Koropatnick, J | 1 |
| Koren, G | 1 |
| Ernst, E | 1 |
| Kjærsgaard, M | 1 |
| Birkebæk, NH | 1 |
| Clausen, N | 1 |
| Andersen, CY | 1 |
| West, DC | 1 |
| Dickman, PS | 4 |
| Dormans, JP | 1 |
| Zhao, J | 1 |
| Fabbri, N | 8 |
| Hervonen, P | 1 |
| Lehtinen, T | 1 |
| Tammela, TL | 1 |
| Kellokumpu-Lehtinen, P | 1 |
| Matsunobu, T | 1 |
| Sakamoto, A | 1 |
| Matsuda, S | 1 |
| Patel, SJ | 1 |
| Lynch, JW | 1 |
| Johnson, T | 1 |
| Carroll, RR | 1 |
| Schumacher, C | 1 |
| Spanier, S | 1 |
| Scarborough, M | 1 |
| Sancéau, J | 1 |
| Poupon, MF | 1 |
| Sastre-Garau, X | 1 |
| Wietzerbin, J | 1 |
| Cohen, MH | 1 |
| Dagher, R | 1 |
| Griebel, DJ | 1 |
| Ibrahim, A | 1 |
| Martin, A | 1 |
| Scher, NS | 1 |
| Sokol, GH | 1 |
| Williams, GA | 1 |
| Pazdur, R | 1 |
| Janinis, J | 1 |
| Driver, D | 1 |
| Mitchell, C | 1 |
| Cassoni, AM | 1 |
| Pringle, J | 1 |
| Kilby, A | 1 |
| Reverter-Branchat, G | 1 |
| Manara, MC | 1 |
| Incaprera, M | 1 |
| Tarbell, NJ | 3 |
| Link, MP | 6 |
| Fryer, CJ | 3 |
| Pritchard, DJ | 3 |
| Perlman, EJ | 3 |
| Donaldson, SS | 3 |
| Moore, S | 2 |
| Rausen, AR | 3 |
| Vietti, TJ | 3 |
| Miser, JS | 6 |
| Macchiagodena, M | 1 |
| Vitali, G | 1 |
| Dalpiaz, O | 1 |
| al Rabi, N | 1 |
| Galfano, A | 1 |
| Martignoni, G | 1 |
| Ficarra, V | 1 |
| Artibani, W | 1 |
| Pötschger, U | 1 |
| Kastner, U | 1 |
| Flege, S | 2 |
| Kempf-Bielack, B | 1 |
| Branscheid, D | 1 |
| Kotz, R | 7 |
| Salzer-Kuntschik, M | 6 |
| Kabisch, H | 1 |
| Gadner, H | 3 |
| Ogose, A | 1 |
| Yazawa, Y | 1 |
| Hotta, T | 1 |
| Kawashima, H | 1 |
| Hatano, H | 1 |
| Morita, T | 1 |
| Donati, D | 5 |
| Bacchini, P | 4 |
| Giacomini, S | 1 |
| Forni, C | 16 |
| Manfrini, M | 4 |
| Galletti, S | 2 |
| Kolb, EA | 1 |
| Kushner, BH | 2 |
| Laverdiere, C | 1 |
| LaQuaglia, MP | 2 |
| Huvos, AG | 1 |
| Qin, J | 1 |
| Vu, HT | 1 |
| Wexler, L | 1 |
| Wolden, S | 1 |
| Boehm, R | 1 |
| Till, H | 1 |
| Landes, J | 1 |
| Schmid, I | 1 |
| Joppich, I | 1 |
| Passone, E | 1 |
| Perilongo, G | 1 |
| De Paolis, M | 1 |
| Setola, E | 1 |
| Harter, C | 1 |
| Meissner, J | 1 |
| Bellos, F | 1 |
| Krasniqi, F | 1 |
| Ho, AD | 1 |
| Egerer, G | 1 |
| Inbar, M | 1 |
| Meller, I | 2 |
| Raj, AB | 1 |
| Bertolone, SJ | 1 |
| Zalupski, MM | 1 |
| Rankin, C | 1 |
| Ryan, JR | 1 |
| Lucas, DR | 1 |
| Muler, J | 1 |
| Lanier, KS | 1 |
| Budd, GT | 1 |
| Biermann, JS | 1 |
| Meyers, FJ | 1 |
| Antman, K | 2 |
| Crews, KR | 1 |
| Liu, T | 2 |
| Tan, M | 1 |
| Meyer, WH | 8 |
| Panetta, JC | 1 |
| Takahashi, S | 2 |
| Okada, K | 1 |
| Nagasawa, H | 1 |
| Shimada, Y | 1 |
| Sakamoto, H | 1 |
| Itoi, E | 1 |
| Patel, SR | 4 |
| Papadopolous, N | 2 |
| Raymond, AK | 1 |
| Donato, M | 1 |
| Seong, CM | 1 |
| Yasko, AW | 1 |
| Champlin, R | 1 |
| Benjamin, RS | 4 |
| Guo, W | 1 |
| Yang, RL | 1 |
| Tang, XD | 1 |
| Tang, S | 1 |
| Li, DS | 1 |
| Goto, T | 2 |
| Kosaku, H | 1 |
| Kobayashi, H | 1 |
| Hozumi, T | 2 |
| Kondo, T | 2 |
| Chuman, H | 1 |
| Krasin, MJ | 2 |
| Merchant, TE | 2 |
| Kun, LE | 2 |
| Corapcioglu, F | 1 |
| Dillioğlugil, O | 1 |
| Sarper, N | 1 |
| Akansel, G | 1 |
| Calişkan, M | 1 |
| Arisoy, AE | 1 |
| Berrak, SG | 1 |
| Pearson, M | 1 |
| Berberoğlu, S | 1 |
| Ilhan, IE | 1 |
| El Weshi, A | 1 |
| Memon, M | 1 |
| Raja, M | 1 |
| Bazarbashi, S | 1 |
| Rahal, M | 1 |
| El Foudeh, M | 1 |
| Pai, C | 1 |
| Allam, A | 1 |
| El Hassan, I | 1 |
| Ezzat, A | 1 |
| Argon, A | 1 |
| Basaran, M | 2 |
| Yaman, F | 1 |
| Dizdar, Y | 1 |
| Sakar, B | 2 |
| Camlica, H | 1 |
| Bavbek, SE | 1 |
| Ozger, H | 2 |
| Darendeliler, E | 1 |
| Onat, H | 2 |
| Yalcin, B | 2 |
| Pamir, A | 2 |
| Buyukcelik, A | 1 |
| Utkan, G | 1 |
| Akbulut, H | 2 |
| Demirkazik, A | 2 |
| Icli, F | 2 |
| Berta, M | 1 |
| Watanabe, A | 1 |
| Taniguchi, M | 1 |
| Suzuki, M | 2 |
| Kume, H | 1 |
| Matsumoto, S | 2 |
| Nishimatsu, H | 1 |
| Tomita, K | 3 |
| Kitamura, T | 1 |
| Kleinerman, ES | 4 |
| Betcher, D | 2 |
| Conrad, E | 1 |
| Ferguson, W | 2 |
| Harris, MB | 3 |
| Huvos, A | 1 |
| Link, M | 2 |
| Montebello, J | 1 |
| Nieder, M | 2 |
| Sato, J | 1 |
| Siegal, G | 1 |
| Weiner, M | 1 |
| Wells, R | 1 |
| Wold, L | 1 |
| Dillman, RO | 1 |
| Barth, NM | 1 |
| VanderMolen, LA | 1 |
| Allen, K | 1 |
| Beutel, LD | 1 |
| Chico, S | 1 |
| Pierga, JY | 1 |
| Barthier, S | 1 |
| Babinet, A | 1 |
| Alapetite, C | 1 |
| Palangié, T | 1 |
| Pouillart, P | 1 |
| Dinçbaş, FO | 1 |
| Koca, S | 1 |
| Mandel, NM | 1 |
| Hiz, M | 1 |
| Dervişoğlu, S | 1 |
| Seçmezacar, H | 1 |
| Oksüz, DC | 1 |
| Ceylaner, B | 1 |
| Uzel, B | 1 |
| Virolainen, P | 1 |
| Inoue, N | 2 |
| Nagao, M | 1 |
| Frassica, FJ | 2 |
| Chao, EY | 2 |
| Pieretti, F | 1 |
| Verri, E | 1 |
| Tolentinis, L | 1 |
| Versari, M | 4 |
| Zolezzi, C | 2 |
| Lamanna, G | 2 |
| Ng, A | 1 |
| Hobson, R | 1 |
| Williams, D | 1 |
| Morland, B | 1 |
| Zak, D | 1 |
| Styler, MJ | 1 |
| Rosenbluth, JZ | 1 |
| Brodsky, I | 1 |
| La, TH | 1 |
| Alektiar, KM | 1 |
| Boland, PJ | 1 |
| Wolden, SL | 1 |
| Meyer, T | 1 |
| Michelagnoli, MP | 2 |
| Eselgrim, M | 1 |
| Grunert, H | 1 |
| Bürger, H | 1 |
| Bernini, G | 3 |
| Müller, C | 1 |
| Gordon, N | 1 |
| Hawkins, DS | 1 |
| Doherty, DK | 1 |
| Inwards, CY | 1 |
| Munsell, MF | 1 |
| Stewart, J | 1 |
| Koshkina, NV | 1 |
| McCarville, MB | 2 |
| Cain, AM | 4 |
| Duan, X | 1 |
| Jia, SF | 1 |
| Koshkina, N | 1 |
| de Camargo, B | 1 |
| Filho, VO | 1 |
| Bruniera, P | 1 |
| Jesus-Garcia, R | 1 |
| Camargo, OP | 1 |
| Pena, W | 1 |
| Péricles, P | 1 |
| Davi, A | 1 |
| Prospero, JD | 1 |
| Alves, MT | 1 |
| Oliveira, CR | 1 |
| Macedo, CR | 1 |
| Mendes, WL | 1 |
| Borsato, ML | 1 |
| dos Santos, TM | 1 |
| Ortega, J | 1 |
| Consentino, E | 1 |
| Milano, GM | 1 |
| Cozza, R | 1 |
| Ilari, I | 1 |
| De Sio, L | 1 |
| Boldrini, R | 1 |
| Jenkner, A | 1 |
| De Ioris, M | 1 |
| Inserra, A | 1 |
| Dominici, C | 1 |
| Donfrancesco, A | 1 |
| Navid, F | 2 |
| Furman, WL | 1 |
| Hale, GA | 1 |
| Pappo, AS | 4 |
| Juergens, C | 1 |
| Weston, C | 1 |
| Sanchez-Mejia, RO | 1 |
| Ojemann, SG | 1 |
| Simko, J | 1 |
| Chaudhary, UB | 1 |
| Levy, J | 1 |
| Lawton, MT | 1 |
| Ruiz Tovar, J | 1 |
| Reguero Callejas, ME | 1 |
| Arano Bermejo, JI | 1 |
| Capote Armas, LF | 1 |
| González-Palacios Martínez, F | 1 |
| Cabañas Navarro, L | 1 |
| Paulino, AC | 1 |
| Nguyen, TX | 1 |
| Mai, WY | 1 |
| Teh, BS | 1 |
| Wen, BC | 1 |
| Escobosa Sánchez, OM | 1 |
| Herrero Hernández, A | 1 |
| Ortega Acosta, MJ | 1 |
| Camacho Alonso, J | 1 |
| Milano Manso, G | 1 |
| Acha García, T | 1 |
| Anderson, P | 2 |
| Kołłataj, B | 1 |
| Zajaczkowska, M | 1 |
| Katski, K | 1 |
| Sikora, P | 1 |
| Pijanowska, M | 1 |
| Majewski, M | 1 |
| Kołłataj, W | 1 |
| Yock, TI | 1 |
| Chen, Z | 2 |
| Laurie, F | 1 |
| Bhatia, S | 1 |
| Burden, L | 1 |
| Askin, FB | 1 |
| Robison, LL | 1 |
| Kalifa, C | 5 |
| Nogi, H | 1 |
| Kobayashi, T | 1 |
| Kawase, K | 1 |
| Tabei, I | 1 |
| Toriumi, Y | 1 |
| Kawakami, M | 1 |
| Morikawa, T | 1 |
| Uchida, K | 1 |
| Naru, T | 1 |
| Nawaz, FH | 1 |
| Rizvi, J | 1 |
| Abe, S | 1 |
| Tsuchiya, H | 2 |
| Yabe, H | 1 |
| Al-Faris, N | 1 |
| Al Harbi, T | 1 |
| Goia, C | 1 |
| Pappo, A | 1 |
| Doyle, J | 1 |
| Gassas, A | 1 |
| Pichon, F | 1 |
| Vanel, D | 2 |
| Dupoüy, N | 1 |
| Takenaka, M | 1 |
| Okamoto, Y | 1 |
| Ikeda, K | 2 |
| Hashimoto, R | 1 |
| Kurokawa, N | 1 |
| Takagi, T | 1 |
| Uejima, E | 1 |
| Takahashi, K | 2 |
| Sakurai, K | 1 |
| Tanaka, H | 1 |
| Fujimoto, Y | 1 |
| Burke, MJ | 1 |
| Walterhouse, DO | 1 |
| Jacobsohn, DA | 1 |
| Duerst, RE | 1 |
| Kletzel, M | 1 |
| Smorenburg, CH | 1 |
| van Groeningen, CJ | 1 |
| Meijer, OW | 1 |
| Visser, M | 1 |
| Boven, E | 1 |
| Hung, MC | 1 |
| Lin, PC | 1 |
| Tiu, CM | 1 |
| Tien, YC | 1 |
| Lorigan, P | 1 |
| Verweij, J | 3 |
| Papai, Z | 1 |
| Rodenhuis, S | 1 |
| Leahy, MG | 1 |
| Radford, JA | 1 |
| Van Glabbeke, MM | 1 |
| Kirkpatrick, A | 1 |
| Okuma, T | 1 |
| Nakada, I | 1 |
| Han, JQ | 1 |
| Han, CY | 1 |
| Bi, YH | 1 |
| Iagaru, A | 1 |
| Masamed, R | 1 |
| Chawla, SP | 1 |
| Menendez, LR | 1 |
| Fedenko, A | 1 |
| Conti, PS | 1 |
| Bavbek, ES | 1 |
| Saglam, S | 1 |
| Eralp, L | 1 |
| Atalar, AC | 1 |
| Bilgic, B | 1 |
| Mahajan, A | 1 |
| Woo, SY | 1 |
| Kornguth, DG | 1 |
| Hughes, D | 1 |
| Huh, W | 1 |
| Chang, EL | 1 |
| Herzog, CE | 2 |
| Pelloski, CE | 1 |
| Ferguson, WS | 2 |
| Harris, M | 1 |
| Kleinerman, E | 1 |
| Siegal, GP | 2 |
| Weiner, MA | 1 |
| Wells, RJ | 1 |
| Takeuchi, S | 1 |
| Akahoshi, Y | 1 |
| Kasai, C | 1 |
| Nishimoto, Y | 1 |
| Utracka-Hutka, B | 1 |
| Czownicki, Z | 1 |
| König, HJ | 1 |
| Hartwich, G | 1 |
| Canpolat, C | 1 |
| Pearson, P | 1 |
| Robertson, R | 1 |
| Küpfer, A | 1 |
| Aeschlimann, C | 1 |
| Wermuth, B | 1 |
| Cerny, T | 2 |
| Carpentier, AF | 1 |
| Chantelard, JV | 1 |
| Henin, D | 1 |
| Poisson, M | 1 |
| Sauer, R | 1 |
| Pape, H | 1 |
| Rübe, C | 5 |
| Sugihara, S | 1 |
| Hamada, M | 1 |
| Nakagawa, Y | 1 |
| Inoue, H | 1 |
| Garcia, AA | 1 |
| Winkler, K | 7 |
| Delling, G | 5 |
| Delepine, N | 3 |
| Delepine, G | 3 |
| Desbois, JC | 2 |
| Razafindrakoto, H | 1 |
| Vassal, G | 1 |
| Contesso, G | 1 |
| Edeline, V | 1 |
| Valteau, D | 1 |
| Lemerle, J | 2 |
| Kattan, J | 1 |
| Culine, S | 1 |
| Theodore, C | 1 |
| Droz, JP | 1 |
| Kawaguchi, N | 1 |
| Manabe, J | 1 |
| Kuroda, H | 1 |
| Shimoji, T | 1 |
| Rodary, C | 1 |
| Raquin, M | 1 |
| Valteau-Couanet, D | 1 |
| Izraeli, S | 1 |
| Adamson, PC | 1 |
| Blaney, SM | 1 |
| Balis, FM | 2 |
| Elomaa, I | 2 |
| Pratt, CB | 5 |
| Parham, DM | 6 |
| Fleming, ID | 1 |
| Rock, MG | 1 |
| Shives, TC | 1 |
| Gilchrist, GS | 1 |
| Smithson, WA | 1 |
| Edmonson, JH | 1 |
| Schaid, DJ | 1 |
| Schvartzman, E | 1 |
| Scopinaro, M | 1 |
| Muriel, FS | 1 |
| Rosen, G | 1 |
| Kjønniksen, I | 1 |
| Winderen, M | 1 |
| Bruland, O | 1 |
| Rosito, P | 6 |
| Ferraro, A | 2 |
| Casadei, R | 2 |
| Kálmánchey, R | 1 |
| Koós, R | 1 |
| Majtényi, K | 1 |
| Borsi, J | 1 |
| Devalck, C | 1 |
| Tempels, D | 1 |
| Ferster, A | 1 |
| De Laet, MH | 1 |
| Bujan, W | 1 |
| Heiman, P | 1 |
| Sariban, E | 2 |
| Fujita, K | 1 |
| Matsushima, H | 1 |
| Nakano, M | 1 |
| Kaneko, T | 1 |
| Crowley, J | 1 |
| Balcerzak, SP | 1 |
| Rivkin, SE | 1 |
| Weiss, GR | 1 |
| Elias, A | 2 |
| Natale, RB | 1 |
| Cooper, RM | 1 |
| Barlogie, B | 1 |
| Trump, DL | 1 |
| Umeda, T | 2 |
| Kitoh, M | 2 |
| Tatezaki, S | 2 |
| Satoh, T | 2 |
| Gururangan, S | 1 |
| Bowman, LC | 1 |
| Wilimas, JA | 1 |
| Rao, B | 2 |
| Douglass, EC | 1 |
| Legha, SS | 1 |
| Nicaise, C | 1 |
| Toma, S | 1 |
| Palumbo, R | 1 |
| Canavese, G | 1 |
| Albanese, E | 1 |
| Cantoni, E | 1 |
| Barisone, A | 1 |
| Reggiardo, G | 1 |
| Rosso, R | 1 |
| Santi, L | 1 |
| Lobo-Sanahuja, F | 1 |
| García, I | 1 |
| Santamaría, S | 1 |
| Barrantes, JC | 1 |
| Lowry, PA | 1 |
| Carstens, C | 1 |
| Soslow, RA | 1 |
| Davis, RE | 1 |
| Warnke, RA | 1 |
| Cleary, ML | 1 |
| Kamel, OW | 1 |
| Demetri, GD | 1 |
| Stein, ME | 2 |
| Ruff, P | 1 |
| Weaving, A | 1 |
| Fried, J | 1 |
| Bezwoda, WR | 1 |
| Iantorno, D | 2 |
| Campanacci, M | 5 |
| DeLaney, TF | 1 |
| Tsokos, M | 1 |
| Avila, N | 1 |
| Steinberg, SM | 1 |
| Weaver-McClure, L | 1 |
| Jacobson, J | 1 |
| Jarosinski, P | 1 |
| Hijazi, YM | 1 |
| Horowitz, ME | 1 |
| Roguin, A | 1 |
| Ben Arush, MW | 2 |
| Higasi, A | 1 |
| Kuten, A | 2 |
| Tella, G | 1 |
| Donehower, RC | 1 |
| Uchida, A | 1 |
| Shinto, Y | 1 |
| Fetscher, S | 1 |
| Brugger, W | 1 |
| Engelhardt, R | 1 |
| Hasse, J | 1 |
| Frommhold, H | 1 |
| Wenger, M | 1 |
| Lange, W | 1 |
| Mertelsmann, R | 1 |
| Leo, E | 1 |
| Schlegel, PG | 1 |
| Lindemann, A | 1 |
| Brunat-Mentigny, M | 7 |
| Demaille, MC | 2 |
| Pein, F | 1 |
| Avet-Loiseau, H | 1 |
| Berger, C | 1 |
| De Lumley, L | 1 |
| Pillon, P | 1 |
| Bernard, JL | 1 |
| Vadhan-Raj, S | 1 |
| Plager, C | 1 |
| Burgess, MA | 2 |
| Hays, C | 1 |
| Bellmunt, J | 1 |
| Eres, N | 1 |
| Ribas, A | 1 |
| Casado, S | 1 |
| Albanell, J | 1 |
| Baselga, J | 1 |
| Sottili, S | 1 |
| Gasbarrini, A | 2 |
| Murad, AM | 1 |
| Guimaraes, RC | 1 |
| Amorim, WC | 1 |
| Morici, AC | 1 |
| Ferreira-Filho, AF | 1 |
| Schwartsmann, G | 1 |
| Tesoro-Tess, JD | 1 |
| Gianni, MC | 1 |
| Fossati-Bellani, F | 1 |
| Lombardi, F | 1 |
| Chap, LI | 1 |
| Mirra, J | 1 |
| Ippolito, V | 1 |
| Rentschler, R | 1 |
| Rosen, P | 1 |
| Nielsen, OS | 1 |
| Therasse, P | 1 |
| van Oosterom, AT | 1 |
| Chou, CW | 1 |
| Liu, JM | 1 |
| Wu, MF | 1 |
| Li, AF | 1 |
| Tie, CM | 1 |
| Chi, KH | 1 |
| Verrill, MW | 1 |
| Wiltshaw, E | 1 |
| Thomas, JM | 1 |
| Harmer, CL | 1 |
| Hirota, T | 1 |
| Takeuchi, M | 1 |
| Iwata, A | 1 |
| Kitagawa, S | 1 |
| Sato, T | 1 |
| Konno, K | 1 |
| Sawada, K | 1 |
| Kobayashi, S | 1 |
| Hamaguchi, N | 1 |
| Agata, H | 1 |
| Katano, N | 1 |
| Moses, M | 1 |
| Drumea, K | 1 |
| Haim, N | 1 |
| Koch Nogueira, PC | 1 |
| Hadj-Aïssa, A | 1 |
| Schell, M | 1 |
| Cochat, P | 1 |
| Ahrens, S | 6 |
| Harms, D | 4 |
| Leyvraz, S | 1 |
| Bacchi, M | 1 |
| Lissoni, A | 1 |
| Sessa, C | 1 |
| Bressoud, A | 1 |
| Hermann, R | 1 |
| Fuchs, N | 1 |
| Epler, D | 1 |
| Bieling, P | 2 |
| Körholz, D | 1 |
| Graf, N | 1 |
| Heise, U | 2 |
| Weinel, P | 2 |
| Werner, M | 1 |
| Cotterill, S | 1 |
| Malcolm, A | 1 |
| Souhami, R | 1 |
| Imeson, J | 1 |
| Gieser, P | 1 |
| Ayala, A | 1 |
| Shochat, SJ | 1 |
| Holbrook, T | 1 |
| Terek, RM | 1 |
| Schwartz, GK | 1 |
| Devaney, K | 1 |
| Glantz, L | 1 |
| Mak, S | 1 |
| Albino, AP | 1 |
| Leone, L | 1 |
| Oliva, C | 1 |
| Frustaci, S | 1 |
| Monteleone, M | 1 |
| Colussi, AM | 1 |
| Dal Canton, O | 1 |
| Bergnolo, P | 1 |
| Boglione, A | 1 |
| Bumma, C | 1 |
| Lindner, NJ | 1 |
| Spanier, SS | 1 |
| Enneking, WF | 1 |
| Hofmann, J | 1 |
| Hillmann, A | 1 |
| Mancini, A | 1 |
| Rimondini, S | 3 |
| Di Liddo, M | 1 |
| Arndt, C | 1 |
| Morgenstern, B | 1 |
| Hawkins, D | 2 |
| Wilson, D | 1 |
| Liedtke, R | 1 |
| Mancini, AF | 1 |
| Baldini, N | 1 |
| Hoffmann, C | 1 |
| Jabar, S | 1 |
| Braun-Munzinger, G | 1 |
| Heinecke, A | 1 |
| Göbel, U | 4 |
| Treuner, J | 3 |
| Lewis, IJ | 1 |
| Gattamaneni, HR | 1 |
| Bailey, CC | 1 |
| Lashford, LS | 1 |
| Fasano, MC | 1 |
| Czyzewski, EA | 1 |
| Goldman, S | 1 |
| Mundt, AJ | 1 |
| Nachman, J | 1 |
| Rubin, C | 1 |
| Hallahan, DE | 1 |
| Le Chevalier, T | 2 |
| Missenard, G | 1 |
| Lepechoux, C | 1 |
| Cojean-Zelek, I | 1 |
| Mesurolle, B | 1 |
| Kondo, N | 1 |
| Tomita, M | 1 |
| Hasegawa, N | 1 |
| Kazama, A | 1 |
| Marina, NM | 3 |
| Poquette, CA | 3 |
| Greenwald, C | 1 |
| Thomson, B | 1 |
| Radich, J | 1 |
| Souid, AK | 1 |
| Fahey, RC | 1 |
| Dubowy, RL | 1 |
| Newton, GL | 1 |
| Philip, T | 1 |
| Iliescu, C | 1 |
| Krakowski, I | 1 |
| Soler-Michel, P | 1 |
| Thiesse, P | 1 |
| Chauvin, F | 1 |
| Shankar, AG | 1 |
| Pinkerton, CR | 1 |
| Atra, A | 1 |
| Ashley, S | 1 |
| Cannon, S | 1 |
| Cotterill, SJ | 2 |
| Loro, L | 1 |
| Mazzei, T | 1 |
| Beghelli, C | 1 |
| Biolchini, A | 1 |
| Simoni, P | 1 |
| Tremosini, M | 1 |
| Strazzari, S | 1 |
| Puggioli, C | 1 |
| Daller, RT | 1 |
| Fenton, JG | 1 |
| Blomqvist, CP | 1 |
| Akerman, M | 1 |
| Stenwig, E | 1 |
| Dinçol, D | 1 |
| Samur, M | 1 |
| Sencan, O | 1 |
| Onur, H | 1 |
| Senler, FC | 1 |
| Skinner, R | 1 |
| Stevens, MC | 1 |
| Meyers, MO | 1 |
| Anthony, LB | 1 |
| McCarthy, KE | 1 |
| Drouant, G | 1 |
| Maloney, TJ | 1 |
| Espanan, GD | 1 |
| Woltering, EA | 1 |
| Fraser, G | 1 |
| Rampling, R | 1 |
| Smith, C | 1 |
| Nicoll, J | 1 |
| Stephen, M | 1 |
| Mahmoud, HH | 1 |
| Harper, J | 1 |
| Neel, M | 1 |
| Fletcher, BD | 3 |
| Böhm, P | 1 |
| Kunz, W | 1 |
| Horny, HP | 1 |
| Einsele, H | 1 |
| Brandao, L | 1 |
| Zavatta, M | 1 |
| Fiorentini, G | 1 |
| De Giorgi, U | 1 |
| Exner, GU | 1 |
| Amann, G | 1 |
| Dockhorn-Dworniczak, B | 1 |
| Müller-Weihrich, S | 1 |
| Welte, K | 1 |
| Kornhuber, B | 1 |
| Janka-Schaub, G | 1 |
| Voûte, PA | 2 |
| Campanacci, L | 1 |
| Biagini, R | 1 |
| Frisk, P | 1 |
| Stålberg, E | 1 |
| Strömberg, B | 1 |
| Stewart, SL | 1 |
| Cormier, JN | 1 |
| Ballo, MT | 1 |
| Feig, BW | 1 |
| Hunt, KK | 1 |
| Raney, RB | 1 |
| Zagars, GK | 1 |
| Pisters, PW | 1 |
| Berend, KR | 1 |
| Pietrobon, R | 1 |
| Moore, JO | 1 |
| Dibernardo, L | 1 |
| Harrelson, JM | 1 |
| Scully, SP | 1 |
| Lehnert, M | 1 |
| Taeger, D | 1 |
| Hense, HW | 1 |
| Wagner, A | 1 |
| Reiter, A | 1 |
| Henze, G | 1 |
| Niemeyer, C | 1 |
| Kremens, B | 1 |
| Fölsch, UR | 1 |
| Aulitzky, WE | 1 |
| Ito, T | 1 |
| Mochida, A | 1 |
| Saito, K | 1 |
| Nishi, K | 1 |
| Sasaki, S | 1 |
| Hisada, T | 1 |
| Morinari, H | 1 |
| Nakahara, K | 1 |
| Tahara, M | 1 |
| Masuda, S | 1 |
| Yakumaru, K | 1 |
| Sokolov, T | 1 |
| Stoianova, A | 1 |
| Mumdjiev, I | 1 |
| Mihova, A | 1 |
| Könemann, S | 1 |
| Rübe, CE | 1 |
| Lari, S | 1 |
| Estrada-Aguilar, J | 1 |
| Greenberg, H | 1 |
| Walling, A | 1 |
| Schroer, K | 1 |
| Black, T | 1 |
| Morse, S | 1 |
| Hvizdala, E | 1 |
| Kun, L | 1 |
| Roberson, P | 1 |
| Parham, D | 1 |
| Fletcher, B | 1 |
| Zülfikar, B | 1 |
| Gedikoğlu, G | 1 |
| Blackledge, G | 1 |
| Steward, WP | 1 |
| Mouridsen, H | 1 |
| Bramwell, V | 1 |
| Schütte, J | 1 |
| van Oosterom, A | 1 |
| Dombernowsky, P | 1 |
| Buesa, J | 1 |
| Van Glabekke, M | 1 |
| Antman, KH | 2 |
| Yasutake, H | 1 |
| Yokogawa, A | 1 |
| Baba, H | 1 |
| Ueda, Y | 1 |
| Habrand, JL | 1 |
| Zucker, JM | 2 |
| Terrier-Lacombe, MJ | 1 |
| Dubousset, J | 1 |
| Ponvert, D | 1 |
| Carrié, C | 1 |
| Scher, CS | 1 |
| Amar, D | 1 |
| McDowall, RH | 1 |
| Barst, SM | 1 |
| Hanna, SL | 1 |
| Fairclough, DL | 1 |
| Le, AH | 1 |
| Thomas, F | 1 |
| Subirana, R | 1 |
| Baldeyrou, P | 1 |
| Ruffie, P | 1 |
| Arriagada, R | 1 |
| Chazard, M | 1 |
| Tursz, T | 1 |
| Lewis, CR | 1 |
| Fossà, SD | 1 |
| Mead, G | 1 |
| ten Bokkel Huinink, W | 1 |
| Harding, MJ | 1 |
| Mill, L | 1 |
| Paul, J | 1 |
| Jones, WG | 1 |
| Rodenburg, CJ | 1 |
| Cantwell, B | 1 |
| Dose, C | 1 |
| Ritter, J | 4 |
| Petrilli, S | 1 |
| Penna, V | 1 |
| Lopes, A | 1 |
| Figueiredo, MT | 1 |
| Gentil, FC | 1 |
| Pignatti, G | 1 |
| De Cristofaro, R | 1 |
| Dallari, D | 1 |
| Avella, M | 1 |
| Marangolo, M | 1 |
| Ferruzzi, A | 1 |
| Fujita, H | 1 |
| Kiyokawa, N | 1 |
| Takada, K | 1 |
| Kyo, K | 1 |
| Ishimoto, K | 1 |
| Yabuta, K | 1 |
| Mizuno, T | 1 |
| Ishida, S | 1 |
| Akiba, Y | 1 |
| Ohosaki, Y | 1 |
| Onodera, S | 1 |
| Fujita, Y | 1 |
| Tagaki, S | 1 |
| Shimizu, T | 1 |
| Sakai, E | 1 |
| Ikushima, Y | 1 |
| Saotome, K | 1 |
| Iwasaku-Fujimoto, M | 1 |
| Fujiwara, F | 1 |
| Todo, S | 1 |
| Morioka, Y | 1 |
| Imashuku, S | 1 |
| Lemmi, MA | 1 |
| Slade, W | 1 |
| Greenshaw, C | 1 |
| Kusnierz-Glaz, C | 1 |
| Erttmann, R | 1 |
| Biron, P | 1 |
| Kohler, R | 1 |
| Blondet, R | 1 |
| Bérard, J | 1 |
| Chauvot, P | 1 |
| Bouffet, E | 1 |
| Carret, JP | 1 |
| Jonas, P | 1 |
| Patricot, LM | 2 |
| Purfürst, C | 1 |
| Nourissat, C | 1 |
| Tachon, G | 1 |
| Manoukian, A | 1 |
| Exner, U | 1 |
| Kühl, J | 1 |
| Ryan, L | 1 |
| Sulkes, A | 1 |
| Collins, J | 1 |
| Aisner, J | 1 |
| Deméocq, F | 1 |
| Benz-Lemoine, E | 1 |
| Boilletot, A | 1 |
| Behar, C | 1 |
| Poutard, P | 1 |
| Olive, D | 1 |
| Tsukagoshi, S | 1 |
| Taillard, F | 1 |
| Desbois, JG | 1 |
| Cornille, H | 1 |
| Jasmin, C | 1 |
| Mathé, G | 1 |
| Legmann, F | 1 |
| Magrath, I | 1 |
| Sandlund, J | 1 |
| Raynor, A | 1 |
| Rosenberg, S | 1 |
| Arasi, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination With Ifosfamide and Etoposide Versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults With Relapsed or Refractory Osteosa[NCT04154189] | Phase 2 | 81 participants (Actual) | Interventional | 2020-03-23 | Completed | ||
| A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas[NCT01830153] | Phase 2 | 41 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy[NCT02711007] | Phase 2/Phase 3 | 37 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99)[NCT00020566] | Phase 3 | 1,200 participants (Anticipated) | Interventional | 2001-02-28 | Recruiting | ||
| Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR[NCT04461223] | 55 participants (Anticipated) | Observational [Patient Registry] | 2019-12-01 | Recruiting | |||
| A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-operative Chemotherapy[NCT00134030] | Phase 3 | 1,334 participants (Actual) | Interventional | 2005-11-14 | Completed | ||
| Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma[NCT00987636] | Phase 3 | 907 participants (Actual) | Interventional | 2009-10-01 | Completed | ||
| OS2006 : Protocole de Traitement Des ostéosarcomes de l'Enfant, de l'Adolescent et de l'Adulte Comportant[NCT00470223] | Phase 3 | 318 participants (Actual) | Interventional | 2007-03-31 | Active, not recruiting | ||
| Multicenter Observational Study on the Treatment of Patients With Localized Osteosarcoma[NCT04890067] | 120 participants (Anticipated) | Observational | 2021-07-30 | Recruiting | |||
| Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment[NCT00824083] | 950 participants (Actual) | Observational | 2009-07-31 | Completed | |||
| Chemotherapy-induced Necrosis in Ewing Sarcoma: Which is the Best Scoring Tool[NCT03968471] | 474 participants (Actual) | Observational | 2019-05-13 | Completed | |||
| EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92][NCT00002516] | Phase 3 | 0 participants | Interventional | 1992-07-31 | Active, not recruiting | ||
| Observational Study on Treatment of Skeletal Ewing Sarcoma at Diagnosis[NCT04845893] | 100 participants (Anticipated) | Observational | 2021-06-01 | Recruiting | |||
| Trial of Chemotherapy Intensification Through Compression in Ewing's Sarcoma and Related Tumors[NCT00006734] | Phase 3 | 587 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| Prospective Evaluation of the Prognostic Relevance of PCR Positivity in Blood and Bone Marrow in Non-Metastatic Ewings Sarcoma[NCT00339898] | 414 participants (Actual) | Observational | 2004-03-12 | Completed | |||
| Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study[NCT03737435] | 80 participants (Anticipated) | Observational | 2018-12-12 | Recruiting | |||
| A Pilot Study of Tumor Vaccination and R-hIL-7 Following Standard Multimodality Therapy in Patients With High Risk Pediatric Solid Tumors[NCT00923351] | Phase 1/Phase 2 | 44 participants (Actual) | Interventional | 2007-06-02 | Completed | ||
| A Phase I Trial and Pharmacokinetic Study of the Oral Platinum Analog Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors[NCT01259479] | Phase 1 | 9 participants (Actual) | Interventional | 2010-12-03 | Completed | ||
| SFOP-OS94: Multicentric Randomised Phase III Trial Comparing Efficacy of Preoperative High-Dose Methotrexate Plus Doxorubicin to Efficacy of High-Dose Methotrexate Plus Etoposide and Ifosfamide, in Children and Adolescents Osteosarcoma[NCT00180908] | Phase 3 | 226 participants | Interventional | 1994-06-30 | Completed | ||
| Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma[NCT00003212] | Phase 3 | 780 participants (Anticipated) | Interventional | 1998-01-31 | Completed | ||
| MISTOSUS: Iscador® P (Mistletoe) Immunotherapy To Improve Event Free Survival In Patients With Relapsed Osteosarcoma After Resection Of Pulmonary Metastases[NCT05726383] | Phase 2 | 32 participants (Anticipated) | Interventional | 2023-12-15 | Not yet recruiting | ||
| Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma[NCT00978471] | Phase 2 | 44 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma[NCT00802880] | Phase 2 | 80 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Comparing the Effectiveness and Toxicity for Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Patients Who Had Received Total Dose of Anthracycline Antibiotics More Than 300mg/m2 With Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus[NCT03342300] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2017-11-06 | Withdrawn (stopped due to No participants enrolled) | ||
| INTENSIVE THERAPY WITH GROWTH FACTOR SUPPORT FOR PATIENTS WITH EWING'S TUMOR METASTATIC AT DIAGNOSIS: A PEDIATRIC ONCOLOGY GROUP PHASE II STUDY[NCT00002643] | Phase 2 | 130 participants (Actual) | Interventional | 1995-04-30 | Completed | ||
| Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients[NCT03542097] | 82 participants (Actual) | Observational | 2014-04-15 | Completed | |||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma[NCT01755195] | Phase 2 | 55 participants (Actual) | Interventional | 2013-01-15 | Active, not recruiting | ||
| Pilot Study of Allogeneic/Syngeneic Blood Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas[NCT00043979] | Phase 2 | 60 participants (Actual) | Interventional | 2002-09-19 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Health-Related Quality of Life (HRQoL): PedsQL 4.0 Generic Core Scale is a multidimensional scale. It included assessment of 4 dimensions: physical functioning (8 items), emotional functioning (8 items), social functioning (8 items), and school functioning (5 items - children greater than or equal to [>=] 5 years, adults; 3 items - toddlers [aged 2-4 years]). Each item was reported using a 5-point Likert scale, items were then reverse-scored and linearly transformed to a 0 to 100 scale. Generic Core Scale total score: sum of all the items divided by the number of items answered across all the scales. Total score ranges from 0 to 100, where higher scores=better HRQoL, lower scores=worse HRQoL. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Baseline and Month 4
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | 2.61 |
| Treatment Arm B: Ifosfamide + Etoposide | 2.65 |
HRQoL: PedsQL 3.0 Cancer Module Scale measured pediatric cancer-specific HRQoL. It included assessment of 8 dimensions: pain and hurt (2 items), nausea (5 items), procedural anxiety (3 items), treatment anxiety (3 items), worry (3 items), cognitive problems (3 items - toddlers [aged 2-4], 4 items - young children [aged 5-7]; 5 items for children aged >=8 years, adults), perceived physical appearance (3 items), communication (3 items). Each item was reported using a 5-point Likert scale, items were then reverse-scored and linearly transformed to a 0 to 100 scale. Cancer Module total score: sum of all items divided by the number of items answered on all the scales. Total score ranges from 0 to 100, where higher scores=better HRQoL, lower scores=worse HRQoL. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Baseline and Month 4
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | 2.66 |
| Treatment Arm B: Ifosfamide + Etoposide | 2.08 |
ORR-4m was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) as determined by IIR using RECIST v1.1 within the first 4 months. CR: defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (<) 10 mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. 95% confidence interval (CI) of ORR was calculated using the method of Clopper and Pearson. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Month 4
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | 15.0 |
| Treatment Arm B: Ifosfamide + Etoposide | 7.3 |
ORR by IIR was defined as the percentage of participants with best overall response of CR or PR determined using RECIST v1.1. CR: defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to <10 mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. 95% CI of ORR was calculated using the method of Clopper and Pearson. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: From the date of randomization to the date of the first documentation of CR or PR, whichever occurred first (up to approximately 14.2 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | 15.0 |
| Treatment Arm B: Ifosfamide + Etoposide | 9.8 |
OS-1y was defined as the time from the date of randomization to the date of death from any cause assessed up to 1 year. OS was calculated using the Kaplan-Meier method. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Month 12 or 1 Year
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | 49.2 |
| Treatment Arm B: Ifosfamide + Etoposide | 72.1 |
PFS-1y rate as assessed by IIR was defined as the percentage of participants who were alive and without PD at 1 year from randomization date using RECIST v1.1. PD was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS-1y rate was estimated using Kaplan-Meier method. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Month 12 or 1 Year
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | NA |
| Treatment Arm B: Ifosfamide + Etoposide | 14.9 |
PFS rate at 4 months as assessed by IIR was defined as the percentage of participants who were alive and without PD at 4 months from the randomization date using RECIST v1.1. PD was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. The PFS-4m was estimated using the Kaplan-Meier method. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Month 4
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | 76.3 |
| Treatment Arm B: Ifosfamide + Etoposide | 66.0 |
PFS as assessed by IIR was defined as the time from the date of randomization to the date of the first documentation of PD or date of death (whichever occurred first), as determined using RECIST v1.1. PD was defined as at least a 20 percent (%) increase or 5 millimeter (mm) increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS was analyzed using Kaplan-Meier method. (NCT04154189)
Timeframe: From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first (up to 14.2 months)
| Intervention | months (Median) |
|---|---|
| Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | 6.5 |
| Treatment Arm B: Ifosfamide + Etoposide | 5.5 |
The palatability and acceptability of lenvatinib oral suspension formulation was assessed using the Palatability Questionnaire. In the questionnaire, participants were asked to answer palatability and acceptability of lenvatinib suspension considering the following elements: taste, appearance, smell, how does it feel in the mouth and overall acceptability in terms of 7 responses: Super good, really good, good, may be good or may be bad, bad, really bad, super bad. In this outcome measure, number of participants have been reported per their overall palatability and acceptability responses. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Cycle 1 Day 1 (Cycle length = 21 days)
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Super Bad | Really Bad | Bad | May be Good or May be Bad | Good | Really Good | Super Good | |
| All Participants: Lenvatinib 14 mg/m^2 | 0 | 0 | 0 | 2 | 2 | 0 | 1 |
Plasma concentration of lenvatinib in participants from Treatment Arm A (Lenvatinib + Ifosfamide + Etoposide) at different time points were reported. As planned, data for this outcome measure was analyzed for treatment arm A only. Lenvatinib concentration in plasma was quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: Pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: Pre-dose (each Cycle length = 21 days)
| Intervention | nanograms per milliliter (ng/mL) (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 1, Day 1: 0.5-4 hours post-dose | Cycle 1, Day 1: 6-10 hours post-dose | Cycle 1, Day 15: Pre-dose | Cycle 1, Day 15: 0.5-4 hours post-dose | Cycle 1, Day 15: 6-10 hours post-dose | Cycle 2, Day 1: Pre-dose | |
| Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | 147.9 | 217.8 | 70.7 | 222.3 | 310.9 | 70.2 |
"EFS is defined as time from randomisation to the first of: death, detection of local recurrence or metastasis, progression of metastatic disease, or detection of a secondary malignancy.~EFS will be assessed using the logrank test and expressed using hazard ratios with appropriate confidence intervals. Follow up per participant will be assessed for up to 10 years. The 3 year EFS is provided as a summary." (NCT00134030)
Timeframe: From date of randomization to date of the event.
| Intervention | Percentage EFS (Number) |
|---|---|
| MAP-GR | 74 |
| MAPifn | 77 |
| MAP-PR | 55 |
| MAPIE | 53 |
"Overall survival is time from randomization until death from any cause.~Will be assessed using the logrank test and expressed using hazard ratios with appropriate confidence intervals. Participants will be assessed for up to 10 years. 5 year overall survival is provided as a summary." (NCT00134030)
Timeframe: From date of randomization to date of death.
| Intervention | Percentage of participants (Number) |
|---|---|
| MAP-GR | 84 |
| MAPifn | 84 |
| MAP-PR | 68 |
| MAPIE | 68 |
Percentages of patients experiencing grade 3 and 4 adverse events. These will be compared using chi-square tests or Fisher's exact tests where appropriate. (NCT00134030)
Timeframe: Adverse events are assessed for up to 10 years per participant.
| Intervention | Participants (Count of Participants) |
|---|---|
| MAP-GR | 348 |
| MAPifn | 340 |
| MAP-PR | 287 |
| MAPIE | 281 |
"A positive response to the tumor vaccine requires a positive reaction in at least one of the two assays below (immune responses to tumor lysates using ex vivo and delayed type of hypersensitivity (DTH).~The presence of a positive delayed type of hypersensitivity (DTH) reaction to the tumor lysate in a patient who did not show a positive DTH reaction prior to immunotherapy. A positive reaction is induration of at least 0.5 cm.~Immunotherapy administered to patients with recurrent or metastatic pediatric solid tumors such as Ewing's sarcoma, rhabdomyosarcoma, or neuroblastoma. Each vaccine is given as 6 separate injections. Three intradermal on one arm or leg and three subcutaneous on the other arm or leg." (NCT00923351)
Timeframe: Week 8, 14, 20 (Arm A) and on Days 42, 84 and 126 (± 7 days) (Arm B)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A - Participants Who Did Not Receive rhIL-7 | 0 |
| Arm B - Participants Who Received rhIL-7 | 15 |
Overall survival is defined as the time between the first day of treatment to the day of death. (NCT00923351)
Timeframe: Time between the first day of treatment to the day of death or at the conclusion of 5 years of follow-up, whichever comes first, assessed up to approximately 11 years.
| Intervention | years (Median) |
|---|---|
| Arm A - Participants Who Did Not Receive rhIL-7 | 2.4 |
| Arm B - Participants Who Received rhIL-7 | 4.3 |
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00923351)
Timeframe: Date treatment consent signed to date off study, approximately 49.5 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A - Participants Who Did Not Receive rhIL-7 | 6 |
| Arm B - Participants Who Received rhIL-7 | 24 |
(NCT00802880)
Timeframe: Until completion of follow-up or patient death (estimated to be 1 year)
| Intervention | months (Median) |
|---|---|
| Dacarbazine | 8.09 |
Approximately 18 weeks (NCT00802880)
Timeframe: Completion of 6 cycles of treatment (18 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Dacarbazine | 22.5 |
"Grade 3 neutropenia = absolute neutrophil count of <1000 - 500/mm^3~Grade 4 neutropenia = absolute neutrophil count of <500/mm^3" (NCT00802880)
Timeframe: Completion of 6 cycles of treatment (18 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Dacarbazine | 7.5 |
-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00802880)
Timeframe: Until completion of follow-up (estimated to be 1 year)
| Intervention | months (Median) |
|---|---|
| Dacarbazine | 2.07 |
"Complete response (CR): disappearance of all target lesions, disappearance of all non-target lesions, normalization of tumor level marker~Partial response (PR): at least 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD, persistence of one or more non-target lesion and/or maintenance of tumor marker level above the upper limits of normal~Stable disease (SD): neither sufficient shrinkage in target lesions to qualify for PR nor sufficient increase to qualify for progressive disease taking as references the smallest sum LD since the treatment started, persistence of one or more non-target lesion and/or maintenance of tumor marker level above the normal limits of normal~Progressive disease (PD): at least 20% increase in the sum of the LD of target lesions and/or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions" (NCT00802880)
Timeframe: After completion of 3 cycles
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete response | Partial response | Stable disease | Progressive disease | |
| Dacarbazine | 0 | 2 | 22 | 30 |
(NCT00802880)
Timeframe: Baseline and after every three cycles of treatment (up to 1 year)
| Intervention | standard uptake value (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | End of cycle 3 | End of cycle 6 | End of cycle 9 | End of cycle 12 | |
| Dacarbazine | 7.42 | 7.57 | 7.7 | 6.89 | 7.48 |
(NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)
| Intervention | months (Median) | ||
|---|---|---|---|
| Partial response | Stable disease | Progressive disease | |
| Dacarbazine | 18.16 | 14.77 | 7.96 |
(NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)
| Intervention | months (Median) | ||
|---|---|---|---|
| Partial metabolic response | Stable metabolic disease | Progressive metabolic disease | |
| Dacarbazine | 18.16 | 18.59 | 8.75 |
-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)
| Intervention | months (Median) | ||
|---|---|---|---|
| Partial response | Stable disease | Progressive disease | |
| Dacarbazine | NA | 4.14 | 1.97 |
(NCT00802880)
Timeframe: After completion of 3 cycles
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| PR | SD | PD | Total | |
| Partial Metabolic Response | 1 | 2 | 1 | 4 |
| Progressive Metabolic Disease | 1 | 8 | 24 | 33 |
| Stable Metabolic Disease | 0 | 10 | 2 | 12 |
| Total | 2 | 20 | 27 | 49 |
-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)
| Intervention | months (Median) | ||
|---|---|---|---|
| Partial metabolic response | Stable metabolic disease | Progressive metabolic disease | |
| Dacarbazine | 3.95 | 5.30 | 2.07 |
(NCT00802880)
Timeframe: 12 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete response | Partial response | Stable disease | Progressive disease | |
| Dacarbazine | 0 | 0 | 5 | 1 |
"Complete metabolic response (CMR)-complete resolution of all metabolically active target and non-target lesions, and no interval development of new lesions.~Partial metabolic response (PMR)~Target lesions: 20% or greater decrease in maximum SUV from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions.~Non-target lesions: decrease in total number of non-target lesions, without complete resolution of metabolically active disease, or unequivocal decrease in degree of FDG activity within >50% of the lesions. No unequivocal new lesions.~Stable metabolic disease (SMD): does not qualify for CMR, PMR, or PMD.~Progressive metabolic disease (PMD):~Unequivocal development of one more new metabolically active lesions~Target lesion: 20% or greater increase in maximum SUV from baseline.~Non-target lesions: unequivocal increase in FDG activity" (NCT00802880)
Timeframe: After completion of 3 cycles
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CMR | PMR | SMD | PMD | |
| Dacarbazine | 0 | 4 | 13 | 34 |
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01755195)
Timeframe: Date treatment consent signed to date off study, approximately 86 months and 3 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cabozantinib | 53 |
Objective response was assessed by the Response Evaluation Criteria in Solid Tumors RECIST) v1.1. Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. (NCT01755195)
Timeframe: Date treatment consent signed to date off study, approximately 86 months and 3 days.
| Intervention | percentage of particpants (Number) |
|---|---|
| Cabozantinib | 11.1 |
Progression in participants with soft tissue sarcomas treated with cabozantinib was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions. (NCT01755195)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Cabozantinib | 49.3 |
Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of HGF. HGF protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Baseline to Cycle 1 Day 1 | Baseline to Cycle 2 Day 1 | |
| Cabozantinib | -51.3 | 344.8 |
Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble MET (sMET). sMET protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Baseline to Cycle 1 Day 1 | Baseline to Cycle 2 Day1 | |
| Cabozantinib | -6.1 | 16.4 |
Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble VEGFR2 (sVEGFR-2). sVEGFR-2 protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome.. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Baseline to Cycle 1 Day 1 | Baseline to Cycle 2 Day 1 | |
| Cabozantinib | -1.0 | -10.9 |
Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of VEGF-A. VEGF-A protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Baseline to Cycle 1 Day 1 | Baseline to Cycle 2 Day 1 | |
| Cabozantinib | 5.6 | 32.5 |
The median CD4 count with a range of 85-1565 (absolute count) was used to determine recovery and were considered recovered if in this range. The CD4 count was established by flow cytometry testing. (NCT00043979)
Timeframe: Day +28-42
| Intervention | mm(3) (Median) |
|---|---|
| Arm 2-Recipients | 284 |
Participants who experienced recurrence or progression of disease following transplant. (NCT00043979)
Timeframe: up to 300 days
| Intervention | Days (Median) |
|---|---|
| Arm 2-Recipients | 100 |
Progression free survival was based on the time from on-study date until progression or last follow-up. (NCT00043979)
Timeframe: up to 77 months
| Intervention | Months (Median) |
|---|---|
| Arm 2-Recipients | 15.9 |
Days for participants to achieve a platelet count of 50,000/mm(3). (NCT00043979)
Timeframe: up to 43 days
| Intervention | Days (Median) |
|---|---|
| Arm 2-Recipients | 15 |
Days for participants to achieve a neutrophil count of 500/mm(3). (NCT00043979)
Timeframe: up to 12 days
| Intervention | Days (Median) |
|---|---|
| Arm 2-Recipients | 9 |
GVT is defined as tumor response after day 42 post-transplantation without cytotoxic therapy. (NCT00043979)
Timeframe: up to day 100
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 2-Recipients | 0 |
Engraftment is defined as rapid conversion to complete donor chimerism and is assessed by blood counts and chimerism, >95% donor engraftment at day 100 in >75% of patients. (NCT00043979)
Timeframe: 100 days
| Intervention | Participants (Number) |
|---|---|
| Arm 2-Recipients | 23 |
Here is the number of participants with adverse events. For a detailed list of adverse events see the adverse event module. (NCT00043979)
Timeframe: 16.5 months
| Intervention | Participants (Number) |
|---|---|
| Arm 2-Recipients | 30 |
Response is defined by the Response Evaluation Criteria in Solid Tumors (RECIST). RECIST criteria offer a simplified, conservative, extraction of imaging data for wide application in clinical trials. They presume that linear measures are an adequate substitute for 2-D (dimensional) methods and registers four response categories: Complete response (CR) is disappearance of all target lesions. Partial response (PR) is 30% increase in the sum of the longest diameter of target lesions. Progressive disease (PD) is 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) is small changes that do not meet above criteria. For the purposes of this study very good partial response ((VGPR) is >75% reduction in disease) was also employed. (NCT00043979)
Timeframe: up to 10 cycles of therapy or 280 days
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response (CR) | Progressive Disease (PD) | Partial Response (PR) | Very Good Partial Response (VGPR) | |
| Arm 2-Recipients | 2 | 4 | 4 | 2 |
Median survival from date of progression is based on the time from on-study date until progression or last follow-up. (NCT00043979)
Timeframe: up to 77 months
| Intervention | Months (Median) | |
|---|---|---|
| Participants who did not receive a transplant(n=7) | Participants who received a transplant (n=23) | |
| Arm 2-Recipients | 3.3 | 19.1 |
Participants who tolerated the transplantation regimen and accepted >95% of the donors blood, marrow, and/or tissue. (NCT00043979)
Timeframe: up to 30 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Day +14 | Day +28 | |
| Arm 2-Recipients | 23 | 23 |
Acute GVHD as by Modified Glucksberg Criteria occurring before day 100. Chronic GVHD as per Seattle criteria occurring after day 100. (NCT00043979)
Timeframe: up to 5 years or death
| Intervention | participants (Number) | |
|---|---|---|
| acute GVHD | chronic GVHD | |
| Recipients -Cyclosporine GVHD Prophylaxis | 12 | 12 |
| Recipients -Tacrolimus/Sirolimus GVHD Prophylaxis | 5 | 5 |
Site of radiotherapy (high energy radiation) and/or toxicity experienced by the participants post HSCT radiotherapy. Grading was preformed using the Modified Glucksberg Criteria. (NCT00043979)
Timeframe: up to 6 cycles or 168 days
| Intervention | Participants (Count of Participants) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Chest wall; G2 skin | Abdomen; G4 GI | Pancreas; G4 LFTs, G4 pancreatitis | Pleura, mediastinum; G4 LFTs, G2 mucositis | Chest wall; G4 skin, G3 mucositis | Spine, skull; G2 nausea+vomiting, G2 fatigue | Pelvis; G4 enteritis | Pulmonary (cyberknife) | Brain; B3 mucositis | Whole lung; G3 mucositis, G3 skin, G5 lung | L arm, R shoulder, B/L femur | |
| Arm 2-Recipients | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Participants who are alive at two years following Allo-Hematopoietic Stem Cell Transplant. (NCT00043979)
Timeframe: 2 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| From date of enrollment | From date of transplantation | |
| Arm 2-Recipients | 39.1 | 34.8 |
52 reviews available for ifosfamide and Bone Neoplasms
| Article | Year |
|---|---|
Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature.
Topics: Bone Neoplasms; Cisplatin; Humans; Ifosfamide; Male; Middle Aged; Neoplasms, Second Primary; Osteosa | 2022 |
Clinical characteristics of primary cutaneous and subcutaneous Ewing sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Etopo | 2023 |
Primary Ewing sarcoma of the larynx with distant metastasis: a case report and review of the literature.
Topics: Antineoplastic Agents; Bone Neoplasms; Chemoradiotherapy; Cyclophosphamide; Dactinomycin; Etoposide; | 2019 |
The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Do | 2020 |
Unusual aggressive breast cancer: metastatic malignant phyllodes tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidi | 2013 |
Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2014 |
Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: a case series and review of the literature.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Cohort | 2014 |
Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; C | 2014 |
The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Deoxycytidine; Doc | 2014 |
Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Ifosfamide; Neoadjuvant Ther | 2015 |
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Humans; Ifosfamid | 2015 |
An update on chemotherapy for osteosarcoma.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Clinical Tri | 2015 |
Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Humans; Ifosf | 2015 |
Efficacy Comparison of Six Chemotherapeutic Combinations for Osteosarcoma and Ewing's Sarcoma Treatment: A Network Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Etoposide; Fe | 2018 |
Leiomyosarcoma of the parotid gland in an HIV-positive patient: therapeutic approach, clinical course and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Biomar | 2009 |
Palifosfamide, a bifunctional alkylator for the treatment of sarcomas.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as Topic; Drug Evaluation, Preclinic | 2010 |
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Humans; Ifosfamide; Sarc | 2010 |
Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects.
Topics: Antidotes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; H | 2010 |
[Clinical characteristics and treatment of desmoplastic small round cell tumor].
Topics: Abdominal Neoplasms; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2010 |
Leiomyosarcoma of the tongue with multiple metastases: a case report and review of literature.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2012 |
Isolated subcutaneous metastasis of osteosarcoma 5 years after initial diagnosis.
Topics: Abdominal Wall; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2011 |
The activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; C | 2012 |
Advanced therapeutic strategy for radiation-induced osteosarcoma in the skull base: a case report and review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality T | 2012 |
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Humans; Ifosfamid | 2012 |
Small cell carcinoma of the bladder: a case report and a literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma, Small Cell; | 2003 |
Ifosfamide in pediatric solid tumors.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Germinoma; Humans; Ifosf | 2003 |
Palliative treatment for advanced or metastatic osteosarcoma.
Topics: Amputation, Surgical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic A | 2004 |
Osteosarcoma occurring in osteogenesis imperfecta.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality | 2004 |
[Soft tissue sarcoma: postoperative chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 2004 |
[Current strategy of chemotherapy for reflactory bone and soft tissue sarcomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Carboplatin; Cisplatin; | 2004 |
Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Anaplastic large cell lymphoma of bone--is it a bad tumor?
Topics: Activin Receptors, Type II; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2007 |
Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Combined Mo | 2005 |
Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; H | 2006 |
[Neoadjuvant treatment in osteosarcomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; D | 2006 |
Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chemotherapy, Adjuvant; | 2007 |
[Clinical features of patients with metastasis in phalanges as first symptom of primary lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcino | 2007 |
Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chemoth | 1995 |
Treatment of osteosarcoma: experience of the Cooperative Osteosarcoma Study Group (COSS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Chemotherapy, Adjuvant; C | 1993 |
An update of Scandinavian studies of osteosarcoma.
Topics: Adolescent; Adult; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla | 1993 |
Osteosarcoma studies at St. Jude Children's Research Hospital from 1968 through 1990.
Topics: Amputation, Surgical; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Cisplatin; Combined Modality Th | 1993 |
Osteosarcoma in adolescents and young adults: new developments and controversies. The Mayo Clinic studies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Child | 1993 |
Results of therapy in osteosarcoma: experience in childrens hospitals in Buenos Aires.
Topics: Antineoplastic Combined Chemotherapy Protocols; Argentina; Bone Neoplasms; Chemotherapy, Adjuvant; C | 1993 |
An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma.
Topics: Acidosis, Renal Tubular; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherap | 1993 |
Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience.
Topics: Acetylcysteine; Bone Neoplasms; Fluid Therapy; Humans; Ifosfamide; Mesna; Randomized Controlled Tria | 1993 |
High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C | 1996 |
How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neopl | 2001 |
Adult Gaucher disease in association with primary malignant bone tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Cyclophosphamide; | 2001 |
Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Child, Preschool; Combined Mo | 2001 |
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Europe; Humans; Ifosfamide; Sarcoma; | 1992 |
Chemotherapy of advanced sarcomas of bone and soft tissue.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Dacarbazin | 1992 |
Local control and survival from the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Austria; Bleomycin; Bone Neoplasm | 1991 |
112 trials available for ifosfamide and Bone Neoplasms
| Article | Year |
|---|---|
Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Dactin | 2023 |
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph | 2022 |
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph | 2022 |
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph | 2022 |
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph | 2022 |
Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Doxorubicin; Etoposide; Human | 2023 |
International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; | 2020 |
Extraskeletal Ewing sarcoma in children, adolescents, and young adults. An analysis of three prospective studies of the Cooperative Weichteilsarkomstudiengruppe (CWS).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosphamide; | 2021 |
OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Etoposide; | 2021 |
Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Female; Follow-U | 2017 |
Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2017 |
Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2018 |
Significance of neoadjuvant chemotherapy (NACT) in limb salvage treatment of osteosarcoma and its effect on GLS1 expression.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms | 2018 |
Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; | 2020 |
Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 2013 |
Treatment of large osteosarcoma in children: new approach.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Doxoru | 2013 |
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E | 2013 |
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E | 2013 |
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E | 2013 |
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E | 2013 |
Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chil | 2014 |
High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2014 |
Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Consolidation Chemotherapy; C | 2014 |
Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2015 |
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combin | 2015 |
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combin | 2015 |
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combin | 2015 |
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combin | 2015 |
Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chemotherap | 2014 |
Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Disease-Free Survival; | 2015 |
Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brazil; Carboplatin; Chi | 2015 |
Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone | 2015 |
Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Dose-Response | 2015 |
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Case-Control Stud | 2016 |
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Case-Control Stud | 2016 |
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Case-Control Stud | 2016 |
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Case-Control Stud | 2016 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Evaluation of chemotherapy response in osteosarcoma with FDG-PET.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone | 2009 |
Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2009 |
Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chil | 2009 |
Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality | 2009 |
Results of RS-99 protocol for childhood solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 2010 |
[Treatment of relapsed osteosarcoma. Role of chemotherapy using ifosamide and carboplatin].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chem | 2010 |
Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; | 2011 |
Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chil | 2011 |
Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 2012 |
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2012 |
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2012 |
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2012 |
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2012 |
A randomised dose-finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC).
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Disease Progression; Dose-R | 2002 |
Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Histi | 2002 |
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp | 2003 |
Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arm; Bone Neoplasms; Child; Child | 2003 |
Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2003 |
Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherap | 2004 |
High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Topics: Adolescent; Adult; Age Factors; Antimetabolites, Antineoplastic; Bone Neoplasms; Child; Child, Presc | 2004 |
A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Diseas | 2004 |
Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2004 |
High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Disease-Free Survival; | 2004 |
Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report.
Topics: Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bo | 2005 |
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols | 2005 |
High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carbo | 2005 |
A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 2006 |
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2005 |
Metastatic osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chil | 2006 |
Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival.
Topics: Adolescent; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Br | 2006 |
High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experie
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Child; Chil | 2006 |
Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined M | 2006 |
Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Child | 2006 |
Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Ch | 2007 |
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2007 |
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2007 |
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2007 |
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2007 |
Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dose-Respon | 2007 |
A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Epirub | 2007 |
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
[Preliminary evaluation of the effectiveness of holoxan in the treatment of malignant soft tissue and bone neoplasms].
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; Child; Child, Preschool; Clinical Trials a | 1981 |
Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined M | 1995 |
Salvage chemotherapy for recurrent Ewing's sarcomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; | 1995 |
Chemotherapy in osteogenic sarcoma: the experience of the Pediatric Department of the Gustave Roussy Institute.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Chemot | 1993 |
Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms | 1995 |
[Ifosfamide-induced hemorrhagic cystitis and its prevention by mesna].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 1995 |
An update of Scandinavian studies of osteosarcoma.
Topics: Adolescent; Adult; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla | 1993 |
Osteosarcoma studies at St. Jude Children's Research Hospital from 1968 through 1990.
Topics: Amputation, Surgical; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Cisplatin; Combined Modality Th | 1993 |
Osteosarcoma in adolescents and young adults: new developments and controversies. The Mayo Clinic studies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Child | 1993 |
Results of therapy in osteosarcoma: experience in childrens hospitals in Buenos Aires.
Topics: Antineoplastic Combined Chemotherapy Protocols; Argentina; Bone Neoplasms; Chemotherapy, Adjuvant; C | 1993 |
No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone: results of two sequential studies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 1993 |
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 1993 |
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 1993 |
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 1993 |
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 1993 |
A phase II study of cisplatin/ifosfamide in recurrent/metastatic undifferentiated nasopharyngeal carcinoma among young blacks in southern Africa.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 1996 |
Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp | 1996 |
Intra-arterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. results of a randomized study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxoru | 1996 |
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Neoplasms; C | 1997 |
Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Etoposide; | 1997 |
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Dose-Response Relationsh | 1997 |
Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; F | 1997 |
Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arm; Bone Neoplasms; Chemotherapy | 1997 |
Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 1998 |
Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chem | 1998 |
Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 1998 |
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dose-Respon | 1998 |
Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arm; Bone Neoplasms; Child, Presc | 1998 |
Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 1998 |
Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combined Mo | 1998 |
Local host response in osteosarcoma after chemotherapy referred to radiographs, CT, tumour necrosis and patient survival.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 1998 |
Radiotherapy in Ewing's sarcoma and PNET of the chest wall: results of the trials CESS 81, CESS 86 and EICESS 92.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 1998 |
Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 1998 |
Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 1999 |
Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 1999 |
Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 1999 |
WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Neo | 1999 |
High-dose methotrexate and HELP [Holoxan (ifosfamide), eldesine (vindesine), platinum]--doxorubicin in non-metastatic osteosarcoma of the extremity: a French multicentre pilot study. Fédération Nationale des Centres de Lutte contre le Cancer and Société F
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 1999 |
Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions.
Topics: Acute Disease; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone | 2000 |
Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Chil | 2000 |
Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chi-Square Distribu | 2000 |
Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 2000 |
A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 2001 |
Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Disease-Fr | 2002 |
Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2001 |
High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chondrocytes; Cis | 2002 |
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Europe; Humans; Ifosfamide; Sarcoma; | 1992 |
Effect of chemotherapy combined with caffeine for osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Caffeine; Calcane | 1992 |
BOP/VIP--a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Brain Neoplasms; Chorioni | 1991 |
Local control and survival from the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Austria; Bleomycin; Bone Neoplasm | 1991 |
Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Moda | 1990 |
Intensified chemotherapy with ifosfamide (IFO) and influence of intraarterial (i.a.) versus intravenous (i.v.) infusion of cisplatinum (DDP). Preliminary results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Humans; Ifosfamide; Infus | 1990 |
Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bra | 1989 |
Initial chemotherapy including ifosfamide in the management of Ewing's sarcoma: preliminary results. A protocol of the French Pediatric Oncology Society (SFOP).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 1989 |
255 other studies available for ifosfamide and Bone Neoplasms
| Article | Year |
|---|---|
A Retrospective Comparative Analysis of Outcomes and Prognostic Factors in Adult and Pediatric Patients with Osteosarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Humans; Ifosfamide; Os | 2021 |
Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Humans; Ifosfamid | 2022 |
Outcomes of Pediatric Patients With Metastatic Ewing Sarcoma Treated With Interval Compression.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2023 |
First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 2022 |
Dual enzyme therapy improves adherence to chemotherapy in a patient with gaucher disease and Ewing sarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosphamide; | 2023 |
Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cause of Death; Cisplati | 2022 |
Successful Treatment of Patient With Ewing Sarcoma in the Setting of Inherited Cholestatic Liver Disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cholestasis; Cholestasis, Intrahepat | 2023 |
Predicting chemosensitivity based on mini patient-derived xenografts in osteosarcoma patients: A retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Heterografts | 2023 |
Outcomes and survival rates of childhood osteosarcoma in Iran, A report from MAHAK Pediatric Cancer Treatment and Research Center, from 2007 to 2020.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2023 |
Total Neoadjuvant vs. Standard Perioperative Cisplatin/ Doxorubicin Chemotherapy in Patients with Extremities Osteosarcoma: A Multi-Center Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Extremities; | 2023 |
Outcomes of extraskeletal vs. skeletal Ewing sarcoma patients treated with standard chemotherapy protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 2020 |
Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 2019 |
Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp | 2020 |
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Dacarbazine; Doxorubicin; Female; Humans; Ifosfamide | 2020 |
Challenges in the management of localized Ewing sarcoma in a developing country.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2020 |
Clinical factors affecting prognosis of limb osteosarcoma in China: a multicenter retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Chin | 2020 |
IAP Chemotherapy Regimen Is a Viable and Cost-effective Option in Children and Adolescents With Osteosarcoma: A Comparative Analysis With MAP Regimen on Toxicity and Survival.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Cost-B | 2021 |
Ifosfamide induced encephalopathy in a child with osteosarcoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Diseases; Female; Humans; Ifosf | 2021 |
A Case of Ewing Sarcoma of the Bladder Presenting in Early Infancy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Etopo | 2021 |
Adolescent-adult nonmetastatic Ewing sarcoma-Experience from a large developing country.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; | 2021 |
Chronic kidney disease consecutive to chemotherapy for chondroblastic osteosarcoma: A report on 6 pediatric cases.
Topics: Adolescent; Bone Neoplasms; Child; Humans; Ifosfamide; Osteosarcoma; Renal Insufficiency, Chronic; R | 2021 |
Adjuvant and neoadjuvant chemotherapy for osteosarcoma: JCOG Bone and Soft Tissue Tumor Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; D | 2021 |
Location of residual viable tumor cells after neoadjuvant chemotherapy: A new concept with high prognostic performance in osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; D | 2017 |
Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
Topics: Adolescent; Adult; Adult Survivors of Child Adverse Events; Aged; Antineoplastic Agents; Bone Neopla | 2017 |
Transition from Tumor Tissue to Bone Marrow in Patients with Appendicular Osteosarcoma after Neoadjuvant Chemotherapy.
Topics: Adolescent; Adult; Bone Marrow; Bone Neoplasms; Child; Cisplatin; Doxorubicin; Female; Humans; Ifosf | 2017 |
Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Topics: Adolescent; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 2017 |
Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2017 |
Possible role of CYP2B6 genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases.
Topics: Administration, Intravenous; Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Di | 2018 |
Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Endostatins; Etoposide; Human | 2017 |
Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 Mutation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cardiotoxicity; Dimethyl Sulf | 2019 |
Curettage, phenolization, and cementation in paediatric Ewing's sarcoma with a complete radiological response to neoadjuvant chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Case- | 2019 |
Mesenchymal chondrosarcoma metastasising to the pancreas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cholangiopan | 2018 |
Prognostic implication of adjuvant/neoadjuvant chemotherapy consisting of doxorubicin and ifosfamide in patients with extraskeletal osteosarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 2019 |
Osteosarcoma journey over two decades in India: Small steps, big changes.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 2019 |
Metastasis of osteosarcoma to stomach made clinically evident by hematemesis: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Cisplatin; Combin | 2013 |
Primary angiosarcoma of bone: a retrospective analysis of 60 patients from 2 institutions.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisp | 2014 |
Osteosarcoma around the knee treated with neoadjuvant chemotherapy and a custom-designed prosthesis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arthroplasty, Replacement, Knee; | 2013 |
Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla | 2013 |
Metastatic malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): results with PNET-based chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin | 2015 |
Ifosfamide induced renal rickets.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child, Preschool; Chronic Kidney Disease-Mineral | 2014 |
Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury.
Topics: Acute Kidney Injury; Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Female; Hemodiaf | 2014 |
Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bone Neoplasms; Cell Dedifferenti | 2014 |
Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy.
Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Brain; Brain Diseases; Female; Hearing Loss; Huma | 2014 |
Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisp | 2013 |
[Value of ifosfamide in neoadjuvant therapy for osteosarcoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; D | 2013 |
Is it important to maintain high-dose intensity chemotherapy in the treatment of adults with osteosarcoma?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Dose-R | 2014 |
Validation of a multi-modal treatment protocol for Ewing sarcoma--a report from the polish pediatric oncology group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2014 |
Secondary malignant neoplasms after osteosarcoma: early onset and cumulative alkylating agent dose dependency.
Topics: Adolescent; Adult; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms | 2015 |
Marginal resection for osteosarcoma with effective neoadjuvant chemotherapy: long-term outcomes.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 2014 |
Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 2015 |
Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.
Topics: Activation, Metabolic; Antineoplastic Agents, Alkylating; Bone Neoplasms; Cell Line, Tumor; Cell Sur | 2015 |
Ifosfamide-containing regimens for treating patients with osteosarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Epirubicin; F | 2014 |
Developing a prognostic model for localized Ewing sarcoma family of tumors: A single institutional experience of 224 cases treated with uniform chemotherapy protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 2015 |
Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfam | 2015 |
Development of tumor-specific caffeine-potentiated chemotherapy using a novel drug delivery system with Span 80 nano-vesicles.
Topics: Abnormalities, Drug-Induced; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Benzoates; Bone | 2015 |
Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; China; Dox | 2015 |
First evidence of treatment efficacy in metastatic carcinoma of the parotid gland with BRD4/NUT translocation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; Cisplatin; Doxorub | 2016 |
A trimodality approach in the management of metastatic low-grade epithelioid hemangioendothelioma of the bone.
Topics: Adult; Antineoplastic Agents; Bone Nails; Bone Neoplasms; Doxorubicin; Femur; Foot; Fracture Fixatio | 2015 |
Identification of Discrete Prognostic Groups in Ewing Sarcoma.
Topics: Adolescent; Adult; Age Factors; Bone Neoplasms; Child; Child, Preschool; Databases, Factual; Etoposi | 2016 |
Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combin | 2015 |
Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cardiotonic Agents; Chil | 2016 |
Treatment of Patients with Distant Metastases from Phyllodes Tumor of the Breast.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neopla | 2016 |
Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Bone Neoplasms; Caspase 3; Cell Line, Tumor; | 2015 |
Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosphamide; Doxorubicin | 2016 |
Ewing Sarcoma: A 15-Year Experience of a Single Center With the MSKCC P6 Treatment Protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2016 |
Singapore Cancer Network (SCAN) Guidelines for the Initial Evaluation, Diagnosis, and Management of Extremity Soft Tissue Sarcoma and Osteosarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Chemotherapy, Adjuvan | 2015 |
Marriage and fertility in long-term survivors of childhood, adolescent and young adult (AYA) high-grade sarcoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro | 2016 |
Treatment outcomes of Japanese patients with Ewing sarcoma: differences between skeletal and extraskeletal Ewing sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bone Neoplasms; Chi | 2016 |
A Pediatric Case of Metastatic Conventional Parosteal Osteosarcoma Treated With Multidrug Chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cispla | 2016 |
Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bone Neoplasms; BRCA2 Protein; Dioxol | 2016 |
Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms | 2016 |
Osteosarcoma: the same old drugs or more?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Humans; Ifos | 2008 |
Osteosarcoma in a patient with xeroderma pigmentosum.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2009 |
Pleomorphic malignant fibrous histiocytoma: response of bone, lung, and brain metastases to chemotherapy.
Topics: Acetabulum; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Neoplasms; Brain; B | 2008 |
Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality | 2009 |
Rapid pain relief and marked sclerotic change of multiple bone metastases from a synovial sarcoma after treatment with intravenous pamidronate and chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neopla | 2009 |
Long-term disease stabilization during second-line gemcitabine in a refractory metastatic haemangioendothelioma.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2009 |
Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Co | 2009 |
Extra-osseous Ewing sarcoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Ch | 2009 |
Local and systemic control of Ewing's bone sarcoma family tumors of the ribs.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bone Plates; Chil | 2009 |
An osteoporotic hip fracture in a 14-year-old girl undergoing chemotherapy and operated for knee osteosarcoma.
Topics: Adolescent; Antineoplastic Agents; Arthroplasty, Replacement, Knee; Bone Neoplasms; Chemotherapy, Ad | 2009 |
Late effects surveillance system after childhood cancer in Germany, austria and parts of Switzerland--update 2009.
Topics: Adolescent; Aftercare; Antineoplastic Combined Chemotherapy Protocols; Austria; Bone Neoplasms; Card | 2009 |
Radiation toxicity following busulfan/melphalan high-dose chemotherapy in the EURO-EWING-99-trial: review of GPOH data.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Chemotherapy, | 2009 |
Immunotherapy with interleukin-18 in combination with preoperative chemotherapy with ifosfamide effectively inhibits postoperative progression of pulmonary metastases in a mouse osteosarcoma model.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Disease Progression; Female; Ifosfamide; Immunotherapy; I | 2009 |
Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide.
Topics: Animals; Biomarkers, Tumor; Bone Neoplasms; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor | 2009 |
Ifosfamide-induced encephalopathy and movement disorder.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Diseases; Child; Female; Humans | 2010 |
Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cisplatin; Dose-R | 2010 |
Metastatic primary angiosarcoma of the breast in a pediatric patient with a complete response to systemic chemotherapy and definitive radiation therapy: case report and review of the literature.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combin | 2010 |
Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosph | 2010 |
Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Membe | 2010 |
Moyamoya in a child treated with interferon for recurrent osteosarcoma.
Topics: Antineoplastic Agents; Bone Neoplasms; Carotid Artery Diseases; Cerebral Arterial Diseases; Cerebral | 2010 |
Pulmonary blastoma in adult: dramatic but transient response to doxorubicin plus ifosfamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Drug Administration Sch | 2011 |
Chest wall Ewing sarcoma family of tumors: long-term outcomes.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla | 2011 |
Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Line, Tumor | 2010 |
Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Disease Models, Animal | 2011 |
Neuroblastoma in an adult: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Brain Neoplasms; Carboplatin | 2010 |
Magnetic resonance imaging is appropriate for determining the osteotomy plane for appendicular osteosarcoma after neoadjuvant chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 2012 |
Treatment outcome of Korean patients with localized Ewing sarcoma family of tumors: a single institution experience.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleom | 2011 |
Relationship between hypermethylated MGMT gene and osteosarcoma necrosis rate after chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 2011 |
Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemo | 2011 |
Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2011 |
Unusual seminoma revealed by bone metastasis.
Topics: Bone Neoplasms; Cisplatin; Drug Therapy, Combination; Etoposide; Humans; Ifosfamide; Magnetic Resona | 2011 |
High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Disease-Free Survival; Female; Human | 2011 |
Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2011 |
Extraskeletal osteosarcoma of the breast in an adolescent girl.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemot | 2012 |
Small cell osteosarcoma successfully treated by high-dose ifosfamide and methotrexate, combined with carboplatin and pirarubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chemotherapy, Adjuvant; | 2012 |
Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Deoxycytid | 2013 |
Ifosfamide in the neoadjuvant treatment of osteogenic sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; D | 2012 |
Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 2012 |
[Organ-preserving interventions in combined therapy of children and adolescents with osteosarcoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bone Transplantation; Ch | 2012 |
Analysis of prognostic factors in 333 Chinese patients with high-grade osteosarcoma treated by multidisciplinary combined therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bone Neoplasm | 2013 |
Ifosfamide and doxorubicin combination chemotherapy for recurrent nasopharyngeal carcinoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamo | 2012 |
Regression of mesenchymal hamartoma of the liver with sarcoma chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Dactinomyci | 2013 |
Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma.
Topics: Amputation, Surgical; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothera | 2014 |
The Effects of N-acetylcysteine on ifosfamide efficacy in a mouse xenograft model.
Topics: Acetylcysteine; Animals; Antineoplastic Agents, Alkylating; Bone Neoplasms; Cell Growth Processes; C | 2012 |
Case report: stimulation of puberty in a girl with chemo- and radiation therapy induced ovarian failure by transplantation of a small part of her frozen/thawed ovarian tissue.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cryopreservation; Cyclophosphamide; | 2013 |
[Treatment and prognosis of stage IV alveolar soft part sarcoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Dacarbazine; | 2012 |
Osteosarcoma of the pelvis: a monoinstitutional experience in patients younger than 41 years.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 2012 |
High-dose chemotherapy and autologous peripheral blood stem-cell transfusion after conventional chemotherapy for patients with high-risk Ewing's tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chil | 2002 |
Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 2002 |
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Neoplasms; Cystitis; Diph | 2002 |
A pilot study of short-course intensive multiagent chemotherapy in metastatic and axial skeletal osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; C | 2002 |
Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arm; ATP Binding Cassette T | 2003 |
Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2003 |
Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Chil | 2003 |
Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisp | 2003 |
Ileoileal intussusception caused by a Ewing sarcoma tumour. An unusual case report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Moda | 2003 |
Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Dose-Response | 2003 |
Preoperative therapy versus immediate surgery in nonmetastatic osteosarcoma.
Topics: Amputation, Surgical; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Humans; Ifosfa | 2003 |
Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoprevention; Female; Huma | 2004 |
Methylene blue reversal of ifosfamide-related encephalopathy.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Electroencephalography; Enzyme Inhibitors; | 2004 |
[Neoadjuvant chemotherapy for osteosarcoma].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 2004 |
Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chil | 2004 |
Spinal cord compression and lung metastasis of Wilms' tumor in a pregnant adolescent.
Topics: Abdominal Pain; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carbopla | 2004 |
[Goal and results of the COSS study].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arm; Bone Neoplasms; Chemotherapy | 2004 |
High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity.
Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Female; Hu | 2005 |
VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug R | 2004 |
Ewing's sarcoma of the axial system in patients older than 15 years: dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; | 2004 |
Long-term survival in high-grade axial osteosarcoma with bone and lung metastases treated with chemotherapy only.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Child, Preschool; Cispl | 2005 |
[A case of oropharyngeal cancer with multiple bone metastases from prostate cancer that responded to docetaxel, ifosfamide and cisplatin combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2005 |
The role of preoperative radiotherapy in nonmetastatic high-grade osteosarcoma of the extremities for limb-sparing surgery.
Topics: Adolescent; Adult; Aged; Amputation, Surgical; Analysis of Variance; Antineoplastic Combined Chemoth | 2005 |
The effect of multidrug chemotherapy on bone graft augmented prosthesis fixation.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che | 2005 |
Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate.
Topics: Acute Kidney Injury; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2005 |
Radiation therapy for Ewing's sarcoma: results from Memorial Sloan-Kettering in the modern era.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2006 |
Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2006 |
Fas expression in lung metastasis from osteosarcoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2005 |
Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases.
Topics: Administration, Intranasal; Animals; Antineoplastic Agents, Alkylating; Bone Neoplasms; Combined Mod | 2006 |
Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Clinical T | 2006 |
Sacral epithelioid angiosarcoma associated with a bleeding diathesis and spinal epidural hematoma: case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Neoplasms; Combined M | 2006 |
Malignant mixed Mullerian tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemo | 2006 |
Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 2007 |
Clearance of methotrexate by means of hemofiltration in a patient with osteosarcoma.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplati | 2006 |
[Acquired Fanconi-de Toni-Debre syndrome due to therapy for Ewing's sarcoma in 5-years old boy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child, Preschool; Dactinomycin; Doxo | 2006 |
Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 2007 |
Primary rhabdomyosarcoma of the breast in a 13-year-old girl: report of a case.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Dactin | 2007 |
Juvenile Ewing sarcoma presenting as a pelvic mass.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therap | 2007 |
Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bone Neoplasms; Chi | 2007 |
Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Combined | 2007 |
[Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles | 2007 |
Necrotic pathway in human osteosarcoma Saos-2 cell death induced by chloroacetaldehyde.
Topics: Acetaldehyde; Adenosine Triphosphate; Annexin A5; Antineoplastic Agents, Alkylating; Blotting, Weste | 2007 |
Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined M | 2007 |
Ewing's sarcoma and primitive neuroectodermal tumour in adults: single-centre experience in The Netherlands.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality | 2007 |
Acute pancreatitis associated with ifosfamide.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Humans; Ifosfamide; Male; O | 2007 |
Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999.
Topics: Adult; Amputation, Surgical; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Bone Ne | 2007 |
Prognosis of radiation-induced bone sarcoma is similar to primary osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combin | 2007 |
Prognostic factors for local and distant control in Ewing sarcoma family of tumors.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Child, Pres | 2008 |
[Preoperative adjuvant therapy for primary malignant bone tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Dactinomycin; Doxo | 2007 |
F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Female; Fluorodeoxyglucose F18 | 2008 |
Multimodality treatment of osteosarcoma: radiation in a high-risk cohort.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 2008 |
[Clinical evaluation on the sensitivity test for anti-cancer agents in malignant bone and soft-tissue tumors].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; | 1984 |
[Cytostatic treatment of hypernephroid renal carcinoma (author's transl)].
Topics: Adenocarcinoma; Bone Neoplasms; Cyclophosphamide; Female; Humans; Ifosfamide; Kidney Neoplasms; Lung | 1980 |
Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Blood; Bone Marrow; Bone Neopl | 1996 |
Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue.
Topics: Administration, Oral; Adolescent; Antidotes; Bone Neoplasms; Brain Diseases; Drug Overdose; Female; | 1994 |
Osteosarcoma following radiation treatment for meningioma: report of a case and effective treatment with chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Cisplatin; Dacti | 1994 |
Ifosfamide-induced Fanconi syndrome.
Topics: Adult; Bone Neoplasms; Fanconi Syndrome; Humans; Ifosfamide; Male; Osteomalacia; Osteosarcoma | 1995 |
A monocentric therapy study: an approach to optimize the results of the treatment of osteosarcoma by protocols based upon HDMTX, associated with systematic conservative surgery.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bo | 1993 |
Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 1994 |
Acute pancreatitis after ifosfamide therapy.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Female; H | 1994 |
Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats.
Topics: Animals; Bone Neoplasms; Cell Line; Doxorubicin; Female; Femur; Ifosfamide; Male; Melanoma, Amelanot | 1994 |
Lung irradiation for Ewing's sarcoma with pulmonary metastases at diagnosis: results of the CESS-studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 1993 |
Wernicke-encephalopathy in children with cancer.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Moda | 1994 |
Long-term disease-free survival in a child with refractory metastatic malignant germ cell tumor treated by high-dose chemotherapy with autologous bone marrow rescues.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Cisplat | 1994 |
[Ifosfamide in combined hormonochemotherapy on prostate cancer].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 1994 |
[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas].
Topics: Administration, Intravesical; Adolescent; Adult; Aluminum Hydroxide; Bone Neoplasms; Child, Preschoo | 1993 |
Primary extracranial rhabdoid tumors. Clinicopathologic features and response to ifosfamide.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Child; Chil | 1993 |
Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1993 |
Case report: pulmonary blastoma in children--response to chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Moda | 1996 |
Intense gallbladder uptake associated with chemotherapy. An unusual finding in pediatric skeletal scintigraphy.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; B | 1995 |
True histiocytic lymphoma following therapy for lymphoblastic neoplasms.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Neoplasms; Child; Cisplati | 1996 |
[Neoadjuvant treatment of Ewing's sarcoma: results obtained in 122 patients treated with a 6-drug chemotherapeutic protocol (vincristine, adriamycin, cyclophosphamide, dactinomycin, ifosfamide and etoposide)].
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Ag | 1995 |
[Ifosfamide in pediatric malignancy--experiences in the Northern Israel Oncology Center].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C | 1996 |
Development of a canine chemotherapeutic model with ifosfamide.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood Platelets; Bone Neoplasms; Dogs; Drug Administrati | 1996 |
Neoadjuvant chemotherapy for pediatric osteosarcoma patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 1997 |
Chemotherapeutic induction of long-term remission in metastatic medulloblastoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cerebellar Neoplasms; Cisplat | 1997 |
Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Breast Neoplasms; Carcinoma, Transitional Cell; D | 1997 |
[The type of local treatment conditions the prognosis in patients with nonmetastatic Ewing's sarcoma of the extremities treated with adjuvant chemotherapy].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arm; Bone Neoplasms; Chemotherapy, Adjuv | 1997 |
Neoadjuvant chemotherapy for osseous malignant fibrous histiocytoma of the extremity: results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen.
Topics: Adolescent; Adult; Amputation, Surgical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplasti | 1997 |
Treatment of childhood post-irradiation sarcoma of bone in cancer survivors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 1997 |
Miliary osteosarcomatosis with associated hypocalcemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antine | 1997 |
The use of a systemic therapy checklist improves the quality of data acquisition and recording in multicentre trials. A study of the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Data Collection; Doxorubicin; Granul | 1997 |
[The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Drug Administration Sch | 1997 |
Prolonged survival in a nasopharyngeal carcinoma patient with multiple metastases: a case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 1997 |
The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; | 1997 |
[Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; | 1998 |
Postsurgical etoposide-ifosfamide regimen in poor-risk nonmetastatic osteogenic sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Disease-Fr | 1998 |
Neoadjuvant chemotherapy for extremity osteosarcoma--preliminary results of the Rizzoli's 4th study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherap | 1998 |
Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 1998 |
Chemotherapy and P-glycoprotein expression in chondrosarcoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 1998 |
Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biot | 1998 |
Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 1999 |
Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 1998 |
Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Drug Administrati | 1999 |
Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 1999 |
Management of cancer in pregnancy: a case of Ewing's sarcoma of the pelvis in the third trimester.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cesarean Section; Disease-Fre | 1999 |
[A case of metastatic liver tumors from prostatic cancer responding to intra-arterial infusion chemotherapy with CDDP and ifosfamide using implantable port].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasm | 1999 |
RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Purging; Bone N | 1999 |
Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2000 |
Local therapy and other factors influencing site of relapse in patients with localised Ewing's sarcoma. United Kingdom Children's Cancer Study Group (UKCCSG).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 1999 |
Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2000 |
Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Child, Preschool; Cross | 2000 |
High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoid Tumor; Cisplatin; E | 2000 |
Long-term survival following extra-neural metastasis from a pineoblastoma.
Topics: Acetabulum; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neopla | 2000 |
Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chil | 2001 |
Selective use of whole-lung irradiation for patients with Ewing sarcoma family tumors and pulmonary metastases at the time of diagnosis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2001 |
Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxoru | 2001 |
Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 2001 |
Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy,.
Topics: Adolescent; Adult; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla | 2001 |
Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 2001 |
Painful peripheral neuropathy after treatment with high-dose ifosfamide.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Combined Modality Therapy; Dose-Respo | 2001 |
Postchemotherapy confusion.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Female; Humans; Ifosfamide; M | 2001 |
Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection.
Topics: Adolescent; Adult; Aged; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone | 2001 |
[An autopsy case of pulmonary and central nervous system metastatic osteosarcoma treated with thirty-six courses of chemotherapy over four years].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; | 2002 |
[Treatment of Ewing's sarcoma with 2 different protocols].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2001 |
Postoperative radiotherapy in the treatment of Ewing tumors: influence of the interval between surgery and radiotherapy.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Primary treatment of pelvic osteosarcoma. Report of five cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Chemot | 1992 |
Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 1992 |
Ewing's sarcoma: experience with 12 cases.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 1992 |
No benefit of ifosfamide in Ewing's sarcoma: a nonrandomized study of the French Society of Pediatric Oncology.
Topics: Bone Neoplasms; Child; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Ifosfamide; Mal | 1992 |
Use of propofol for the prevention of chemotherapy-induced nausea and emesis in oncology patients.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Bone Neoplasms; Cyclophosphamide; Female; Hum | 1992 |
Assessment of osteosarcoma response to preoperative chemotherapy using dynamic FLASH gadolinium-DTPA-enhanced magnetic resonance mapping.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 1992 |
A phase II study of the combination of carboplatin and ifosfamide in previously untreated metastatic small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma, | 1991 |
IIB osteosarcoma. Current management, local control, and survival statistics--São Paulo, Brazil.
Topics: Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brazil; Cispla | 1991 |
Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities.
Topics: Adolescent; Adult; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Length | 1991 |
[Successful treatment of metastatic and refractory osteosarcoma by ifosfamide, carboplatin and vindesine: case report].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Drug Admini | 1991 |
[Two cases of Ewing's sarcoma originating from the adult rib].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality | 1991 |
[Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
Topics: Bone Neoplasms; Child; Cyclophosphamide; Cystitis; Female; Hematuria; Humans; Ifosfamide; Leukemia; | 1990 |
Use of MR imaging to assess results of chemotherapy for Ewing sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp | 1990 |
[Developments in the treatment of osteosarcoma since 1979. Report of the statistics at the Centre Léon-Bérard].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 1990 |
[Desmoid fibroma of the scapula. Recurrence with pulmonary metastasis].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dactinomycin; Female; Fibroma | 1989 |
High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasm | 1989 |
[Ifomide].
Topics: Animals; Bone Neoplasms; Carcinoma, Small Cell; Female; Humans; Ifosfamide; Leukemia, Experimental; | 1987 |
CNS-side effects induced by Ifosfamide-Mesna in children with osteosarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Central Nervous System D | 1986 |
[Objective response of desmoid fibroma to chemotherapy].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dactinomycin; Dru | 1987 |
A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people.
Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Drug Evaluation; Femal | 1986 |